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Whilst pituitary-derived luteinising hormone is the primary regulator of corpus luteum
(CL) function, it is becoming increasingly apparent that other factors of extra- and intra-
ovarian origin have the potential to modulate the luteal response to gonadotrophins. The
insulin-like growth factor (IGF) system is thought to play a central role in these
interactions, and studies in vitro have shown that both IGF-I and -II have wide ranging
effects on ovarian function. The aim of this work was to investigate the role of the IGF
system in regulating corpus luteum function.
Bovine CL were collected on days 5, 10, and 15 of the oestrous cycle following
synchronised oestrus (day of oestrus = day 0). In addition, CL were collected following
prostaglandin-induced luteolysis. In situ hybridisation detected luteal expression of IGF-
I, -II and the type 1 IGF receptor messenger ribonucleic acid (mRNA) throughout the
oestrous cycle. The expression of IGF-I mRNA varied significantly during the oestrous
cycle. IGF-I mRNA concentrations were significantly higher on day 15 than on day 10,
and IGF-I mRNA in the regressing corpus luteum 48 hours after exogenous
prostaglandin was significantly greater than in the early or mid-luteal phase (days 5 and
10). In contrast, there was no significant effect of day of the oestrous cycle on IGF-II
and the type 1 IGF receptor mRNA concentrations in the corpus luteum. IGF-II mRNA
expression was localised to a subset of steroidogenic luteal cells and was also associated
with cells of the luteal vasculature. Messenger RNA encoding the type 1 IGF receptor
was widely expressed, in a pattern suggestive of steroidogenic luteal cell expression.
The actions of the IGFs are modulated by their association with members of a family of
IGF-specific binding proteins (IGFBPs), which regulate the transport of IGFs and their
presentation to specific receptors. In situ hybridisation detected mRNA encoding
IGFBP-2, -3, and —4 in the bovine corpus luteum throughout the luteal phase. IGFBP-2
and -4 mRNA concentrations were low within the corpus luteum, and showed no
temporal variation. In addition, a subset of large vessels in the periphery of the CL
showed moderate to intense hybridisation for IGFBP-2 mRNA. IGFBP-3 mRNA
concentrations were high throughout the luteal phase, and expression was localised
predominantly to cells lining microvessels, suggestive of endothelial cell expression.
The administration of gonadotrophin releasing hormone (GnRH) to cattle in the early
luteal phase (day 6) induces ovulation and the formation of an additional CL in greater
than 80% of animals. Progesterone profiles indicate that GnRH-induced CL are
functional, however progesterone levels are reduced and they display a short lifespan
when compared to spontaneously formed CL. Based on the ability of the IGFs to
modulate the ovarian response to gonadotrophins, we hypothesised that changes in
concentrations of mRNA encoding components of the IGF system were responsible.
GnRH was administered to cows on day 6 and ovarian dynamics monitored by rectal
ultrasound and daily blood sampling. Ovaries were collected on day 10 and 15, and
GnRH-induced CL compared to similar aged control CL and spontaneous CL present at
GnRH treatment. Induced CL expressed mRNA encoding IGF-I, IGF-II, the type 1 IGF
receptor and IGFBP-3. The patterns of expression were not significantly different
between control and induced CL, however, concentrations of mRNA expression were
ii
altered. IGFBP-3 mRNA concentrations were increased in induced CL, whilst type 1
IGF receptor mRNA concentrations were decreased when compared to control CL. We
suggest that these changes will reduce both the bioavailability and bioactivity of IGF-I
and —II, thus compromising the induced CL response to luteotrophic support.
In conclusion, these data demonstrate that the bovine corpus luteum is a site of IGF
production, reception and regulation throughout the luteal phase, and further support the
hypothesis that the IGF system is important in regulating luteal function in the cow.
iii
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The corpus luteum has key functions in the control of ovarian cyclicity and embryo
survival. The establishment of pregnancy and continued embryo development are
dependent on the inhibition of luteal regression and hence maintained secretion of the
primary luteal product progesterone. A lack of appropriate progesterone secretion has a
detrimental effect on pregnancy success (Mann et al., 1999).
During the past twenty years there has been a marked decline in the reproductive
performance of the UK dairy herd. The pregnancy rate to first service has fallen annually
by approximately 1%, and is now only 39.7%. This declining fertility is associated with
an increase in the proportion of animals displaying atypical ovarian hormone patterns,
and abnormal luteal function is thought to be a primary contributory factor (Royal et al.,
2000). Sub-fertility represents a significant loss of revenue for the dairy farmer through
reduced milk output and calf production, and increased insemination and replacement
costs (Esslemont and Peeler, 1993; Stott et al., 1999). In addition, there are considerable
animal welfare implications associated with increased veterinary intervention and a high
rate of culling. An increased understanding of the mechanisms regulating luteal function
should lead to the development of procedures aimed at improving reproductive
efficiency, and help to reverse the current trend of decreasing fertility in the national
dairy herd.
This study is concerned with the role of the IGF system in the regulation of luteal
function. IGF-I and -II have multiple effects on the regulation of follicular development
xi
and steroidogenic activity. IGF-I stimulates follicular steroidogenesis via enhanced
gonadotrophin receptor numbers, sterol delivery, and steroidogenic enzyme activity
(Adashi et al., 1985c; Veldhuis, 1989; Magoffin et al., 1990; Magoffin and Weitsman,
1993; Balasubramanian et al., 1997). Evidence also suggests that IGF-II augments the
steroidogenic response to gonadotrophin stimulation (Garmey et al., 1993).
Comparatively little is known about the effects of the IGFs on luteal function. However,
an important role for the IGFs in the CL is supported by the regulatory actions of the
IGFs on steroidogenesis, as demonstrated in the follicle, and by the stimulation of
progesterone production by luteal cells in vitro in response to both IGF-I and IGF-II
(McArdle and Holtorf, 1989; Talavera and Menon, 1991; Sauerwein et al., 1992; Khan-
Dawood et al 1994; Devoto et al., 1995; Yuan and Lucy, 1996a). The IGFs may also
have important functions in addition to the regulation of steroidogenesis, including the
stimulation of angiogenesis (Hansson et al., 1989; Grant et al., 1993; Vialettes et al.,
1994) and control of apoptosis (Chun et al., 1994), and therefore have great potential to
regulate luteal events. This study aims to characterise the IGF system during the growth
and development of the bovine CL.
xii
Chapter 1. Literature Review
1.1 The Bovine Corpus Luteum; Formation, function and regression.
1.1.1 Historical background
The first detailed description of the corpus luteum (CL) is credited to Regnier de
Graaf (cited by Short, 1977) whose publication on female reproduction in 1672
describes the formation of "globular bodies" that form to replace "ova". In addition,
de Graaf observed that the "testicles of the female" did not always contain these
"globules" rather that they could be seen to diminish and disappear.
The term "corpus luteum" was first ascribed to these globules by the anatomist
Malpighi (1628-1694) following his observation of the "yellow body" of the cow
(cited by Short, 1977). However, it was not until the late 1800s that specific
functions were suggested for the corpus luteum. In 1897, John Beard proposed that
the CL prevents ovulation during pregnancy and that the degeneration of the
structure towards the end of gestation, or in the absence of fertilisation removes
inhibition and allows for a new ovulation (cited by Amoroso, 1968). Prenant, in
1898, was the first to suggest that the corpus luteum acts as an endocrine gland.
Based on his histological observations, he proposed that the corpus luteum was "a
gland of internal secretion, releasing one or more products into the
bloodstream"(cited by Short, 1977).
Confirmation of the role of the corpus luteum in the maintenance of pregnancy was
first provided by Fraenkel (1903) and Magnus (1901) who showed that removal of
the ovaries or luteal ablation induced abortion or embryo resorption (cited by
Amoroso, 1968). A further role for the corpus luteum in pregnancy preparation and
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survival was demonstrated by Bouin and Ancel (1910) who showed in the rabbit that
endometrial gland proliferation was CL-dependent, thus providing a bioassay that
enabled luteal extracts to be tested for their active principle (cited by Amoroso,
1968). Corner and Allen (1929) extended the results of the CL ablation studies by
successfully inducing endometrial proliferation and maintaining early pregnancy in
ovariectomised animals following the administration of a porcine luteal extract.
Subsequently progesterone was isolated and purified as the primary endocrine
secretion of the corpus luteum (Allen and Wintersteiner, 1934).
1.1.2 Follicular and luteal dynamics
A pool of approximately 2-3 million primordial follicles are established in the ovary
of the cow during fetal development (Gosden and Telfer, 1987), each consisting of
primary oocytes arrested in prophase I of meiosis, surrounded by a single layer of
pre-granulosa cells and enclosed by a basal lamina. These arrested follicles enter the
growth phase during the lifetime of the animal in response to an as yet undetermined
stimulus (Hirshfield, 1991; Webb et al., 1999). The initiation of primordial follicle
growth is characterised by a change in granulosa cell shape from flattened to
cuboidal, granulosa cell proliferation and oocyte enlargement. With continued
growth the granulosa cells of the primary follicle become multi-layered and a zona
pelucida is secreted around the enlarging oocyte.
Outside the basement membrane, the theca interna and externa are formed by
differentiation of stromal cells, and a blood capillary network is increasingly
apparent. Once the follicle has reached 100-300pm in diameter, spaces between
granulosa cells join together to form a fluid-filled antral cavity (Lussier et al., 1987).
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Having left the resting pool a follicle faces one of two fates, continued growth and
ovulation, or degeneration and atresia, and only a small percentage of follicles
proceed to the final stages of follicular development (Figure 1.1).
Antral Ovulation
Preantral Follicle
Figure 1.1 Stages of follicular growth and development.
(Adapted from Webb et al., 1999).
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Real-time ultrasonography has enabled the tracking of follicular and luteal
dynamics. In the bovine oestrous cycle large antral follicle growth occurs in two or
three waves. Each wave is characterised by the simultaneous growth of a group of
antral follicles, one of which is selected to become dominant, while other cohort
follicles regress (Figure 1.2). The follicle that is dominant at luteolysis progresses to
become the ovulatory follicle (Fortune, 1994; Webb et al., 1999). Ovulation releases
the oocyte, and the corpus luteum forms from the granulosa and theca interna cells
of the collapsed follicle.
The length of the bovine oestrous cycle is 21 days for cows and 20 days for heifers,
with a normal range of 17-24 days (Hawk and Bellows, 1980). The corpus luteum is
the dominant structure on the ovary for approximately 17 days, and the follicular
phase lasts 3-4 days. The oestrus period of sexual receptivity is of short duration,
with a mean length of 12-16 hours, ranging in individual animals from 3-28 hours
(Allrich, 1994) and is designated day 0 of the cycle. Ovulation usually occurs 18-48
hours after the onset of oestrus, or 10-12 hours after the end of oestrus.
1.1.3 Formation and structure of the corpus luteum
1.1.3.1 Gross morphology of the corpus luteum
The corpus luteum is formed from the ruptured follicle following ovulation
(Donaldson and Hansel, 1965a), and exhibits rapid growth, to reach its maximal size
around mid-cycle (Ireland et al., 1980; Reynolds et al., 1994). Indeed, the dramatic
growth of the CL is comparable to that of the fastest growing tumours (Jablonka-
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Figure 1.2 Waves of follicular development in cattle during the oestrous cycle.
A three wave pattern of follicular development is illustrated. S and D represent
phases of follicular selection and dominance respectively.
(Adapted from Webb et al., 1999).
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Gross changes in the appearance of corpora lutea throughout the bovine oestrous
cycle have been described in detail and are used to estimate the day of the cycle in
animals of unknown reproductive history (Ireland et al., 1980). In stage I (days 1-4)
the CL is red, between 0.5 - 1.5 cm in diameter and the point of follicle rupture is
not covered by epithelium. In stage II (days 5-10) the CL has increased in size to its
maximal diameter of 1.6 - 2.0 cm, the ovulation point is now covered and red or
brown in colour, whilst the remainder of the CL is orange. In stage III (days 11-17)
the apex of the CL appears tan or orange, and has a visible vasculature, on bisection
the CL is bright orange or yellow. In the final stage of luteal development (stage IV,
days 18-20) the CL undergoes regression, decreasing in size to less than 1 cm in
diameter, and becomes paler in colour (Ireland et al., 1980).
1.1.3.2 Angiogenesis
The female reproductive organs undergo cyclical growth and regression, which is
accompanied by extensive changes in vasculature and blood flow. Few other tissues in
the adult exhibit the growth of new blood vessels (angiogenesis) unless they are
undergoing tissue repair. Irregularities in the control of angiogenesis, either by the over
or under production of vascular growth, are associated with a number of pathological
conditions, therefore ovarian angiogenesis is expected to be tightly controlled (Redmer
and Reynolds, 1996).
The vascular bed of the Graafian follicle is confined to the theca cell layer by a
basement membrane, which separates the avascular granulosa layers of the follicular
interior from the network of blood vessels. Around the time of ovulation, the basement
membrane breaks down, allowing rapid capillary outgrowth. The subsequent formation
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of the luteal vasculature is both rapid and extensive. Indeed, tissue growth is dependent
upon the growth of new blood vessels and the establishment of a functional blood
supply (Folkman and Klagsbrun, 1987). During early luteal development capillary
sprouts invade the granulosa-derived tissue, and by mid-cycle an abundant capillary
network has formed within the mature CL. Indeed, the vascular network is so dense
that most steroidogenic cells appear in immediate contact with at least one capillary
(Zheng et al., 1993). Endothelial cells, which line blood vessels, are a prominent cell-
type within the corpus luteum, occupying around 15% of luteal tissue volume, and
representing around 50% of all cells at mid-cycle (O'Shea et al., 1989). In addition, the
mature corpus luteum receives one of the highest rates of blood flow to any organ.
Blood flow to the CL-bearing ovary is correlated with progesterone concentrations,
reaching maximal levels during the mid-cycle and showing a rapid decrease associated
with luteolysis (Niswender et al., 1976).
Corpora lutea produce angiogenic factors throughout the oestrous cycle and pregnancy
(Grazul-Bilska et al., 1992b; Ricke et al., 1995). Heparin binding growth factors,
namely the fibroblast growth factors (FGF) and the vascular endothelial growth factors
(VEGF) are considered key mediators of luteal neovascularisation, and are the subject
of recent review (Reynolds and Redmer, 1998).
Acidic FGF (aFGF/ FGF-1) and basic FGF (bFGF/ FGF-2) are known to stimulate
angiogenesis (Klagsbrun and D'Amore, 1991), and both proteins have been detected in
the bovine CL (Zheng et al., 1993). In addition luteal bFGF mRNA expression is
correlated with angiogenic activity (Stirling et al., 1991). Immunoneutralisation of
aFGF and bFGF markedly reduced luteal angiogenic activity, and demonstrated that
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bFGF was responsible for stimulating the majority of the luteal vascular response
(Grazul-Bilska et al., 1992a).
VEGF mRNA expression has been detected in the ovine CL, and was maximal early in
the cycle (Redmer et al., 1996). The temporal association between high luteal VEGF
expression and extensive neovascularisation supports an important role for VEGF in
luteal vascular development. In addition, endothelial cell proliferation and migration,
stimulated by the products of luteal explants in culture, was reduced by anti-VEGF
antibodies, and the greatest reduction in angiogenic activity was observed in the early
CL (Doraiswamy et al., 1995).
Specific receptors for FGF and VEGF have been demonstrated in the corpus luteum of
sheep, rats and women (Asakai et al., 1993; Doraiswamy et al., 1998; Otani et al.,
1999). Basic-FGF binding capacity and mRNA encoding the FGF receptor-1 (FGFR-
1) which is activated by bFGF decreases with advancing luteal age (Asakai et al.,
1993). FGFR-1 and -2 have been detected in vascular and parenchymal cells of the
ovine CL. Parenchymal FGFR-1 concentrations are reduced in the late luteal phase,
whilst vascular FGFR-1 was detected in endothelial cells throughout the oestrous
cycle. In contrast, FGFR-2 was localised to luteal parenchymal cells at all stages of
oestrous cycle, and vascular expression was limited to large microvessels and was only
detectable during the late luteal phase (Doraiswamy et al., 1998). Messenger RNA
encoding the VEGF receptor Fit-1 is expressed in the human corpus luteum. Fit-1
protein was localised to human granulosa and theca lutein cells and luteal endothelial
cells during the menstrual cycle and early pregnancy (Otani et al., 1999). In addition,
treatment with truncated soluble Fit-1 receptors to inhibit VEGF bioactivity caused
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near absolute suppression of luteal angiogenesis, demonstrating that VEGF is essential
for neovascularisation (Ferrara el al., 1998).
Futeal angiogenic activity appears to be regulated by luteotrophic and luteolytic
factors. Futeinising hormone (FH) stimulated bFGF mRNA expression in cultured
bovine luteal cells, whilst prostaglandin (PG)F2a reduced bFGF mRNA (Stirling et al.,
1991). VEGF is also subject to modulation by FH; FH significantly increased VEGF
production and mRNA expression by luteinising granulosa cells (Christenson and
Stouffer, 1996; Garrido et al., 1993).
1.1.3.3 Cellular components of the corpus luteum
The corpus luteum consists of a number of different cell types. These include
steroidogenic cells, endothelial cells and pericytes, fibroblasts and immune cells
(Farin et al., 1986; O'Shea et al., 1989; Parry et al., 1980). The most numerous cells
are those associated with the luteal vasculature, whilst the steroidogenic cells occupy
most of the volume of the CF.
At least two populations of steroidogenically-active luteal cells can be distinguished.
These are characterised by size and referred to as "large" and "small" luteal cells.
Both luteal cell types possess ultrastructural features characteristic of steroid
secreting cells, including a well-developed smooth endoplasmic reticulum (SER),
abundant mitochondria containing tubular cristae, an extensive Golgi apparatus and
cytoplasmic lipid droplets (Parry et al., 1980). Fipid droplets, which may serve as
steroid precursor stores, are inversely related to progesterone synthesis (Parry et al.,
1980).
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In addition to their difference in size, other distinguishing structural features have
been attributed to the small and large luteal cells (Fields and Fields, 1996; Parry et
al., 1980). The small cells characteristically display whorls of SER and adherens-
type junctions, whilst large cells contain a notable abundance of membrane-bound
electron-dense secretory granules within their cytoplasm which are extruded from
the cell by exocytosis.
It was initially proposed that these granules contained progesterone, based on the
correlation between progesterone secretion and granule formation and release
(Sawyer et al., 1979), although an autoradiographic study suggested that labelled
progesterone-precursors synthesised into progesterone did not concentrate in the
granules (McClellan et al., 1979). Immunocytochemistry has subsequently localised
oxytocin and neurophysin to the same secretory granule (Fields et al., 1992).
Secretory granules have also been reported to contain tissue inhibitor of
metalloproteinases (TlMP)-l, which plays an important role in regulating
extracellular matrix (ECM) remodelling (Mclntush et al., 1996).
Whilst both large and small luteal cells possess the cellular machinery associated
with steroid synthesis, they are also well equipped for protein secretion (Niswender
et al., 1985; Parry et al., 1980).
In addition to displaying structural differences, the two cell populations appear to be
functionally distinct. Whilst both large and small cells secrete progesterone,
steroidogenesis appears to be controlled by different regulatory pathways. In vitro
studies have shown that large luteal cells produce higher amounts of progesterone in
the absence of LH stimulation than small cells (Brannian et al., 1993; Ursely and
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Leymarie, 1979). However, physiological doses of LH stimulate small luteal cells to
synthesise progesterone whilst eliciting only a modest response from the large luteal
cells.
1.1.4 Function of the corpus luteum
1.1.4.1 Steroidogenesis
The first reaction in steroidogenesis is the conversion of cholesterol to pregnenolone.
This conversion is catalysed by the cytochrome P450 side chain cleavage (P450scc)
enzyme in complex with adrenodoxin and adrenodoxin reductase. P450scc has been
immunolocalised to both large and small luteal cells in the bovine CL (Rodgers et al.,
1986a) and luteal content of P450scc has been characterized throughout the bovine
oestrous cycle. Levels ofP450scc and its electron donor adrenodoxin in the developing
CL are not different from follicular concentrations. However, subsequent luteal
maturation leads to a substantial increase in the tissue content of luteal P450scc in
parallel with changing progesterone production, followed by a decline associated with
luteolysis (Rodgers et al., 1986b). Expression of mRNA encoding P450scc and
adrenodoxin has been demonstrated in the bovine corpus luteum during luteal growth
and development, and was undetectable during luteal regression (Rodgers et al., 1987).
Steroid hormone biosynthesis is regulated by both the levels of regulatory enzymes
and substrate availability. Steroid secreting cells may derive cholesterol from the
uptake of lipoprotein cholesterol extracted from the circulation, from intracellular
cholesterol ester stores, or by de novo synthesis. Bovine luteal cells have been shown
to depend on lipoproteins as the cholesterol source for progesterone synthesis
(O'Shaughnessy and Wathes, 1985). Low density (LDL) or high-density (HDL)
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lipoproteins transport the majority of blood cholesterol, and the lipoprotein class
utilised appears species-specific. In the cow both LDL and HDL are able to stimulate
progesterone production (Carroll et al., 1992), although LDL may be the preferred
lipoprotein (O'Shaughnessy and Wathes, 1985).
P450scc activity was considered the rate-limiting step in steroid hormone biosynthesis.
However, recent observations have indicated that the acute regulation of steroids is
indispensably regulated by the actions of a protein involved in substrate delivery.
P450scc is located within the inner mitochondrial membrane: therefore, steroid
precursors must firstly be transported to the outer mitochondrial membrane and then
across the intermembrane space to the inner membrane. This intra-mitochondrial
transport is facilitated by the actions of a protein namely the steroidogenic acute
regulatory (StAR) protein (Clark and Stocco, 1996). StAR mRNA and the protein
product have been detected in bovine luteal homogenates. StAR mRNA abundance is
low in developing bovine CL, elevated in the mid-to late-luteal phase and virtually
absent in regressing CL (Pescador et al., 1996).
Pregnenolone produced by the actions ofP450scc must travel from the mitochondria to
be converted to progesterone in the SER. The final steps in progesterone biosynthesis
are performed by 3-p-hydroxysteroid dehydrogenase/ A 4-5 isomerase (3P-HSD). This
enzyme is bi-functional, catalysing the dehydrogenation and isomerisation of A-5, 3-p
hydroxysteroid precursors into A-4, 3-ketosteroids (Penning, 1997).
3P-HSD mRNA, protein product and enzymatic activity have been characterised in the
bovine ovary. Prior to ovulation, bovine follicles display low and constant 3p-HSD
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activity. However, shortly after oestrus 3P-HSD levels undergo a marked increase,
reaching maximal levels on days 8-11, before declining dramatically coincident with
luteal regression (Couet et al., 1990).
The changing levels of steroidogenic enzymes may offer an explanation for the marked
changes in progesterone secretion during the oestrous cycle. However, studies
following induced luteolysis do not support the hypothesis that the decline in
progesterone associated with regression is due to a reduction in tissue concentrations
of P450scc or 3{3-HSD (Rodgers et al., 1995). Whilst mRNA levels have been shown
to decline, the authors argued that since P450scc and 3p-HSD enzymes have long half
lives, changes in their mRNA levels do not cause a sufficiently rapid reduction in the
tissue content of the enzymes to be responsible for the decline in plasma progesterone
concentrations.
Whilst both large and small luteal cells have been shown to possess the necessary
regulatory enzymes for progesterone production, they appear to vary in their secretory
ability. In the absence of hormonal stimulation, basal progesterone production is much
higher in large bovine luteal cells than small luteal cells (Ursely and Leymarie, 1979).
However, the large cells appear less sensitive to LH, requiring supraphysiological
concentrations of LH to achieve stimulation in vitro (Alila et al., 1988; Ursely and
Leymarie, 1979). Ovine large luteal cells possess LH receptors, but at considerably
lower levels than small luteal cells (Fitz et al., 1982). Messenger RNA encoding the
LH receptor was highly expressed in small bovine luteal cells and theca-derived luteal
cells luteinised in culture (Mamluk et al., 1998; Yuan and Lucy, 1996b). Intracellular
levels of cyclic adenosine monophosphate (cAMP) were significantly elevated in ovine
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small luteal cells stimulated by LH. However, LH did not stimulate cAMP levels in
large luteal cells. In addition, treatments that dramatically increased cAMP levels
failed to stimulate large luteal cell progesterone production. This suggests that large
luteal cell steroidogenesis is independent of elevated cAMP levels, despite the
similarity in protein kinase A activity observed in ovine small and large cells (Hoyer et
al., 1984; Wiltbank etal., 1989).
1.1.4.2 Biological functions of progesterone
The primary function of the corpus luteum is to secrete progesterone, which has a
range of effects on the reproductive tract that are essential for pregnancy (Graham
and Clarke, 1997).
Progesterone influences events from early in gamete transport, regulating oviductal
contractility and secretory activity that support early development of the conceptus
and the timing of its delivery to the uterus. Once within the uterus progesterone has
an important, if incompletely understood, role in the preparation and support of
implantation, with actions on both the uterine environment and the blastocyst. In the
event of successful fertilisation, transport and implantation, progesterone secreted by
the rescued corpus luteum continues to support uterine growth and function. In
addition, it inhibits contractions of the myometrium, which if unopposed could result
in the expulsion and subsequent loss of the growing foetus.
1.1.5 Hormonal control of luteal function
Regulation of luteal function and lifespan involves a number of hormonal factors
produced outside of the ovary. The adenohypophysis, or anterior pituitary gland, in
response to GnRH signals from the hypothalamus, secretes LH which is considered
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the primary luteotrophic hormone in most species. If pregnancy occurs the corpus
luteum is maintained in response to the presence of the conceptus. However, in the
absence of conception the corpus luteum must undergo morphological and functional
regression, so releasing the inhibition on follicular development and ovulation,
allowing the next cycle of follicle development to begin, and so creating the next
chance for fertilisation. In non-primate species the uterus produces this luteolytic
signal.
1.1.5.1 Luteinising hormone
Early experiments in the ewe suggested that pituitary hormones were not obligatory
in the formation and maintenance of corpora lutea. However subsequent studies have
shown that the removal of pituitary gland early after ovulation can prevent CL
formation, and hypophysectomy on day 5 causes luteolysis (Kaltenbach et al., 1968),
therefore supporting a positive role for one or more pituitary products.
The pituitary hormones LH and prolactin are both candidate luteotrophs. Prolactin
has been shown to be an important luteal regulator in several rodent species. The
maintenance of luteal function following prolactin therapy in hypophysectomised-
hysterectomised ewes suggested that prolactin may also be an important regulator in
ruminants (Denamur et al., 1973). However, subsequent prolactin depletion studies
showed no concurrent diminishment of luteal function in sheep and cattle (Hoffman
et al., 1974; Niswender, 1973). In addition, prolactin infusions could not stimulate
luteal steroidogenesis or lifespan, and were unable to overcome the inhibitory effects
of oxytocin (Donaldson et al., 1965).
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In contrast, a range of evidence supports the role of LH as the primary luteotroph in
ruminants (Hansel and Seifart, 1967). Administration of LH can prolong the lifespan
of the corpus luteum (Donaldson and Hansel, 1965b; Karsch et al., 1971), whilst
administration of antiserum to LH reduces luteal weight and progesterone content
and can induce luteolysis (Fuller and Hansel, 1970; Snook et al., 1969). In addition,
LH stimulates luteal progesterone in vivo (Carlson et al., 1971) and in vitro when
incubated with luteal cells or slices (Seifart and Hansel, 1968).
1.1.5.1.1 Mechanism of action of LH
Binding of LH to its membrane-bound receptor causes the activation of two second-
messenger systems leading to a biological response (Davis et al., 1996). Cyclic AMP
is considered the primary intracellular mediator of LH action in the corpus luteum,
and is synthesised from adenosine triphosphate (ATP) by the enzyme adenylate
cyclase. The gonadotrophin receptors are members of the super-family of G-protein-
coupled, seven transmembrane receptors (McFarland et al., 1989). Functionally
these receptors are characterised by interactions with a guanosine triphosphate
(GTP)-binding regulatory protein (or G-protein) upon hormone binding which
couples the activated receptor to adenylate cyclase.
In its inactive form the stimulatory G-protein (Gs) binds guanosine diphosphate
(GDP). When activated by binding to a receptor-hormone complex the guanyl-
nucleotide binding site is altered, allowing GDP to be replaced by GTP. The binding
of GTP causes a further conformational change, resulting in the dissociation of
heterotrimeric G proteins into a subunits and (3y dimers. The GTP-bound a-subunit
then binds to the catalytic component of adenylate cyclase, which is subsequently
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activated to produce cAMP. Following a short period of G-protein activation, Gs
hydrolyses bound GTP to GDP, dissociates from adenylate cyclase, reassociates with
the Py dimer and returns to its inactive form (Taussig and Gilman, 1995).
Intracellular cAMP, the product of adenylate cyclase activation, in turn stimulates
protein-kinase A (PKA). It is also rapidly destroyed by one or more cAMP
phosphodiesterases which hydolyze cAMP to adenosine monophosphate. The
binding of cAMP causes the dissociation of the regulatory (R) subunits of protein
kinase A from its catalytic (C) subunits, enabling the free C-subunits to
phosphorylate target proteins. C-subunits phosphorylate serine and threonine
residues when recognised as part of a target sequence present in a number of
cytosolic and nuclear proteins: the serine/threonine residue must be downstream
from a pair of basic amino acids, separated by a single neutral amino acid
(Spaulding, 1993). A major role of protein kinase phosphorylation is the regulation
of transcription factor activity. Active PKA modulates nuclear factors which bind to
cAMP-responsive elements (CREs) in the promoter regions of cAMP-inducible
genes, resulting in either the activation or inhibition of transcription. CRE-binding
factors, which include CRE-binding proteins (CREB), CRE modulator (CREM) and
activating transcription factor-1 (ATF-1) are members of the basic region/ leucine
zipper (bZIP) transcription factor class, some of which can also interact with
components of the protein kinase C pathway (Lalli and Sassone-Corsi, 1994;
Spaulding, 1993).
LH stimulates multiple signal transduction pathways. In addition to adenylate
cyclase mediated events, LH also activates inositol phospholipid-specific
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phospholipase C (PLC). PLC generates two second-messengers, inositol
triphosphate (IP3) and diacylglycerol (DAG). IP3 acts to release Ca2+ from
intracellular calcium stores. DAG can be cleaved to release arachidonic acid which
can itself act as a messenger or be utilised in eicosanoid synthesis. However, its
major role is the activation of a crucial serine/threonine protein kinase, Ca2+
dependent protein kinase C (PKC) (Newton, 1995). Jun and Fos proteins are targets
of activated PKC phosphorylation, and can dimerize to form the nuclear factor AP-1.
AP-1 in turn binds to TPA (12-O-tetradecanoylphorbol-13-acetate) responsive
elements (TREs) present in the promoters of various genes to regulate their
expression (Karin and Hunter, 1995).
1.1.5.2 Follicle Stimulating Hormone
LH is secreted in a pulsatile manner, and causes the pulsatile release of progesterone
in response. However, the frequency of progesterone pulses exceeds that of LH, and
led to the suggestion that progesterone secretion was not solely under LH-control
(Hixon et al., 1983). Indeed, almost all pulses of Follicle Stimulating Hormone
(FSH) were associated with progesterone release, suggesting that FSH may be a
principle regulator of progesterone secretion (Walters et al., 1984). In addition to
this temporal relationship, binding characteristic of FSH receptors has been detected
in the bovine CL (Manns et al., 1984). However, whilst FSH stimulated
progesterone release by granulosa cells, FSH has not been shown to have a direct
luteotrophic effect (Hansel et al., 1973). Indeed, early studies of FSH receptor
binding and activation which suggested a possible role for FSH in stimulating luteal
function utilised preparations of FSH that were contaminated with LH. More recent
studies suggest that the corpus luteum is not under the influence of FSH. Low levels
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of mRNA encoding the full-length FSH-receptor have been detected in the bovine
CL on day 1. However, by day 3 no full-length transcripts were detectable. Splicing
of the FSH-receptor primary transcript was also observed in granulosa cells
luteinised in vitro. The loss of full-length FSH-receptor transcripts associated with
luteinisation is likely to prevent FSH action (Rajapaksha et al., 1996).
1.1.5.3 Prostaglandins
Corpora lutea have been shown to produce prostaglandins PGI2 and PGE2 (Rodgers et
al., 1988), which stimulate progesterone secretion by luteal cells in vitro (Alila et al.,
1988; Milvae and Hansel, 1980). A regulatory role for these prostaglandins is further
supported by the demonstration of PGI2 and PGE2 binding sites in the bovine CL
(Chegini et al., 1991).
Bovine luteal cells also secrete PGF2a and production is greatest in the early luteal
phase (Del Vecchio and Sutherland, 1997; Milvae and Hansel, 1983; Rodgers et al.,
1988). Binding sites for PGF2a have been detected in the bovine corpus luteum and
were predominantly localised to large luteal cells (Chegini et al., 1991). In ovine
corpora lutea, mRNA encoding the PGF2a (FP) receptor was also largely limited to
large steroidogenic cells (Juengel et al., 1996; Tsai et al., 1998). In the cow, mRNA
encoding PGF2a was present in both large and small steroidogenic luteal cells and
endothelial cells, with greatest expression detected in large luteal cells (Mamluk et al.,
1998). Whilst the role of uterine PGF2a in luteolysis is established (see section 1.1.6.2),
PGF2a has also been shown to stimulate progesterone release, suggestive of a
luteotrophic role for luteal PGF2a (Miyamoto et al., 1993).
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Administration of the prostaglandin synthetase inhibitor indomethacin, early in the
cycle reduced progesterone secretion and luteal lifespan, indicating that prostaglandins
are required for early luteal development and function (Milvae and Hansel, 1985). This
correlates with the observation that luteal biosynthesis of prostaglandins is highest
during the early luteal phase (Rodgers et al., 1988).
The vasodilatory effects of prostaglandins may also influence luteal function, by
altering blood flow and luteotrophin supply.
1.1.5.4 Oxytocin
Oxytocin is a major luteal peptide product in cattle and sheep. Whilst there is
considerable evidence to support a role for oxytocin in control of luteal regression, the
evidence indicating a role for oxytocin in luteinisation and luteal steroidogenesis
remain inconclusive.
Bovine granulosa cells isolated from the preovulatory follicle show a dramatic increase
in oxytocin mRNA expression in response to the LH surge (Voss and Fortune, 1992).
Indeed, oxytocin gene expression is considered a marker of luteinisation (Smith et al.,
1994c). Oxytocin mRNA and protein have been localised to the large steroidogenic
cells of the bovine corpus luteum (Fehr et al., 1987; Fields et al., 1992). Luteal
oxytocin mRNA peaks around days 1-3, whilst oxytocin concentrations are maximal in
the mid-luteal phase (Fehr et al., 1987; Jones and Flint, 1988).
Oxytocin has been suggested to have direct effects on luteal progesterone release. An
inhibitory effect of high doses of oxytocin on steroidogenesis in bovine luteal cells of
early pregnancy has been demonstrated (Tan et al., 1982), and oxytocin infusions
during the early luteal phase inhibited luteal development (Wathes et al., 1991). Others
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have reported limited effects of oxytocin on luteal cell progesterone production
(Hansel and Dowd, 1986; Rodgers et al., 1985). In further contrast, intraluteal
administration of oxytocin using microdialysed bovine corpora lutea stimulated
progesterone in a dose dependant manner, and was most effective during the early to
mid-luteal phase (Miyamoto and Schams, 1991). A luteotrophic role for oxytocin is
supported by the detection of oxytocin receptors in the bovine CL, which display
maximal binding in the mid-luteal stage (Okuda et al., 1992).
1.1.6 Luteolysis
Luteal regression or "luteolysis" occurs at the end of the luteal phase of the non¬
pregnant ovarian cycle, and also at the end of pregnancy. This loss of luteal function is
characterised by decreased progesterone secretion, followed by breakdown of luteal
tissue.
1.1.6.1 Role of the uterus
The importance of the uterus in luteolysis was first recognised by Loeb, who
demonstrated that hysterectomy resulted in extension of luteal lifespan in guinea
pigs (cited by McCracken et al., 1999). Hysterectomy has since been shown to cause
maintenance of luteal function in the cow, pig, sheep, mare and the pseudopregnant
hamster, rat and rabbit (Andersen et al., 1969; Wiltbank and Casida, 1956).
However, in a number of other species the uterus is not required for luteolysis to
occur. Hysterectomy does not cause luteal maintenance in a number of primate
species, including women and rhesus and cynomologous monkeys, the dog, the
opossum or the ferret (Andersen et al., 1969; Beling et al., 1969; Castracane et al.,
1979; Neill et al., 1969).
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In most species where hysterectomy demonstrated a uterine involvement in
luteolysis, the effect was unilateral. Removal of the uterine horn adjacent
(ipsilateral) to the ovary bearing the CL prevented luteal regression. However,
removal of the uterine horn contralateral to the CL did not lengthen luteal lifespan,
demonstrating that uterine effects on the ovary were via local rather than systemic
pathways (Andersen et al., 1969). In addition, autotransplantation of either the ovary
or the uterus to the neck, extended luteal function in ewes, whilst transplantation of
the one uterine horn and the adjacent ovary with associated blood system maintained
normal ovarian cyclicity (Harrison et al., 1968). In the rabbit and the mare, the
uterine luteolysin may be mediated systemically (Ginther and First, 1971; Hunter
and Casida, 1967).
The local transport of a uterine luteolysin to the corpus luteum in the sheep and cow is
via a veno-arterial countercurrent system. The uterine factor appears to pass from the
uterine vein to the ovarian artery directly, despite a lack of vascular connections
between the two vessels. The ovarian artery is highly convoluted, and is closely
apposed to the uterine vein, creating extensive regions of contact. Surgical
manipulations of the veno-arterial system support the theory that a factor borne by the
uterine venous output causes regression of the ipsilateral corpus luteum. In addition,
ovine uterine venous plasma collected around the time of luteolysis reduces
progesterone secretion following infusion into the ovarian artery (Caldwell and Moor,
1971).
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1.1.6.2 Nature of the luteolytic factor
Elevated PGF2a concentrations in uterine venous output (Baird et al., 1976),
endometrial tissue (Shemesh and Hansel, 1975) and uterine flushings (Bartol et al.,
1981) are temporally associated with falling progesterone and expected luteolysis.
Exogenous administration of PGF2a causes premature luteal regression in cattle and
sheep (McCracken et al., 1970; Rowson et al., 1972; Thorburn and Nicol, 1971),
whilst inhibition of uterine prostaglandin synthesis prevents spontaneous luteolysis,
and maintains luteal weight and plasma progesterone concentrations (Lewis and
Warren, 1977). In addition, immunisation of cyclic ewes against PGF2a prolongs luteal
maintenance (Scaramuzzi and Baird, 1976), suggesting that prostaglandin, in particular
PGF2a is required for luteolysis, thus providing further evidence that PGF2a is the
natural luteolysin.
1.1.6.3 Secretion of PGF2a
In the ewe, the first significant increases in PGF2a concentrations in utero-ovarian
venous blood occur on days 12-14 (Baird et al., 1976), and the primary PGF2a
metabolite 15-keto-13, 14 dihydro PGF2a(PGFM) is detectable in bovine plasma and
uterus, at increasing concentrations from around day 14 (Parkinson and Lamming,
1990; Shemesh and Hansel, 1975). PGF2a secretion is pulsatile, and PGF2a is released
from the uterus in a series of pulses which are typically 6-8 hours apart. Low level
PGFM episodes can be detected on day 14 (Parkinson and Lamming, 1990), the
amplitude of pulses of PGFM are markedly increased during luteolysis and in contrast
are inhibited in the pregnant animal (Kindahl et al., 1984).
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1.1.6.4 Regulation of uterine secretion of PGF2a
1.1.6.4.1 The role of oxytocin
Uterine secretion of PGF2o can be stimulated by oxytocin (Laffance and Goff, 1990;
Roberts and McCracken, 1976). Oxytocin is released primarily from the corpus luteum
(Hooper et al., 1986) where it is stored in large luteal cell secretory granules. Around
the time of luteolysis, spontaneous episodes of PGF2a secretion occur concurrently
with elevated oxytocin concentrations (Hooper et al., 1986; Vighio and Liptrap, 1986).
In addition, immunoneutralisation of oxytocin in ewes significantly extended the
oestrous cycle, reflecting prolonged luteal lifespan (Sheldrick et al., 1980), and
exogenous administration of oxytocin causes premature luteolysis (Armstrong and
Hansel, 1959), providing support for a regulatory role for oxytocin in luteolysis.
Furthermore, the observation that ovarian secretion of oxytocin is stimulated by
prostaglandin analogue (Flint and Sheldrick, 1982) has led to the suggestion that a
positive feedback loop exists between the two hormones (Flint and Sheldrick, 1983).
Uterine PGF2a initiates luteal oxytocin release (Moore et al., 1986), which
subsequently stimulates further PGF2ct release from the uterus. Pulsatile secretion may
be established by a combination of effects, with the interval between episodes
determined by transient uterine refractoriness to further oxytocin stimulation, luteal
desensitisation to PGF2a, and depletion of oxytocin stores or PGF2a precursors (Flint et
al., 1990; Silvia et al., 1991).
However, others have failed to demonstrate both a role for oxytocin in modulating
luteal function in vivo, as determined by cycle length, luteal weight and progesterone
concentration (Milvae et al., 1991), and a link between PGF2a and oxytocin in vitro
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(McCann and Flint, 1990). Furthermore, frequent sampling of ovine uterine-ovarian
venous output demonstrated that whilst most pulses of PGF2a coincided with a pulse of
oxytocin, a number of oxytocin pulses occurred in the absence of a PGF2a pulse
(Hooper et al., 1986). In the ewe, surgical lutectomy did not affect the frequency of
pulsatile PGF2a release, although pulse amplitude was reduced (Mann and Lamming,
1995), and depletion of oxytocin stores did not affect luteolysis or length of the
oestrous cycle in cattle (Kotwica and Skarzynski, 1993).
Oxytocin is synthesised de novo in the ruminant corpus luteum. Messenger RNA
encoding oxytocin is expressed at high levels in the early luteal phase and declines
thereafter (Fehr et al., 1987; Ivell et al., 1990; Jones and Flint, 1988), whilst oxytocin
concentrations peak at mid-cycle, and decline during the late luteal phase, prior to
functional regression (Jones and Flint, 1988; Wathes et al., 1984;). Indeed the lack of
temporal association between maximal oxytocin levels and luteolysis seems
paradoxical in light of oxytocins' expected role in luteolysis.
In order that oxytocin can stimulate PGF2a release, the uterus must acquire
responsiveness to oxytocin. Uterine sensitivity develops during the late luteal phase
(Roberts et al., 1976; Silvia and Taylor, 1989) and is the likely product of increased
oxytocin receptors (Fuchs et al., 1990; Roberts et al., 1976), increased PGF2aprecursor
utilisation (Silvia et al., 1991), and PGF2a synthetic capacity (Basu and Kindahl, 1987).
1.1.6.4.2 The role of steroids
The timing and extent of PGF2ct production are thought to be further regulated by the




Supplemental progesterone administration in the early luteal phase induces premature
PGF2a release and subsequent luteolysis in sheep and cows (Ginther, 1970; Ottobre et
al., 1980), whilst luteal regression is delayed following progesterone antagonist
treatment. Furthermore, progesterone priming is required in order for oxytocin to
stimulate uterine PGF2a secretion in ovariectomised cows or ewes (Homanics and
Silvia, 1988; Lafrance and Goff, 1988).
Progesterone regulates the capacity of the uterus to synthesise prostaglandins, by
increasing precursor accumulation (Brinsfield and Hawk, 1973) and prostaglandin
synthase/ cyclooxygenase concentration and activity (Raw et al., 1988). Whilst
progesterone increases the synthetic capacity of the uterus to produce prostaglandins,
luteal phase levels may prevent the premature release of PGF2a. This effect is proposed
to be the result of progesterone inhibiting oestradiol receptor formation, and hence
oestradiol-dependant up-regulation of the oxytocin receptor. The inhibitory effect of
progesterone is thought to be lost in the late luteal phase, allowing increased uterine
responsiveness to oxytocin at an appropriate time (McCracken et al., 1999). Indeed,
progesterone withdrawal during the late luteal phase has been shown to stimulate
uterine PGF2a secretion, and oxytocin receptor numbers increase following the loss of
progesterone action (Leavitt et al., 1985).
1.1.6.4.2.2 Oestradiol
Oestradiol also appears to regulate uterine PGF2a secretion, and the stimulatory effects
of oestradiol can be further enhanced by a prior period of progesterone priming
(Homanics and Silvia, 1988; Laffance and Goff, 1988).
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Oestradiol may up-regulate prostaglandin synthesis by increasing both the release of
arachidonic acid from phospholipids by the enzyme phospholipase A2 (PLA2) and the
conversion of arachidonic acid to PGF2aby PG synthase (Raw et al., 1988). However,
the treatment of ovariectomised ewes with oestradiol-17(3 markedly reduced mRNA
encoding prostaglandin synthase in the ovine endometrium (Salamonsen et al., 1991).
In addition, oestradiol is thought to enhance the uterine response to oxytocin
stimulation, an effect that may be mediated by increased oxytocin receptors (Nissenson
et al., 1978).
Whilst both progesterone and oestradiol have been implicated in the control of uterine
PGF2a secretion, and are thought to regulate oxytocin receptor concentration, there is
little evidence for direct steroid stimulation of the oxytocin receptor gene (Ivell and
Walther, 1999). Indeed, detailed analysis of the oxytocin receptor gene in a range of
species has failed to find functional response elements for either oestrogen or
progesterone.
The expression of oxytocin receptors may also be regulated by specific non-genomic
actions of sex steroids. In the rat uterus, progesterone directly inhibits oxytocin-
binding and signal transduction, without interacting with nuclear receptors (Grazzini et
al., 1998). However, this effect may prove to be highly species-specific (Ivell and
Walther, 1999).
1.1.6.5 Mechanism of PGF2aaction
1.1.6.5.1 Receptors
Prostaglandin binding sites have been identified on luteal cells of both cattle (Powell et
al., 1975) and sheep (Balapure et al., 1989), and two classes of receptor can be
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distinguished on the basis of affinity and capacity for PGF2a. Large ovine luteal cells
possess predominantly high affinity binding sites, whilst PGF2c( binds small luteal cells
with low affinity (Balapure et al., 1989). PGF2a binding sites are also more numerous
in large luteal cells (Chegini et al., 1991). High affinity binding PGF2ct activity is
increased during the late luteal phase in bovine corpora lutea (Rao et al., 1979) and
luteal cells (Chegini et al., 1991), and PGF2a receptor mRNA follows the same pattern
(Sakamoto et al., 1995).
The identification of specific luteal receptors for PGF2a supports a role for PGF2a
acting directly on luteal cells. However, whilst PGF2ct is clearly luteolytic in ruminants
in vivo, studies in vitro have provided inconsistent results. Indeed, PGF2a has been
shown to both stimulate (Speroff and Ramwell, 1970) and inhibit (Wiltbank et al.,
1990) luteal progesterone production.
1.1.6.5.2 Multiple sites of action
PGF2a is thought to have multiple sites of action (Auletta and Flint, 1988; McCracken
et al,. 1999; Michael et al., 1994), and can inhibit a range of steroidogenic responses to
LH. LH receptor numbers are reduced following luteal regression (Garverick et al.,
1985), however, the PGF2a-stimulated reduction in progesterone has been shown to
occur before a decline in occupied or unoccupied LH receptors (Diekman et al., 1978).
The LH receptor was thought to become "uncoupled" from adenylate cyclase in
response to PGF2a as demonstrated by decreased adenylate cyclase activity in day 19
bovine CL (Garverick et al., 1985). It has also been proposed that the decrease in
adenylate cyclase activity during luteolysis may be the result of altered interactions of
the enzymes regulatory and catalytic subunits (Agudo et al., 1984). The concurrent
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increase in phosphodiesterase activity may additionally reduce cAMP levels, and
hence alter the response to LH stimulation (Garverick et al., 1985). Alterations in
membrane fluidity associated with luteolysis and loss of cell function may also
influence receptor-mediated events (Carlson et al., 1982; Goodsaid-Zalduondo et al.,
1982).
PGF2(i may also exert actions subsequent to cAMP generation, and a primary target
may be cholesterol transport. PGF2a causes inhibition of luteal steroidogenesis that
results in part from reduced utilisation of lipoprotein substrate (Wiltbank et al., 1990).
Messenger RNA encoding StAR, which facilitates cholesterol transport across the
mitochondrial membrane, was significantly reduced within 12 hours of induced
regression in ewes (Juengel et al., 1995). A similarly rapid decline in StAR mRNA
was observed in the bovine CL, with levels becoming undetectable after 24 hours,
whilst levels of P450scc mRNA decreased more slowly (Pescador et al., 1996). In
addition to effects prior to pregnenolone production, PGF2a has also been shown to
markedly reduce 3P-HSD mRNA concentrations (Flawkins et al., 1993), which is in
agreement with the dramatic fall observed around the time of natural luteolysis (Couet
et al., 1990).
An alternative means of action for PGF2ct to induce luteolysis was thought to be
alterations in luteal blood flow, and subsequent hypoxia. Decreased luteal blood flow
has been demonstrated during natural and PGF2a-induced luteolysis (Ford and
Chenault, 1981; Nett et al., 1976). However, blood flow reduction is not thought to
initiate functional luteal regression, but may play a role in structural luteolysis.
(McCracken et al., 1999).
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The cellular mechanisms of PGF2a inhibition are thought to be mediated by an increase
in intracellular calcium concentration, which can be cytotoxic to luteal cells (Hansel et
al., 1991), and can also cause activation of the calcium dependant PKC (Michael et al.,
1994; Wiltbank et al., 1991j.
1.1.6.6 Local PGF2a production in the corpus luteum
The corpus luteum contains substantial levels of arachidonic acid (Lukaszewska and
Hansel, 1980) and has the ability to convert arachidonic acid to PGFs (Milvae and
Hansel, 1983). However, luteolysis is not temporally associated with high levels of
luteal PGF2a production (Milvae and Hansel, 1983). In contrast, some cytokine
products of immune cells which increase around the time of luteolysis such as
interferon (IFN)-y, tumour necrosis factor (TNF)-a, and interleukin (IL)-1 (3, can
stimulate luteal cell PGF2a production, and may play autocrine/ paracrine regulatory
roles (Fairchild and Pate, 1991; Fairchild Benyo and Pate, 1992; Nothnick and Pate,
1990).
Interest in the ability of accessory cells of the corpus luteum such as endothelial cells,
fibroblasts, pericytes and macrophages to modulate corpus luteum function is
increasing. Luteal cells cultured in the presence of accessory cells show elevated PGF2a
synthesis (Del Vecchio and Sutherland, 1997). In addition, there is considerable
evidence to support a role for an endothelial cell product, endothelin-1 (ET), in
mediating the luteolytic actions of PGF2a. ET content in the bovine CL was highest on
days 17-21 of the cycle, and ET-1 mRNA was significantly increased around the time
of luteolysis (Girsh et al., 1996b). PGF2a rapidly increased luteal ET-1 mRNA, when
administered to heifers, or luteal slices in vitro, and the endothelial cells of bovine
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luteal microvessels respond to PGF2a with increased ET production and expression
(Girsh et al., 1996a, 1996b). ET-1 production was also elevated in response to
oxytocin (Girsh et al., 1996b). ET-1 is thought to mediate the response of CLs to
PGF2a, since ET-1 suppressed progesterone release from both bovine corpus lutea
microdialysed in vitro (Miyamoto et al., 1997), and granulosa and theca cells
luteinised in culture (Girsh et al., 1996a). In addition, the inhibitory effect of PGF2a on
LH-stimulated progesterone secretion was prevented by the addition of an ET receptor
antagonist (Girsh et al., 1996a). The ET-1 receptor gene is expressed by small and
large steroidogenic luteal cells, and luteal endothelial cells, and is maximal during
luteal regression (Mamluk et al., 1999). ET-1 may act directly to reduce the
progesterone production by steroidogenic cells, and may in addition contribute to a
reduction in luteal blood flow, since ET-1 is a potent vasoconstrictor.
1.1.6.7 Role for immune cells in luteal regression
A potential role for immune cells in luteal regression has long been recognised,
following the detection of an influx of leukocytes into the corpus luteum around the
time of luteolysis. However, whilst immune cells were thought to be primarily
phagocytotic, involved in the removal of cell debris associated with regression, they
are now thought to have more active luteolytic functions (Pate, 1995).
Immune cell populations have been detected in corpora lutea from a range of species
including guinea pig, rabbit, pig, mare, human and cattle (Bagavandoss et al., 1988;
Duncan et al., 1998b; Lawler et al., 1994; Paavola, 1979; Spanel-Borowski et al.,
1997; Standaert et al., 1991), and a number of studies have demonstrated increased
immune cell numbers prior to luteolysis. The stimulus for macrophage migration is
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undefined. However there is increasing interest in a specific chemoattractant for
monocytes/ macrophages namely monocyte chemoattractant protein (MCP-1). MCP-
1 mRNA is expressed in the corpora lutea of pigs, rats, sheep, cattle and women
(Haworth et al., 1998; Hosang et al., 1994; Penny et al., 1998; Senturk et al., 1999;
Townson et al., 1996) and is increased during functional luteolysis. In addition to
this temporal correlation, the administration of exogenous luteolytic stimuli induces
MCP-1 expression in the corpora lutea of sheep, rats and cattle (Bowen et al., 1996;
Tsai et al., 1997).
Changes in the expression of cell surface glycoproteins, the major histocompatibility
complex (MHC) molecules, may be important for immune cell activation within the
corpus luteum. Luteal cells of the early bovine CL (day 6) express Class I MHC
molecules, but exhibit limited Class II MHC expression. However, Class II MHC
expression increases during the oestrous cycle, and maximal expression was
observed prior to luteolysis. Class II MHC expression can be induced following
PGF2a administration and is significantly reduced in corpora lutea of pregnancy
(Fairchild Benyo et al., 1991).
The expression of Class II MHC molecules is largely restricted to antigen-presenting
cells, and is involved in antigen recognition. Hence, it is thought that the luteal cell
expression of Class II MHC molecules may stimulate an immune response, despite
the non-immune cell location. Indeed, bovine luteal cells can stimulate T-cell
proliferation in a Class Il-restricted manner, and the proliferative response was
greatest in the presence of cells from regressing corpora lutea (Petroff et al., 1997).
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Secreted products of activated immune cells can have important effects on luteal cell
function. Cytokines can be directly cytotoxic, can inhibit progesterone production
and can stimulate luteal cell prostaglandin production (Pate and Townson, 1994).
Immune cells have also been implicated in the regulated production of reactive
oxygen species (ROS) which may further mediate luteolytic events. Indeed activated
leukocytes are among the most potent generators of ROS. ROS such as the
superoxide anion (O2") and hydrogen peroxide (H2O2), and lipid peroxides (formed
by the actions of ROS on polyunsaturated fatty acids) are generated in the rat CL at
luteolysis (Riley and Behrman, 1991; Sawada and Carlson, 1991; Shimamura et al.,
1995). In addition, levels of the protective antioxidant ascorbic acid (Vitamin C) are
reduced in response to PGF2a. This rapid depletion of ascorbic acid is the result of
PGF2a inhibiting ascorbic acid uptake from the circulation, combined with increased
luteal cell ascorbic acid secretion (Musicki et al., 1996). The corpus luteum has
other mechanisms to protect against ROS damage, that include degradative enzyme
activity, antioxidant Vitamin E, and radical scavengers such as the carotenoids (Aten
et al., 1992; Chew et al., 1984).
ROS have several luteal sites of action, damaging the plasma membranes of luteal
cells (Wu et al., 1993), and inhibiting rat luteal cell steroidogenesis. The anti-
steroidogenic effect may result from the inhibition of adenylate cyclase activation,
impaired delivery and utilisation of steroid precursors, and inhibition of protein
synthesis (Behrman and Aten, 1991; Behrman and Preston, 1989; Kodaman et al.,
1994; Musicki et al., 1994). Whilst ROS can clearly influence important aspects of
luteal function directly, they may stimulate other effector systems with luteolytic
results.
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The heat shock proteins (Hsp) may form such a system, and are produced in
response to ROS in other cells (Heufelder et al., 1992). Hsp 70 is induced in the
corpora lutea of rats and sheep following either exogenous PGF2a or natural
luteolysis (Khanna et al., 1995a; Murdoch, 1995). A role for Hsp 70 in luteal
regression is further supported by its ability to inhibit rat luteal progesterone
secretion, an effect that is reversed by blocking Hsp synthesis (Khanna et al.,
1995b).
1.1.6.8 Apoptosis in luteolysis
Apoptosis is a form of cell death, distinct from pathological or necrotic cell death,
which serves an important physiological role in the maintenance of tissue
homeostasis (Martin et al., 1994; Steller, 1995; Ueda and Shah, 1994).
Cells undergoing physiological cell death by apoptosis display a series of
characteristic changes. Typically cells shrink and lose cell-cell contacts. Nuclear
condensation creates dense aggregates of chromatin and membrane alterations result
in the fragmentation of the cell into membrane-bound "apoptotic bodies". Apoptotic
cells are commonly phagocytosed, and the removal of cellular debris does not evoke
an inflammatory reaction. Cell death caused by apoptosis is commonly associated
with marked deoxyribonucleic acid (DNA) fragmentation, caused by endonuclease-
mediated internucleosomal chromatin cleavage. The resultant "DNA laddering" is
often used as a marker.
The morphological changes characteristic of the process now known as apoptotic
cell death, were first observed in the ovary over a century ago, and apoptosis is now
thought to be important in perinatal germ cell loss, follicular atresia and luteal
34
regression (Amsterdam and Selvaraj, 1997; Tilly, 1993). Indeed, apoptotic cells have
since been detected in regressing corpora lutea of many species, and endonuclease-
mediated DNA fragmentation has been identified at the time of structural luteal
degeneration (Bacci et al., 1996; Boone and Tsang, 1998; Juengel et al., 1993;
McCormack et al., 1998; Murdoch, 1995; Young et al., 1997; Yuan and Giudice,
1997; Zeleznik et al., 1989).
The fate of ovarian cells is thought to be determined by the complex interplay of
survival factors and apoptotic signals. The gonadotrophins are crucial to the growth
and development of follicles. Reduced gonadotrophin concentrations induce
follicular apoptosis, whilst gonadotrophin treatment is anti-apoptotic, suggesting that
FSH and LH act as follicle survival factors (Chun et al., 1994, 1996). The treatment
of ovarian cells in culture with serum deprivation has identified numerous additional
factors that can regulate cell survival when replaced in vitro. Ovarian steroids,
glucocorticoids, ECM components and a range of growth factors and cytokines (e.g.
IGF-I, epidermal growth factor (EGF), transforming growth factor (TGF)a, bFGF,
IL-1 (3, IL-6) may all influence apoptotic pathways (Amsterdam et al., 1999; Hsu and
Hsueh, 1997).
Apoptotic pathways (White, 1996) appear to be well-conserved across species from
the nematode Caenorhabditis elegans to mammals, and among different cell types.
One such well-conserved gene with an important regulatory role in apoptosis is the
proto-oncogene bcl-2. The protein product of bcl-2 inhibits apoptosis resulting from
a range of stimuli. Several genes related to bcl-2 also encode proteins with key roles
in mediating cell death. BAX interacts with BCL-2 and potentially antagonises its
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protective activity. The BAX: BCL-2 ratio is thought to be critical in determining
susceptibility to cell death. A further member of the bcl-2 gene family bcl-x, is
uniquely processed via alternative splicing, to produce a long and short form with
markedly different regulatory potential: BCL-Xlong has death suppressor activity,
whereas BCL-Xshort inhibits cell survival (Adams and Cory, 1998).
Cell fate is further influenced by the products of tumour suppressor genes. The p53
protein can arrest cell-cycle progression following cellular DNA damage, via
alterations in kinase activity. Alternatively, when DNA damage is too extensive to
be repaired, high levels of p53 can induce apoptosis. The mechanism of p53 action
may involve cross-talk with 6c/-2-related genes, since p53 protein can directly
activate bax gene transcription and repress bcl-2 expression. In addition, alterations
in murine double minute-2 (mdm-2) oncogene expression may be important in
controlling a cell's entry into apoptosis, based on the ability of mdm-2 to complex
with the p53 protein and to neutralise p53-mediated transactivation (Evan and
Littlewood, 1998; Oren, 1999).
A family of cytoplasmic proteases are thought to be important executors of cell
death, promoting apoptosis through the degradation of proteins crucial to cellular
integrity. This family comprises of at least ten cysteine proteases or "caspases",
related to the interleukin-ip converting enzyme (ICE), which are structurally and
functionally homologous to the C.elegans death gene ced-3 (Thornberry and
Lazebnik, 1998). Pro-survival proteins such as BCL-Xl0ng may function by
inactivating caspase activity.
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Known regulators of cell death have been localised to corpora lutea undergoing
regression, in addition to the identification of physiological markers of apoptosis.
For example, luteal cells of several species express a number of hc/-2-related genes.
In the bovine corpus luteum, pro-apoptotic bax mRNA expression was significantly
elevated during luteal regression and was accompanied by increased p53 mRNA
levels (Rueda et al., 1997). In the rabbit, withdrawal of luteotropic oestradiol results
in luteal cell apoptosis and a coincident increase in bax mRNA (Goodman et al.,
1998). In contrast, in women luteal BAX production was not altered at luteolysis
(Rodger et al., 1998). Anti-apoptotic bcl-2 family members have also been localised
within the regressing CL, and bcl-x mRNA levels decreased in the rabbit CL
coincident with apoptosis (Goodman et al., 1998). However, limited changes in
BCL-2 protein and longform bcl-x were observed in the human and bovine CL
respectively (Rodger et al., 1995; Rueda et al., 1997). Caspase mRNA and protein
activity has also been detected in luteolytic tissue. A PGF2a-initiated increase in both
caspase-3 mRNA expression and activity was detected in ovine CL (Rueda et al.,
1999) and high levels of caspase-3 have been detected in the human corpus luteum
(Krajewska et al., 1997). Studies in the rat found no difference in the distribution or
intensity of caspase-3 immunostaining in CL that were positive or negative for
apoptosis, however this study did not distinguish between the proenzyme and the
mature activated form of caspase-3 (Boone and Tsang, 1998). Whilst in the cow,
ICE/caspase-1 mRNA levels were significantly higher in day 21 regressed CL than
day 21 functional pregnant CL (Rueda et al., 1997). A role for additional regulatory
pathways such as Fas and Fas ligand (Roughton et al., 1999) and ubiquitin (Murdoch
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et ai, 1996) in luteal apoptosis has also been suggested, although their mechanisms
of action are not well characterised.
1.1.6.9 Structural luteal regression
Luteolysis is characterised by both functional and structural changes. In the absence
of pregnancy the ECM undergoes extensive remodelling to enable the removal of
non-functional luteal tissue. The ECM not only provides a physical structure for
cellular attachment, it can also influence aspects of cellular function. The ECM can
sequester growth factors and their binding proteins and hence influence their
mobilisation. In addition, cell-matrix interactions can directly influence cell
behaviour. The dissolution of matrix components therefore has considerable
regulatory potential (Streuli, 1999).
There is limited information on the composition and organisation of the luteal ECM.
However, the ruminant luteal ECM is thought to be composed primarily of collagen
(types I and IV), fibronectin and laminin (Silvester and Luck, 1999; Zhao and Luck,
1995). Indeed, collagen is a major component of the bovine corpus luteum,
accounting for up to one sixth of luteal dry weight (Luck and Zhao, 1993).
A number of enzymes are responsible for ECM remodelling. These include the
plasminogen activator (PA)/ plasmin system, and the large family of matrix
metalloproteinases (MMPs).
1.1.6.9.1 Plasminogen activators
Two plasminogen activators, the tissue-type PA (tPA) and urokinase-type PA (uPA),
are responsible for converting the zymogen plasminogen into the proteolytically
active enzyme plasmin. Plasmin has fibrinolytic activity, can activate other proteases
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involved in matrix breakdown, and can degrade both laminin and fibronectin. To
prevent uncontrolled tissue destruction, the proteolytic activity of the plasminogen
activator-plasmin system is regulated by the actions of two specific protease
inhibitors, PA inhibitor type 1 (PAI-1) and type 2 (PAI-2).
Plasminogen activators have been identified as luteal secretory products of the
rhesus monkey (Feng et al., 1993), rat (Liu et al., 1995, 1996) and sheep (Smith et
al., 1997), and luteolysis was temporally associated with increased expression of
mRNA encoding rat tPA (Liu et al., 1996). Luteal PA activity is controlled by the
local production of PAI-1, and unexpectedly mRNA encoding PAI-1 also increased
following both prostaglandin induced (Smith et al., 1997) and natural luteolysis (Liu
et al., 1996). However, despite the increase in inhibitor expression, net PA activity
was elevated at the time of luteolysis in the rat and monkey supporting a role for PA
activity in the dissolution of matrix components (Feng et al., 1993; Liu et al., 1995,
1996). It has also been suggested that tPA may play a role in functional luteal
regression, since the addition of tPA to rat luteal cells in culture decreased
progesterone production (Liu et al., 1995), and immunoneutralisation of endogenous
tPA increased progesterone production in the rat and monkey (Feng et al., 1993; Liu
et al., 1995).
1.1.6.9.2 Matrix Metalloproteinases
Considerable attention has focused on the role of matrix metalloproteinases in ECM
degradation in the ovary (Duncan, 2000; Mclntush and Smith, 1998; Smith et al.,
1999). The family of MMPs has at least 17 members, which display different
specificities for ECM proteins. MMPS are largely secreted in a latent proenzyme
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form and undergo proteolytic cleavage to produce the active enzyme. Association
with specific inhibitors, the TIMPs, further regulates MMP activity.
Structural luteolysis induced by prolactin or GnRH agonist treatment caused an
increase in total proteinase activity in the rat CL, and was associated with increased
activated MMP-2 (Endo et al., 1993) and MMP-2 mRNA expression (Goto et al.,
1999). Others have shown that mRNA encoding MMP-13 is uniquely expressed in
the regressing rat CL (Liu et al., 1999). Evidence from human corpora lutea also
supports a role for MMPs in regulating structural luteolysis. MMP-2 activity and
mRNA expression peaked in the late luteal phase. MMP-9 activity was also high
around the time of luteolysis, however MMP-9 levels were also raised in the early
luteal phase suggesting an additional role in luteinisation (Duncan et al., 1998a).
Gelatinase activity has been detected in the developing bovine corpus luteum, and
attributed to MMP-2 and MMP-9 (Goldberg et al., 1995), however, the potential role
ofMMPs in luteal regression has not been addressed.
TIMPs, most notably TIMP-1, have been detected in bovine (Goldberg et al., 1996),
ovine (Smith et al., 1994a), porcine (Smith et al., 1994b), murine (Bagavandoss,
1998), marmoset (Duncan et al., 1996), and human (Duncan et al., 1998a) luteal
tissue. TIMPs are important regulators of MMP activity, and the ratio of TIMPs to
active MMPs largely determines the extent of ECM degradation. Therefore luteal
regression might be expected to be associated with reduced inhibitor levels. In the
marmoset corpus luteum induced luteal regression was correlated with a significant
reduction in mRNA encoding TIMP-1, which may allow for increased ECM
degradation by MMPs (Duncan et al., 1996). In addition, levels of TIMP-1 protein
were reduced in the ovine CL following PGF2a treatment (Mclntush and Smith,
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1997). However, others have failed to demonstrate a correlation between luteolysis
and reduced TIMP concentrations or mRNA expression. In the cow CL
concentrations of mRNA encoding both TIMP-1 and TIMP-2 showed transient
increases following induced luteal regression (Juengel et al., 1994). In the
pseudopregnant rat, luteal TIMP-1 mRNA expression was highest on day 1,
decreased from days 2 to 12, and increased again around the time of luteolysis
(Nothnick et al., 1995). Whilst the proteolytic activity of MMPs must be tightly
regulated, it is unclear why in some species the regressing CL is a site of abundant
TIMP production. However, it has been suggested that since MMPs and TIMPs
occupy different cellular sites, that MMP activity can occur despite the high levels of
inhibitor (Bagavandoss, 1998; Duncan et al., 1998a). Alternatively, the balance of
active MMPs to TIMPs may be further regulated by the destruction of TIMPs, which
may favour ECM degradation. TIMP-1 has been shown to be subject to inactivation
by proteolytic degradation or reaction with oxygen radicals (Frears et al., 1996; Itoh
and Nagase, 1995).
Whilst TIMPs are responsible for much of the MMP-inhibitory activity, broad
spectrum protease inhibitors such as the a-macroglobulin-type inhibitors have also
been shown to contribute to the regulation of MMP activity in the ovary (Nothnick
et al., 1995). Indeed, a2-macroglobulin protein content and mRNA expression
declines in the pregnant rat CL when functional luteolysis occurs at parturition
(Gaddy-Kurten et al., 1989).
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1.1.6.10 Maternal recognition of pregnancy
In the event of pregnancy, the corpus luteum must be maintained. The inhibition of
luteolysis requires the 'maternal recognition of pregnancy' in response to the products
of conception, and subsequent interruption or modification of luteolytic prostaglandin
release (Thatcher et al., 1997).
The critical period for recognition of pregnancy in the cow is around day 16 after
conception. Luteal lifespan is extended despite the removal of bovine embryos on day
17 but not day 15. Furthermore, infusion of day 17 or day 18 embryo homogenates into
the uterine lumen of non-pregnant heifers has an anti-luteolytic effect (Northey and
French, 1980).
The embryos of ruminants regulate luteal maintenance via the secretion of
antiluteolytic interferons. In the sheep and cow, the embryonic signal is provided by
ovine (o) or bovine (b) trophoblast protein-1 (TP-1), which has since been
characterised as a type IIFN, and subsequently renamed IFN-x (Roberts et al., 1992).
Homologous proteins have also been identified as products of goat and red deer
conceptuses (Demmers et al., 1999; Guillomot et al., 1998). Intrauterine infusion of
purified trophoblast proteins or recombinant IFN-x extends luteal function in cyclic
cattle (Helmer et al., 1989b; Meyer et al., 1995), ewes (Godkin et al., 1984; Martal et
al., 1990), goats (Ott and Newton, 1993) and red deer (Demmers et al., 2000). In
addition, uterine administration of IFN-x is associated with attenuation of both basal
and oxytocin-induced endometrial prostaglandin secretion, both in vivo and in vitro
(Danet-Desnoyers etal., 1994; Helmer et al., 1989a; Meyer et al., 1995).
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Embryonic antiluteolysin production is further supported by the detection of
messenger RNA encoding bTP-1 and bTP-1 protein in the trophectoderm of bovine
conceptuses (Farin et al., 1990; Lifsey et al., 1989). In addition, bTP-I mRNA and
protein levels were highest at blastocyst elongation, coincident with maternal
recognition of pregnancy around days 15-17 of gestation (Bartol et al., 1985; Farin et
al, 1990).
IFN-x is thought to prevent the development of the luteolytic mechanism, and to act
on the uterus rather than the corpus luteum. The primary targets of the inhibitory
effects of IFN-t are endometrial oxytocin receptors. Intrauterine injection of ovine
conceptus secretory proteins decreased the number and binding affinity of oxytocin
receptors (Mirando et al., 1993), and inhibited subsequent second messenger
generation (Mirando et al., 1990). IFN-x may regulate the oxytocin receptor directly
or indirectly by down-regulating endometrial oestrogen receptors and/or maintaining
endometrial progesterone receptors.
In cyclic cows, endometrial oestrogen receptor numbers increased dramatically from
day 14 to day 16, to reach levels ninefold higher than in pregnant ewes on day 16
(Ott et al., 1993). Furthermore, intrauterine injection of ovine conceptus secretory
proteins from day 11 to day 15 post-oestrus reduced endometrial oestrogen receptor
concentration and mRNA (Mirando et al., 1993). Oestrogen receptor mRNA and
protein levels were also suppressed by infusion of recombinant oIFN-x into the
uterus of cyclic ewes (Spencer et al., 1995). However, in cows the presence of an
embryo was not associated with any alteration in oestrogen receptor mRNA
expression (Robinson et al., 1999).
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Interferon-x does not appear to regulate oxytocin receptor number via maintenance
of progesterone receptors in the cow, since progesterone receptor mRNA and protein
concentrations were not different between pregnant and non-pregnant animals at the
time of luteolysis (Robinson et al., 1999). The influence of IFN-t on regulation of
progesterone receptor levels in sheep is unclear, although the loss of endometrial
progesterone receptors may be prevented during pregnancy (Ott et al., 1993).
In addition to inhibiting oxytocin reception, the embryo may also inhibit prostaglandin
synthesis, by down-regulation of cycloxygenase-2 and prostaglandin F synthase
expression (Xiao et al., 1999).
1.2 Overview of the IGF System
The insulin-like growth factors, IGF-I and IGF-II, are homologous polypeptide
growth factors with widespread roles in growth and development. IGF-I binds
preferentially to the type 1 IGF receptor, a tyrosine kinase receptor related to the
insulin receptor. The type 1 IGF receptor also binds IGF-II with slightly lower
affinity than IGF-I, and binds insulin with still lower affinity. The IGF-II receptor,
which is identical to the mannose-6-phosphate receptor, binds IGF-II with high
affinity, binds IGF-I with lower affinity and does not recognise insulin. In addition,
at high concentrations both IGF-I and -II can stimulate the insulin receptor. The
IGFs are regulated by the specific interaction with high affinity IGFBPs, which have
been shown to both inhibit and enhance IGF actions. IGFBPs are subject to post-
translational modifications including proteolytic cleavage, which can alter binding of




The growth promoting activities of pituitary-derived somatotrophin or growth
hormone (GH) are well established in vivo and in vitro. The administration of GH to
hypohysectomised rats was found to stimulate the release of a factor in serum, which
mediates GH actions on cartilage growth and sulphate incorporation (Salmon and
Daughaday, 1957). Subsequently, this sulphation factor was renamed somatomedin,
due to its generalised ability to mediate the actions of somatotrophin on target tissues
(Daughaday et al., 1972). At around the same time, studies were underway to
characterise serum-borne factors with insulin-like effects. Distinct from insulin, the
bioactivity of these factors in vitro would be unaffected by the addition of an anti-
insulin antibody and was hence described as non suppressible insulin-like activity
(NSILA). Following the observation that both the NSILA extract and somatomedin
stimulated sulphate incorporation into cartilage and affected glucose metabolism,
similarity of identity was proposed. The amino acid sequence of purified NSILA was
deduced and it was shown that its insulin-like activity was accompanied by insulin¬
like structure, with NSILA showing 48% homology with human proinsulin, and was
renamed IGF-I. A second insulin-like factor was shown to be structurally
homologous, but not identical to IGF-I, and was designated IGF-II. Subsequently the
similarity of identity between NSILA and somatomedin was confirmed by amino




The IGFs are both low molecular weight, single chain polypeptides, with structural
similarity to proinsulin. Human IGF-I was first purified and sequenced by
Rinderknect and Humbel in 1978 (Rinderknect and Humbel, 1978a). It consists of 70
amino acids, has a molecular weight of 7646 Da, and a basic (8.5) isoelectric point.
The amino acid sequences of both IGF-I and IGF-II are highly conserved (Rotwein,
1991). Bovine (Honegger and Humbel, 1986) and porcine (Francis et al., 1989b)
IGF-I sequences are identical to human IGF-I, whilst ovine IGF-I has a single
substitution at residue 66 (Francis et al., 1989a). There are three amino acid
differences between rat and human IGF-I (Shimatsu and Rotwein, 1987), and an
additional fourth substitution in the mouse sequence (Bell et al., 1986).
Human IGF-II is a 67-amino acid polypeptide, with a molecular weight of 7470 Da
and an acidic (<6.5) isoelectric point (Rinderknecht and Humbel, 1978b). IGF-II is
approximately 70% homologous with IGF-I and 50% homologous with proinsulin.
The IGF-II peptide sequence is also highly conserved with sixty of sixty seven
residues being invariant for the human, cow, pig, sheep, rat and mouse (Rotwein,
1991). Porcine IGF-II differs from human IGF-II by just one substitutive change
(Francis et al., 1989a), while bovine (Honegger and Humbel, 1986) and ovine IGF-II
(Francis et al., 1989b) have three and four amino acid changes respectively.
1.2.1.3 Gene structure
The human IGF-I gene spans more than 90 kilobases, and comprises six exons, five
introns and a number of promoter sites (Figure 1.3). Exons 1 and 2 encode part of
the signal peptide. Exons 3 and 4 encode the mature IGF-I peptide, plus a portion of
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the signal peptide and E domain. Exons 5 and 6 encode the E domain and are the site
of potential polyadenylation (Rotwein, 1991; Sussenbach et al., 1992).
The mature IGF peptides are the products of complex processing at both the peptide
and mRNA levels. The primary IGF-I transcript undergoes alternative splicing to
produce precursor peptides IGF-IA and -IB, which have different carboxy-termini
(Jansen et al., 1983; Rotwein, 1986). The two precursors have 16 residues of the E
domain in common, the remaining amino acids of the human IGF-IA precursor are
derived from exon 5, whilst IGF-IB is derived from exon 6. Divergent IGF
precursors have also been reported for the rat and mouse (Bell et al., 1986; Shimatsu
and Rotwein, 1987). The heterogeneity of IGF-I transcripts is further increased by
the use of alternative promoters and variable polyadenylation. The mechanism for
post-translational cleavage of the mature peptide from its precursors is unknown.
The processing of IGF-II is similarly complicated (Figure 1.3). The IGF-II gene in
the mouse, rat and human contains a number of untranslated 5' exons. The regions
coding for the signal peptide, the mature IGF-II peptide, and E domain are found
within the last 3 carboxy-terminal exons in all three species. Multiple IGF-II
mRNAs are produced by the use of alternative promoters, transcription start sites,
and polyadenylation. The combination of variables enables the production of at least
8 different human IGF-II mRNAs. However, the positioning of promoters adjacent
to non-coding exons and the absence of alternative splicing of coding exons
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Figure 1.3. Structure of human IGF-I and IGF-II genes.
The exon-intron organization of the human IGF-I (a) and IGF-II (b) genes are
shown.
Exons are represented by boxes, with coding regions in black and non-coding
regions in white. Asterix represents polyadenylation sites, P represents promoter
regions and dotted lines represent regions yet to be determined.
(Adapted from Rotwein, 1991).
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1.2.1.4 Regulation of IGF-I expression
IGF-I and -II mRNAs are synthesised at multiple sites. A range of factors regulate
IGF-I expression, and for many tissues GH is the principal modulator. GH
administration increases both circulating IGF-I levels (Lemal et al., 1989) and IGF-I
mRNA abundance (Hynes et al., 1987; Murphy et al., 1987; Roberts et al., 1987).
The increase in IGF-I mRNA is the product of enhanced transcription (Mathews et
al., 1986) and differential processing (Lowe et al., 1988) and has been demonstrated
in the primary site of IGF-I synthesis, the liver, and in extra-hepatic tissues. In
addition, cattle with a GH receptor deficiency have reduced blood IGF-I (Chase et
al., 1998). Furthermore, the response to GH stimulation occurs rapidly, nuclear IGF-
I transcripts are induced within 15 minutes of hormone treatment (Gronowski and
Rotwein, 1995), and IGF-I mRNA levels in hypophysectomised rats are restored to
normal within 4 hours (Hynes et al., 1987). The molecular mechanisms by which
GH stimulates IGF-I gene expression remain incompletely understood (Carter-Su et
al., 1996; Gronowski and Rotwein, 1995; Thomas, 1998).
A number of other factors are involved in the regulation of IGF gene expression
(Daughaday and Rotwein, 1989; Rotwein, 1991; Simmen, 1991). In reproductive
tissues IGF-I mRNA abundance can be modulated by steroid hormones. In the pig,
uterine IGF-I mRNA levels are increased by administration of both oestradiol and
progesterone, and IGF-I levels secreted into uterine luminal fluid are also raised
(Simmen et al., 1990). In the rat ovary, IGF-I mRNA is localised to the granulosa
cell layer, and oestradiol treatment doubles ovarian IGF-I transcripts in immature
hypophysectomised animals (Hernandez et al., 1989).
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IGF-I production may also be regulated by other growth factors, including platelet-
derived growth factor (PDGF), FGF, EGF, and TGF-a and (3-1 although
understanding of the complexity of growth factor interactions remains limited
(Simmen, 1991).
Nutrition is an important modulator of IGF-I. The restriction of dietary energy or
metabolizable protein, adversely affects IGF-I synthesis and action (Thissen et al.,
1994; Wester et al., 1995). A reduction in serum IGF-I levels following food
restriction has been demonstrated in a range of species including swine (Buonomo
and Baile, 1991), dog (Maxwell et al., 1998), cow (Yambayamba et al., 1996), sheep
(Hua et al., 1995), rat (Goldstein et al., 1991; Straus and Takemoto, 1990) and
human (Thissen et al., 1994). Hepatic IGF-I mRNA is co-ordinately reduced
following fasting and protein restriction. The reduction in mRNA abundance
following such nutritional regulation has been proposed to be the result of changes at
the level of gene transcription (Hayden et al., 1994; Straus and Takemoto, 1990)
and/or post-transcriptional mechanisms such as altered RNA splicing or stability
(Zhang et al., 1997). IGF-I expression has also been shown to be induced during
development, and in a number of tissues undergoing growth or regeneration.
1.2.1.5 Regulation of IGF-II expression
The regulation of gene expression is less well defined for IGF-II than for IGF-I
(Daughaday and Rotwein, 1989; Rotwein, 1991). IGF-II has been implicated as an
important modulator of embryonic development. Targeted mutagenesis in mice has
demonstrated that IGF-II has a major post-implantation growth-promoting role, and
mutation of the IGF-II gene results in a 40% reduction in birth weight (Baker et al.,
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1993). Investigations into this developmental role have demonstrated that the IGF-II
gene undergoes parental imprinting, such that the gene is expressed from only one
parent-specific allele (Bartolomei and Tilghman, 1997; Lyle, 1997), and is subject to
tissue-specific regulation. The paternal IGF-II gene is transcriptionally active in
most mouse embryonic tissues, whereas the maternal gene is silent, with the
exception of the choroid plexus and leptomeninges of the brain, where both maternal
and paternal alleles are expressed (DeChiara et al., 1991). Imprinting of the IGF-II
gene is evolutionarily conserved from mouse to man (Ohlsson et al., 1993). Ovine
parthenogenetic embryos, which lack a paternal genome, display growth retardation
and subsequent foetal lethality. In addition, whilst normal sheep foetuses express
IGF-II, parthenogenetic embryos do not (Feil et al., 1998). Subsequent molecular
studies have confirmed that IGF-II is subject to genomic imprinting in the sheep, and
that most embryonic tissues express the paternal allele (McLaren and Montgomery,
1999). IGF-II is implicated in the promotion of carcinogenesis, and is highly
expressed in a variety of tumours, including embryonal tumours (Scott et al., 1985).
It has been suggested that disruption of the normal pattern of imprinting of IGF-II
may be important in the regulation of tumorigenesis (Lyle, 1997).
1.2.2 IGF reception
The IGF-I receptor, or type 1 IGF receptor, mediates most of the effects of both IGF-
I and IGF-II. The IGF-II receptor, or type 2 IGF receptor, specifically binds both
IGF-I and -II, and is identical to the cation-independent-mannose 6-phosphate
receptor (MPR), which is involved in targeting lysosomal enzymes to lysosomes
(Oshima et al., 1988). However, the type 2 IGF receptor is not thought to have an
IGF signalling function. In addition, the insulin receptor has low binding affinity for
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the IGFs and hybrid IGF/ insulin receptors may also have IGF-mediated signalling
functions (Nissley and Lopaczynski, 1991; Oh et al., 1993a).
1.2.2.1 The type 1 IGF receptor
1.2.2.1.1 The type 1 IGF receptor: structure
The type 1 IGF receptor and the insulin receptor are heterotetramers, comprised of
two classes of subunits, a and P, which are linked in a p-a-a-p conformation
(Figure 1.4). The a- and P- subunits are the product of a common precursor, which
is proteolytically cleaved to yield the subunits. They are subsequently linked by
disulphide bonds, to form an a.p- pro-receptor. The mature receptor is then
assembled by the dimerisation and linking of two pro-receptors (Treadway et al.,
1989; Ullrich et al., 1985, 1986).
Each a- subunit is entirely extracellular, and contains the ligand binding domain,
whilst the p- subunit has a transmembrane domain and a cytoplasmic domain which
confers the receptor's tyrosine kinase activity.
Structural similarity of the insulin receptor and the IGF-I receptor has been indicated
by a range of functional studies, and subsequently confirmed by sequencing of the
complementary DNA (cDNA) encoding the human IGF-I receptor. The two
receptors show considerable homology. Overall the two sequences exhibit 50-60%
sequence identity, with the greatest homology (84%) being located in the tyrosine
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Figure 1.4. Receptor structure of the insulin receptor, type 1 IGF receptor and type 2
IGF receptor.
The insulin and type 1 IGF receptor are structurally related heterotetramers,
composed of extracelluar a-subunits which confer ligand binding specificity and
transmembrane P-subunits that contain cytoplasmic tyrosine kinase activity. The
type 2 IGF receptor is structurally distinct from both the insulin and type 1 IGF
receptor, lacks an intrinsic tyrosine kinase domain and is characterised by fifteen
extracellular repeats.
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1.2.2.1.2 The type 1 IGF receptor: signalling
The type 1 receptor preferentially binds IGF-I with high affinity, IGF-II with up to
15-fold lower affinity, and insulin with low affinity (Steele-Perkins et al., 1988).
IGF-I can also bind to the insulin receptor, albeit with 100-fold lower affinity than
insulin. A cysteine-rich domain of the IGF-I receptor confers IGF-I binding
specificity, whilst the determinants of insulin recognition appear more complex, and
are discontinuous (Fabry et al., 1992; Gustafson and Rutter, 1990; Kjeldsen et al.,
1991; Schumacher et al., 1991). Ligand occupancy of the a-subunit causes
phosphorylation of specific p-subunit tyrosine residues (Jacobs et al., 1983). This
ligand-stimulated autophosphorylation occurs as a "trans" intra-molecular reaction
between P-subunits within an 012P2 receptor, in both the IGF-I and insulin receptor
(Fratalli and Pessin, 1993).
The P subunit contains a tyrosine kinase catalytic domain, which when disrupted by
mutagenesis abrogates IGF action, suggesting that IGF-I receptor signalling requires
tyrosine kinase activity (Kato et al., 1993). Intrinsic tyrosine kinase activity has also
been shown to be important in mediating most, if not all, of the functions of insulin
(Debant et al., 1988; Murakami and Rosen, 1991). Subsequent signal transduction
also appears similar for the IGF-I and insulin receptors (Figure 1.5).
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Figure 1.5 Proposed signalling pathways for the type 1 IGF receptor.
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A protein with a key role in insulin receptor signalling, the insulin receptor substrate
(IRS-1) and its homologues IRS-2 and IRS-3, are also phosphorylated in response to
IGF-induced receptor activation (He et al., 1996; Myers et al., 1993; Xu et al.,
1999). IRS-1, -2 and -3 contain a number of potential tyrosine phosphorylation sites,
and a recognition sequence for interaction with src homology-2 (SH2) domain-
containing proteins. Following activation, they act as docking molecules linking the
insulin and IGF receptors to signalling pathways.
Despite the high level of conservation between the IRS proteins, and common
functional features, evidence now suggests that they are not functionally
interchangeable: rather they may play important distinct roles in IGF-I and insulin
signalling. Targeted gene knockout of IRS-1 in mice reduces growth by up to 80 %
(Brunig et al., 1997), and alters glucose homeostasis (Tamemoto et al., 1994). IRS-2
disruption causes type-2 diabetes in mice, and indicates that IRS-2 is of particular
importance in glucose regulation (Withers et al., 1998).
SH2 domain binding by the IRS proteins activates several signalling cascades (Sun
et al., 1993). The phosphatidylinositol-3 kinase (PI-3 kinase) is activated via binding
of its p85 regulatory subunit, leading to production of the cell-growth signal
phosphatidylinositol-3 phosphate (PIP3) (Myers et al., 1993).
The growth factor receptor-bound protein 2 (Grb2) contains Src homology domains.
Binding of Grb2 to phosphorylated IRS leads to the eventual activation of mitogen
activated protein (MAP) kinase, which signals to the nucleus, and acts as an
important intermediate in cellular differentiation and growth (Davis, 1993). Grb2
binding induces the guanine nucleotide releasing factor, Son of Sevenless (Sos), to
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activate the GTP-binding protein Ras. In turn, Ras activates the MAP-kinase kinase
kinase Raf, which activates the MAP-kinase kinase Mek, leading to the
phosphorylation of MAP-kinase on threonine and tyrosine residues and its
subsequent activation (LeRoith et al., 1995).
The tyrosine phosphatase Syp can mediate growth factor-stimulated signal
transduction, including responses to insulin and IGF-I (Xiao et al., 1994). Syp
contains two SH2 domains, and can associate with IRS-1. In addition, direct
interaction with the insulin and IGF-I receptors has been suggested (Seely et al.,
1995).
The GTPase-activating protein (GAP) also has an SF12 domain, and an association
with tyrosine kinase receptor signal transduction. GAP negatively regulates Ras
activation, and can also directly interact with the IGF-I receptor via its SH2 domain
(Seely et al., 1995).
IGF-I-induced autophosphorylation of the IGF-I receptor can also result in the
tyrosine phosphorylation of a cytosolic protein termed She (Src-homology 2/
collagen), which is considered a major mediator of IGF-I receptor signalling.
Phosphorylated She can then complex with Grb2/Sos and subsequently activate the
Ras/Raf/MAP kinase pathway, independent of IRS binding (Giorgetti et al., 1994).
IGF-I and insulin receptor signalling appear therefore to share many features, whilst
resulting in markedly different physiological outcomes. Signal divergence could be
achieved in many ways. The identification of an IGF-I receptor specific substrate,
Crk-II (Beitner-Johnson and LeRoith, 1995), suggests potential mechanisms for
specificity. Proteins of the Crk family contain SH2 and SH3 domains, and are
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considered to be important modulators of growth factor-stimulated signal
transduction.
Phosphorylated Crk-II binds guanine nucleotide-releasing factors, which can activate
the Ras/Raf/MAP kinase pathway (Tanaka et al., 1994) and/or the Jun kinase
pathway (Tanaka et al., 1997). Indeed, the suggestion that IGF-I inducible signalling
pathways must exist in addition to PI-3-kinase and MAP kinase activation
(Scrimgeour et al., 1997) supports a role for Crk-mediated Jun kinase activation.
1.2.2.2 The type 2 IGF receptor
1.2.2.2.1 The type 2 IGF receptor: structure
The type 2 IGF receptor has a large extracellular domain, composed of 15 repeats,
each of around 150 amino acids (Lobel et al., 1988). Within each repeat, there is a
conserved pattern of 8 cysteine residues. Repeat number 13 is characterised by a 43
amino acid insertion with homology to fibronectin. The intracellular domain is short,
contains sequences known to be potential protein kinase substrates and can be
phosphorylated at a number of these sites. The MPR was first described for its role
in the recognition of newly synthesised lysosomal enzymes and their subsequent
transport to lysosomes from the Golgi apparatus and cell surface (Kornfeld and
Mellman, 1989).
The MPR was shown to be multifunctional, following the demonstration that the
human IGF-II receptor and the bovine cation-independent MPR had a similar
general structure, and 80% amino acid identity (Morgan et al., 1987). The receptor
has distinct sites for IGF-II and lysosomal enzyme binding (MacDonald et al.,
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1988), and can bind both ligands simultaneously (Waheed et al., 1988). However,
simultaneous binding may cause noncompetitive alterations in binding.
1.2.2.2.2 The type 2 IGF receptor: signalling
Cell surface type 2 IGF receptors bind IGF-II with high affinity. The ligand-bound
receptor is then rapidly internalised, segregated from IGF-II and recycled back to the
cell surface, whilst IGF-II undergoes degradation (Oka et al., 1985). This scavenging
role for the type 2 IGF receptor is well established, however the receptor's signalling
potential remains in question (Nielsen, 1992; Nissley and Lopaczynski, 1991). IGF-
II receptor-blocking antibodies fail to affect the response to IGF-II stimulation in a
range of cell types, including ovarian granulosa cells (Adashi et al., 1990). In
addition, inhibition of IGF-I receptor activation has demonstrated that many of the
biological responses to IGF-II are mediated by the type 1 IGF receptor. In contrast,
others have demonstrated that blocking the type 1 IGF receptor does not alter IGF-II
stimulation (Minniti et al., 1992). The IGF-II receptor, despite the absence of the
seven transmembrane helices characteristic of the G-protein-coupled receptor
family, may mediate signal transduction via G-protein coupling to the receptor
(Nishimoto et al., 1989), which can then activate the MAP-kinase dependant
pathway (Groskopf et al., 1997). IGF-II receptor coupling may be cell-type specific,
as others have failed to demonstrate functional coupling to G-proteins (Korner et al.,
1995).
The type 2 IGF receptor has also been implicated in binding additional mannose-6-
phosphate-containing ligands, such as latent TGF-P (Dennis and Rifkin, 1991),
leukemia inhibitory factor (LIF) (Blanchard et al., 1999), and proliferin (Lee and
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Nathans, 1988). In addition, recent reports have extended the potential functions of
the IGF-II receptor by the demonstration that the IGF-II receptor binds retinoic acid
and urokinase-type plasminogen activator receptor at sites distinct from the IGF-II
and mannose-6-phosphate binding sites (Kang et al., 1998; Nykjaer et al., 1998).
1.2.3 IGF binding proteins
1.2.3.1 Structure and function
In addition to binding their cognate receptors with high affinity, the IGFs bind a
family of structurally related secreted proteins, the IGFBPs with comparable affinity
(Clemmons, 1997; Jones and Clemmons, 1995; Rechler and Clemmons, 1998). Six
high affinity IGFBPs have been identified and characterised, and are numbered
according to the order of their discovery. In addition, several related proteins
comprise a family of low affinity IGFBPs, designated IGFBP-related proteins
(IGFBP-rPs) (Hwa et al., 1999; Kim et al., 1997). The IGFBPs are synthesised and
secreted by many tissues, and they can act locally as autocrine or paracrine factors,
or as endocrine factors effecting targets distant from the site of production. The
IGFBPs transport IGFs, regulating their half-life and clearance. In addition, the high
affinity of binding prevents interaction with cell surface receptors, hence regulating
IGF bioavailability, and inhibiting IGF activity.
Approximately 75% of IGFs are present as a complex of IGF-I or IGF-II, IGFBP-3
and a glycoprotein termed the acid labile subunit (ALS). Association of IGFs into
this ternary complex of approximately 150kDa limits efflux of IGFs out of the
vascular compartment, so increasing their half lives, and creating a pool of IGFs
unable to exert undesirable insulin-like metabolic effects.
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The IGFBPs display considerable structural similarities. Consisting of around 2-300
amino acids, they show between 47 to 67% overall amino acid similarity in the rat,
and 49 to 62% in the human. The highest regions of similarity are the N and C
terminal domains. In particular, all IGFBPs except IGFBP-6 have 18 conserved
cysteines, 12 at the N terminal and 6 at the C terminal. These are conserved both in
number and position (Shimasaki and Ling, 1991), and may be important in ligand
binding (Lalou et al., 1996).
Whilst the IGFBPs are structurally and functionally homologous, they also exhibit
distinctive characteristics. Human IGFBP-1 contains a C-terminal Arg-Gly-Asp
(RGD) integrin recognition sequence, which is conserved in the IGFBP-1 sequence
of the rat, cow and mouse, (Luthman et al., 1989; Murphy et al., 1990; Schuller et
al., 1994; Sneyers et al., 1991b) and in human, mouse, rat, sheep and chick IGFBP-2
(Binkert et al., 1989; Delhanty and Han, 1992; Margot et al., 1989; Schuller et al.,
1994).
Integrins mediate adhesion of cells to the ECM. In addition, whilst they lack intrinsic
tyrosine kinase activity, there is increasing evidence that integrins are important in
intracellular signal transduction. Indeed, integrins can generate signals following
ligand-binding, or can mediate signals originating from growth factor and cytokine
receptors (Giancotti, 1997; Howe et al., 1998).
IGFBP-1 has been shown to interact with the a5pi integrin receptor. In Chinese
hamster ovary cells IGFBP-1 stimulates cell migration via specific binding to the
a5pi integrin receptor, an effect that was abrogated by mutation of the RGD
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sequence (Jones et al., 1993c). In the rabbit, IGF-1-stimulated wound healing
requires activation of the a5pi integrin receptor by IGFBP-1 (Galiano et al., 1996).
Whilst the RGD sequence is conserved in IGFBP-2, there is limited information on
the mediation of its actions via association with integrin receptors. IGFBP-3 and
IGFBP-5 lack an RGD sequence, but can adhere to the surface of cells in culture
(Booth et al., 1995), and IGFBP-5 additionally binds to the ECM (Jones et al.,
1993b). Glycosaminoglycans such as heparin and heparan sulphate are abundant
components in ECM, and both IGFBP-3 and IGFBP-5 contain C-terminal heparin-
binding sequences, and exhibit heparin binding affinity (Booth et al., 1995). IGFBP-
5 binding to ECM proteoglycans markedly reduces IGF-I binding affinity, and the
resultant dissociation of the IGF/IGFBP complex may then potentiate IGF action by
increasing potential IGF receptor activation. Binding of IGFBP-3 to cell surfaces
also results in reduced IGF-I binding affinity. The cellular response to IGFBP-3
binding is further complicated by the recent discovery of an IGFBP-3 receptor (Leal
et al., 1997), identified as the type V TGF-|3 receptor (TpR-V) which mediates a
growth inhibitory IGF-independent signalling pathway (Leal et al., 1999).
1.2.3.2 Post-translational modification
1.2.3.2.1 Glycosylation and phosphorylation
The IGFBPs also vary in the extent to which they are post-translationally modified.
Structural analysis has demonstrated that IGFBP-3 and IGFBP-4 can be subject to
N-glycosylation, IGFBP-5 and IGFBP-6 have potential O-glycosylation sites, and
IGFBP-1, IGFBP-3 and IGFBP-5 occur as phosphoproteins. The functional
significance of glycosylation is unknown, although it has been suggested that
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glycosylation slows the rate of proteolytic degradation of IGFBP-3 (Kubler et al.,
1998). Functional consequences of phosphorylation have been described for IGFBP-
1. In vitro, the affinity for IGF-I of IGFBP-1 phosphorylated on serine residues is up
to six fold higher than non-phosphorylated IGFBP-1 (Jones et al., 1991). IGFBP-1
mutated at a primary site of phosphorylation displayed reduced IGF-I affinity (Jones
et al., 1993a). In addition, physiological significance of phosphorylated IGFBP-1 is
suggested by the presence of phosphorylated isoforms in vivo (Jones et al., 1991).
1.2.3.2.2 Proteolysis
In order for interaction with the cell surface receptors the IGFs must be released
from the IGFBPs. In general terms, this is achieved by a reduction in binding affinity
of IGFBPs for IGFS. As described above, association of IGFBPs with cell surfaces
or ECM can alter IGFBP binding affinity, as can the degree of phosphorylation.
However, the major mechanism for regulating IGF bioavailability may be
proteolytic degradation of the IGFBPs (Fowlkes, 1997; Maile and Holly, 1999).
IGFBP proteolysis was first described in human pregnancy serum (Guidice et al.,
1990). IGFBP-degrading protease activity has since been described in a wide range
of biologic fluids such as amniotic fluid (Claussen et al., 1994), seminal plasma (Lee
et al., 1994), skin interstitial fluid (Xu et al., 1995a), synovial fluid (Matsumoto et
al., 1996) and follicular fluid (Cwyfan Hughes et al., 1997) under normal
physiological conditions. In addition, IGFBP-proteolysis has been identified in
clinical conditions such as arthritis (Matsumoto et al., 1996) and has been shown to
be elevated in patients suffering an acute catabolic state associated with severe
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illness (Davies et al., 1991), in patients suffering from advanced cancer (Frost et al.,
1996) and in cases of untreated diabetes (Bang et al., 1994).
IGFBP-1 to 6- all appear susceptible to proteolytic degradation: however, this is not
thought to be the result of the activity of a common enzyme. A number of candidate
enzymes have been identified which are capable of IGFBP proteolysis, and in
general are characterised as serine proteinases, matrix metalloproteinases or
cathepsins (Fowlkes, 1997).
Numerous studies have demonstrated that the major consequence of IGFBP
proteolysis is a reduction in affinity of the binding protein for the IGFs. The addition
of prostate specific antigen (PSA), an IGFBP-3 protease, to prostatic epithelial cells
reversed the inhibitory effects of IGFBP-3 on IGF mitogenesis, by the generation of
IGFBP-3 fragments with a ten-fold reduction in IGF-I binding affinity (Cohen et al.,
1994). In human pregnancy plasma, limited proteolysis of IGFBP-3 resulted in
diminished affinity for IGF, thus accelerating dissociation of the IGF-IGFBP
complex and increasing free-form IGF-I (Lassare and Binoux, 1994). Porcine aortic
smooth muscle cells secrete an IGFBP-2 specific serine protease, which cleaves
IGFBP-2 into two fragments that do not bind the IGFs (Gockerman and Clemmons,
1995). Degradation of IGFBP-4 is associated with reduced IGF-I binding capacity
and increased IGF-I stimulated DNA synthesis (Cohick et al., 1993). In human
osteosarcoma cells, plasmin caused dissociation of IGF-I and IGF-II from IGFBPs
and reversed the inhibitory effects of IGFBP-1 on IGF-I stimulated DNA synthesis
(Campbell et al., 1992). The creation of an IGFBP-5 mutant with IGF-I binding
affinity and protease resistance, demonstrated that proteolysis prevents the inhibition
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of IGF-I-stimulated events by IGFBP-5, and regulates the responsiveness of porcine
smooth muscle cells to 1GF-I (Imai et al., 1997).
Flowever, whilst most IGFBP fragments display limited IGF binding affinity, in
some circumstances proteolysis may generate biologically active fragments.
Plasmin-induced proteolysis of recombinant human IGFBP-3 in vitro generated two
major fragments, of 22/25 kDa and 16 kDa respectively. The 22/25 kDa fragment
displayed a marked reduction in affinity for IGFs. Furthermore, inhibition of IGF-I
stimulation of chick embryo fibroblast DNA synthesis (Lalou et al., 1996) and
prostate carcinoma cell (PC-3) proliferation (Angelloz-Nicoud et al, 1998) were
diminished in comparison to intact IGFBP-3. In contrast, the 16 kDa fragment lost
all ability to bind radiolabeled IGF, but remained a potent inhibitor of IGF-I
activity. The anti-mitogenic effects of the 16 kDa proteolytic fragment of IGFBP-3
were also demonstrated in mouse fibroblasts carrying a targeted disruption of the
type 1 IGF receptor, confirming that the action was IGF-independent (Zadeh and
Binoux, 1997). The fragments of IGFBP-3 generated by plasmin digestion have also
been shown to block insulin-stimulated mitogenesis of chick embryo fibroblasts
(Lalou et al., 1996), insulin-receptor auto-phosphorylation (Vorwerk et al., 1998)
and activation of the FGF signalling pathway (Zadeh and Binoux, 1997).
In contrast to the inhibitory effects of IGFBP fragments, others have demonstrated
stimulatory activity following proteolysis. A 23- kDA fragment of IGFBP-5 purified
from human osteosarcoma cell conditioned media, stimulated mitogenesis in the
absence of IGF, and further enhanced cell proliferation when coincubated with IGF-I
or IGF-II (Andress and Birnbaum, 1992).
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1.3 The IGF system and the ovary
1.3.1 Actions of IGFs in the ovary
IGFs influence critical aspects of ovarian function in follicular and luteal cells of
many species (Poretsky et al., 1999; Spicer and Echternkamp, 1995).
1.3.1.1 Follicular growth
IGF-I stimulates cell proliferation and DNA synthesis in human (Yong et al., 1992),
rodent (Bley et al., 1992), porcine (May et al., 1988), ovine (Monniaux and Pisselet,
1992) and bovine (Spicer et al., 1993) granulosa cells in culture, and this potent
autogenic effect can be further enhanced in synergy with gonadotrophins. FSF1
enhances IGF-I-stimulated granulosa cell mitosis in the rat and human. Similarly,
the proliferation of bovine granulosa cells from small follicles (< 5mm) is increased
following stimulation by IGF-I plus FSH or LH. The mitogenic effects of IGF-I do
not appear to be granulosa cell specific; IGF-I has also been shown to enhance DNA
synthesis and/or proliferation in human and rat theca cells (Duleba et al., 1997,
1998), and in bovine luteal cells (Chakravorty et al., 1993).
In vivo studies also support a role for IGF-I in promoting follicle growth. In cattle
and pre-pubertal gilts, somatotropin treatment increased both circulating IGF-I
concentrations and the number of small follicles, without alterations in
gonadotrophin levels (Gong et al., 1991; Spicer et al., 1992). In addition,
superovulated heifers treated with somatotropin showed an increase in ovulation rate
correlated with raised serum IGF-I concentrations (Gong et al., 1993).
Whilst studies of the growth promoting effects of the IGFs on ovarian cells in culture
have concentrated primarily on IGF-I, IGF-II also stimulates cell proliferation and
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DNA synthesis in porcine granulosa (Kamada et al., 1992) and human granulosa-
luteal cells (Di Blasio et al., 1994).
1.3.1.2 Steroidogenesis
The IGFs have been shown to be important promoters of steroidogenesis with the
potential to act at multiple sites.
1.3.1.2.1 Progesterone
IGF-I and -II stimulate granulosa cell progesterone production in numerous species.
In the human, IGF-I augments progesterone production by granulosa-luteal cells in
synergy with gonadotrophins (Erickson et al,. 1991), whilst IGF-II stimulates basal
progesterone secretion (Kamada et al., 1992). In the rat, IGF-I enhances FSH-
stimulated progesterone secretion, but has limited effect alone (Adashi et al., 1985b).
IGF-I stimulates progesterone production by granulosa and theca cells of domestic
animals, which is further increased by FSH treatment (Spicer and Echternkamp,
1995). In addition, LH receptor acquisition is enhanced in rat granulosa cells in
culture, in synergy with FSH (Adashi et al., 1985c), an effect that may be mediated
via increased LH receptor mRNA stability (Hirakawa et al., 1999).
Increased progesterone release in response to IGF stimulation is the result of actions
at a number of loci. In porcine granulosa cells IGF-I augments the metabolism of the
steroid precursors LDL and HDL (Veldhuis, 1989). IGF-I can enhance the
subsequent delivery of cholesterol from the outer to inner mitochondrial membrane,
by up-regulation of the mitochondrial transport protein StAR (Balasubramanian et
al., 1997). Once within the mitochondria, cholesterol is converted to pregnenolone
by the side chain cleavage enzyme complex comprised of cytochrome P450scc,
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adrenodoxin and adrenodoxin reductase, which are all regulated by IGF-I (deMoura
et al., 1997; Magoffin et al., 1990). The final conversion of pregnenolone to
progesterone is performed by 3|3-HSD, which increases in concentration following
IGF-I stimulation (Magoffin and Weitsman, 1993).
Whilst the cellular actions of IGF-II are less well defined, IGF-II has been shown to
increase progesterone production. In porcine granulosa cells the potent stimulatory
effects of IGF-II on progesterone biosynthesis are the result of enhanced sterol
delivery, via increased lipoprotein binding, internalisation and utilisation, and
P450scc enzyme activity (Garmey et al., 1993).
Direct stimulatory effects of IGFs on luteal cells have been demonstrated, and
consistently result in enhanced progesterone production (Devoto et al., 1995; Khan-
Dawood et al., 1994; McArdle and Holtorf, 1989; Sauerwein et al., 1992; Talavera
and Menon, 1991; Yuan and Lucy, 1996a). Whilst the sites of IGF action on luteal
steroidogenesis are undefined, it is clear from follicular studies that the IGFs have
great potential to modulate critical components of progesterone production.
1.3.1.2.2 Oestradiol
IGF-I stimulates basal oestradiol secretion in human granulosa cells and granulosa-
luteal cells, and this is enhanced in synergy with gonadotrophins (Erickson et al.,
1989). IGF-II also stimulates oestradiol secretion by human granulosa cells, and is
most effective following a period of insulin pre-incubation (Mason et al., 1994). In
rat granulosa cell cultures IGF-I stimulates oestradiol production in co-treatment
with FSH, and aromatase activity is significantly greater than following FSH
treatment alone (Adashi et al., 1985a). Both IGF-I and IGF-II stimulate porcine
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granulosa cell oestradiol production (Howard and Ford, 1994; Kamada et al., 1992).
In cattle IGF-I stimulated the secretion of oestradiol by granulosa cells from small,
medium and large follicles (Gong et al., 1994). However, it has been suggested that
insulin is a more potent promoter of oestradiol biosynthesis than IGF-I. In addition,
changes in follicular fluid oestradiol content have not always been correlated with
changes in IGF-I concentrations in vivo, although this may be influenced by
concurrent changes in IGFBPs and hence IGF-bioavailability (Spicer and
Echternkamp, 1995).
1.3.1.2.3 Androgen
IGF-I can stimulate androgen biosynthesis induced by LH in the theca cells of rats
(Cara and Rosenfield, 1988; Hernandez et al., 1988), pigs (Caubo et al., 1989), and
women (Bergh et al., 1993). In contrast, IGF-I was unable to stimulate basal
androstenedione secretion by bovine theca cells obtained from large follicles
(Meidan et al., 1990). In the rat the stimulatory effect of IGF-I on androgen
production is mediated via increased cytochrome P450 17a-hydroxylase/C 17-20 lyase
(P450cl7) enzyme content and mRNA expression (Magoffin et al., 1990).
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1.3.2 The intra-ovarian IGF system
Ovarian patterns of expression and production for components of the IGF system
show marked variation between species.
1.3.2.1 Ovarian IGF production and reception
1.3.2.1.1 Human
Limited IGF-I mRNA expression has been detected in the human ovary (Zhou and
Bondy, 1993). Follicular IGF-I mRNA expression was restricted to the theca cells of
small follicles and was absent from dominant follicles (El-Roeiy et al., 1993).
Immunohistochcmistry also localised IGF-I peptide to the thecal compartment
(Hernandez et al., 1992), although others failed to detect IGF-I immunoreactivity in
the human ovary (El-Roeiy et al., 1993).
Follicular fluid IGF-I levels did not vary with stage of the menstrual cycle, and were
not correlated with follicular fluid oestradiol levels or follicular size (Van Dessel et
al., 1996). Clinical observations also suggest that IGF-I may not play an obligatory
role in follicular development. Women with Laron-type dwarfism exhibit GH
receptor deficiency, elevated peripheral GH concentrations and very low levels of
both circulating and follicular fluid IGF-I. However, despite these hormonal
alterations, there are cases of fertility and response to gonadotrophin stimulation
(Dor et al., 1992).
In contrast, abundant IGF-I I mRNA and protein was detected in the granulosa cells
of dominant follicles, and follicular fluid IGF-II levels were correlated with follicle
diameter and oestradiol levels, leading the authors to suggest that IGF-II may have
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greater influence in the regulation of human follicular growth than IGF-I (El Roiey
et al., 1993).
In the human, abundant type 1 IGF receptor mRNA was localised by in situ
hybridisation to oocytes, and the granulosa cells of antral follicles, where expression
increased with follicular dominance (El-Roeiy et al., 1993; Zhou and Bondy, 1993).
1.3.2.1.2 Rodent
In the rat, IGF-I gene expression is exclusively localised to the granulosa cell layer
of healthy follicles, and is absent from follicles undergoing atresia. In addition,
mRNA encoding IGF-I was undetectable in the corpus luteum (Oliver et al., 1989;
Zhou et al., 1991). In contrast, the expression of mRNA encoding IGF-II is theca
cell-specific (Hernandez et al., 1990). Whilst IGF-II mRNA expression was detected
in the immature and mature rat ovary by RNase protection assay, others have failed
to detect ovarian IGF-II mRNA expression in the adult rat by Northern analysis
(Murphy et al., 1987). In addition, others have suggested that IGF-II must play a
limited role in the regulation of ovarian function, based on the decline in ovarian
IGF-II levels observed postnatally (Levy et al., 1992).
In the rat, the type 1 IGF receptor protein is present in both the granulosa and theca
cells, does not vary according to the maturational status of the follicle and was
present in both healthy and atretic follicles (Hernandez et al., 1990; Zhou et al.,
1991).
Whilst most rodent work has focused on the rat, the IGF-I system has also been
characterised in the mouse. As in the rat, mouse ovarian IGF-I mRNA expression is
granulosa-specific and restricted to healthy growing follicles. Messenger RNA
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encoding the type 1 IGF receptor was also concentrated in granulosa cells and was
detected in small, large, healthy and atretic follicles (Adashi et al., 1997).
1.3.2.1.3 Livestock species
The ovaries were first suggested to be a local site of IGF-I production following
studies in the pig, which demonstrated that IGF levels in follicular fluid from pre¬
ovulatory follicles were greater than those in serum or in immature follicles
(Hammond et al., 1985). In addition, following gonadotropin-induced follicular
development, follicular fluid IGF-I levels were correlated with oestradiol levels
(Hammond et al,. 1988). IGF-I has since been detected in the follicular fluid of
mares (Spicer et al., 1991), cows (Spicer et al., 1988) and sheep (Monget et al.,
1993).
In the porcine ovary IGF-I mRNA expression was granulosa cell-specific and
restricted to healthy follicles (Yuan et al., 1996; Zhou et al., 1996). In porcine
granulosa cell culture, FSH and GH increased levels of IGF-I mRNA and protein
(Samaras et al., 1996). IGF-II mRNA has also been localised to granulosa cells
where expression was independent of follicle health (Zhou et al., 1996). However,
others have found IGF-II mRNA expression to be theca specific (Yuan et al., 1996).
Messenger RNA encoding the type 1 IGF receptor has been detected in porcine
granulosa cells (Zhou et al., 1996).
IGF-I mRNA expression patterns in the bovine follicle remain controversial. IGF-I
mRNA was localised by in situ hybridisation to the granulosa cell layer of
developing follicles in heifers, and was greatest in the dominant follicle (Yuan et al.,
1998). Low and inconsistent follicular IGF-I mRNA expression has also been
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demonstrated (Perks et al., 1999). In contrast, others have failed to detect both IGF-I
protein in bovine granulosa cell conditioned medium (Gutierrez et al., 1997) and
follicular IGF-I mRNA expression (Armstrong et al., 2000a). Reports of follicular
IGF-II expression show more agreement. IGF-II mRNA expression is theca-specific,
and was detected throughout the growth of antral follicles, from antrum formation to
the development of dominance (Armstrong et al., 2000a; Yuan et al., 1998).
Messenger RNA encoding the type 1 IGF receptor was detected in both granulosa
and theca cells of preantral and antral bovine follicles (Armstrong et al., 2000a),
whilst others have shown that receptor expression was restricted to the granulosa
layer (Perks et al., 1999).
In sheep, IGF-II as opposed to IGF-I is thought to have a major role in regulating
ovarian function. IGF-I mRNA was undetectable in the ovine follicle, whilst mRNA
encoding IGF-II was detected in the theca cell layer and varied significantly with the
size and health of the follicle. IGF-I receptor mRNA was detected in both granulosa
and theca cells (Perks et al., 1995).
1.3.2.2 Ovarian IGF binding proteins
IGFBPs also appear to have important roles in regulating ovarian function, and one
or more IGFBPs are produced by the ovary of the rabbit (Ricciarelli et al., 1991),
sheep (Perks and Wathes, 1996), human and non-human primate (El-Roiey et al.,
1994; Fraser et al., 1998), cow (Armstrong et al., 1998), pig (Zhou et al., 1996),
mouse (Adashi et al., 1997) and rat (Nakatani et al., 1991).
The addition of IGFBPs to ovarian cells in culture, or to whole ovaries perfused in
vitro, has resulted in the attenuation of IGF action. IGFBPs have been shown to
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block ovarian steroidogenesis (Mason et al., 1998; Spicer et al., 1997; Ui et al.,
1989), inhibit cell proliferation (Bicsak et al., 1990), decrease ovulation rate and
oocyte maturation (Yoshimura et al., 1996), and remove IGF-I-mediated suppression
of apoptosis (Chun et al., 1994).
A number of studies have demonstrated that follicular fluid IGFBP concentrations
are correlated with the size and health of the follicle, thus suggesting a physiological
significance of IGFBP action in vivo. In cattle, the establishment of follicular
dominance is associated with a reduction in low molecular weight IGFBPs (IGFBP-
2, -4 and -5) (Echternkamp et al., 1994: Stewart et al., 1996), whilst follicular atresia
is associated with increased IGFBP levels (Echternkamp et al., 1994). IGFBP
profiles in follicular fluid from women demonstrated similar increases in IGFBP
concentrations during atresia (Cataldo and Guidice, 1992). Messenger RNA
encoding IGFBPs has been detected in the ruminant follicle and the patterns of
expression have been related to follicular development (Armstrong et al., 1998;
Perks and Wathes, 1996). Follicular fluid IGFBP-2 concentrations are reduced in
large healthy bovine follicles in parallel with decreased granulosa cell IGFBP-2
mRNA expression (Armstrong et al., 1998; Perks and Wathes, 1996).
Changes in follicular fluid IGFBP profiles may be attributed to alterations in local
production or degradation of IGFBPs, and/or transudation from the serum. The
resultant changes in IGF availability are thought to influence follicular sensitivity to
gonadotrophins, and hence regulate follicle selection and dominance. In addition,
alterations in bovine follicular IGFBP mRNA expression observed following
increased dietary energy regimes is suggestive of a role for IGFBPs in mediating the
effect of nutrition on follicular growth (Armstrong et al., 2000b).
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Enzymes capable of cleaving IGFBPs have been reported in follicular fluid and
ovarian cell conditioned media, and such proteolytic activity is thought to be an
important mechanism for increasing IGF bio-availability at critical points during
follicle growth and development (Besnard et al., 1996, 1997; Cwyfan Hughes et al.,
1997; Grimes and Hammond, 1994; Mason et al., 1996).
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Chapter 2. Materials and Methods
The composition of buffers are detailed in the appendix. The sources of individual
chemicals are detailed within the experimental protocols and suppliers listed in the
appendix. Frequently used materials and chemicals including solvents, chemicals for
buffers and plastic or glassware were obtained from the Sigma-Aldrich Company Ltd
.2.1 Total RNA isolation
2.1.1 Controlling ribonuclease activity
To obtain good preparations of RNA it is necessary to minimise the actions of
RNases. Polypropylene centrifuge tubes (50 ml) used throughout the isolation
procedure were filled with 0.1% (v/v) diethyl pyrocarbonate (DEPC), allowed to
stand for 1 hour at room temperature and then autoclaved. Wherever possible
solutions were treated with 0.1% (v/v) DEPC overnight at room temperature and
then autoclaved. Solutions not suited to DEPC (e.g. Tris) were prepared in DEPC-
treated water (0.1% v/v) and autoclaved. Solutions not suited to autoclaving (e.g.
dithiothreitol; DTT) were prepared using DEPC-treated water (0.1% v/v), baked
glassware and sterile filtered. RNA was isolated in an area with restricted air
movement and all surfaces were treated with an RNase decontamination solution
(RNase Zap; AMS Biotechnology (UK) Ltd). Disposable gloves were worn




Total cellular RNA was prepared according to the method of Chomczynski and
Saachi (1987) from bovine ovarian and liver tissue collected from the local abattoir.
Denaturing solution (2.5ml) containing the potent RNase inhibitor guanidine
thiocyanate was dispensed into 50ml DEPC-treated centrifuge tubes, 17.9jul of P-
mercaptoethanol (P-ME) was added, mixed and held on ice. Frozen tissue (250mg)
was placed into the solution and immediately dissociated using a high-speed polytron
homogeniser for 3x 10 sec. To the homogenate was added 62.5pl of 20% (w/v)
sodium lauryl sarcosine (SLS) to aid in the breakdown of nucleoprotein complexes.
RNA was isolated from contaminants by phenol: chloroform extraction performed at
low pH. The acid environment was created by the addition of 250pl of 2M NaAc (pH
4). Aquaphenol (2.5ml) (Appligene Oncor) was added and mixed by inversion,
followed by 500pl of chloroforrmisoamyl alcohol (24:1 v/v). The tube was then
vigorously shaken for 10 sec and placed on ice for 15 min. The sample was then
centrifuged at 9100rpm (Beckman J-20) for 20 min at 4°C. RNA is selectively
partitioned to the aqueous phase, which was carefully removed avoiding the
interphase and transferred to a fresh DEPC-treated tube. An equal volume of
isopropanol was added, mixed and placed at -20°C for at least lhr. The RNA was
pelleted by centrifugation at 9100rpm (Beckman J-20) for 20 min at 4°C and then re-
dissolved in 750pl of denaturing solution plus 18.75pl of 20% (w/v) SLS and 5.35pl
of P-ME. An equal volume of isopropanol was added, mixed and placed at -20°C for
at least lhr. The sample RNA was again pelleted by centrifugation (9100rpm
Beckman J-20) for 10 min at 4°C. The pellet was washed with 75% (v/v) ethanol,
vortexed and spun for a further 10 min (9100rpm Beckman J-20) at 4°C. The pellet
was then air dried, and resuspended in lOOpl of DEPC water.
2.1.3 Assessing total RNA yield
The optical density of a suitable dilution (typically 1/200) was measured at 260nm
using a Beckman Du-63 Spectrophotometer and a 1 cm-pathlength
spectrophotometric cuvette and the concentration calculated using the formula;
optical density of 1 at 260nm=40pg RNA.
Thus the concentration ofRNA = optical density at 260nm x 40 x dilution factor.
RNA was stored at -80°C in 50pg aliquots until required.
2.1.4 Assessing RNA integrity
The integrity of the purified RNA was determined following denaturing gel
electrophoresis. Typically 10-15pg of RNA was mixed with 12.5pl of deionised
formamide (AMS Biotechnology (UK) Ltd), 4pl of formaldehyde (37% v/v) and
2.5pl of lOx MOPS in a total volume of 25pl, and incubated at 65°C for 10 min. The
mixture was chilled on ice for 20 sec and 2.5pi of loading buffer (0.01% (w/v)
bromophenol blue in 50% (v/v) glycerol) added. The RNA was electrophoresed
through a 1.1% (w/v) standard agarose gel containing lx MOPS, and 17% (v/v)
formaldehyde (37% stock) using lx MOPS as running buffer. If electrophoresis was
performed overnight, buffer was constantly recirculated, and the gel run at 20V.
After electrophoresis, the gel was stained with dilute ethidium bromide (0.5pg/ml; 30
min), destained in water (30 min) and photographed under UV transillumination
(Polapan 55PN film, Polaroid, supplied by HA West). RNA resolved by denaturing
gel electrophoresis characteristically exhibits 28s and 18s ribosomal RNAs, which in
the absence of gross degradation display a near 2:1 ratio by ethidium bromide
staining.
2.2 Synthesis of cDNA
Total RNA extracted as described above was used as the template for cDNA
synthesis. Total RNA (lpg) was mixed with random hexamers (125pmol; Promega)
in the presence of 20 units of ribonuclease inhibitor (RNasin, Promega) to a total
volume of 1 lpl. This RNA/primer mix was incubated for 10 min at 70°C and then
held on ice. Following the annealing of primers to template RNA, cDNA synthesis
was initiated by the addition of 9pl of reverse transcription mix, incubated at 20°C
for 10 min, followed by 42°C for lhr. The reaction was terminated by incubation at
95°C for 5 min. Prior to cDNA amplification the synthesis reaction was diluted with
4pi of 50mM MgCh (Life Technologies) and 8pl of lOx RTase buffer (Promega) to
a total volume of lOOjul and stored at -70°C.
Reaction tubes were prepared without RNA or without reverse transcriptase to assess
contamination of reagents with DNA and genomic contamination of RNA samples
respectively. These control tubes were included in subsequent polymerase chain
reactions.
2.3 Polymerase Chain Reaction (PCR9
Primers were designed to amplify target sequences of bovine IGF-I, IGF-II, the type
1 IGF receptor, and the insulin receptor using published DNA sequences available in
the European Molecular Biology Laboratory (EMBL) database (http://srs.ebi.ac.uk)
and the Prime programme of the GCG Wisconsin sequence analysis package (GCG).
Details of the primer pairs, their target sequences and subsequent PCR conditions are
shown in Table 2.1.
Plasmids containing porcine IGF-I, bovine IGFBP-2, -3 and -4, human P450arom
and ovine LH receptor probes were already available and target sequences are
detailed in the relevant experimental chapters.
A PCR reaction mixture (20pl) for each sample was prepared by adding 6pl of
RTase reaction, lpl of lOx PCR buffer (Promega) and 12pl of dFFO. A reaction tube
was prepared in the absence of the cDNA synthesis reaction to assess reagent
contamination. The tubes were vortexed and then placed in the thermocycler
(Personal Cycler, Biometra Ltd), and heated to 93°C. At this point lpl of Taq/primer
mix was added to each sample. Taq/primer mix (25pl) contained 5pl of Taq
polymerase (5U/pl; Roche Diagnostics Ltd), and 100-200pmol of both the 5' and 3'
primers (Cruachem). The tubes were held at 93°C for 5 min. This was followed by
30 cycles of denaturing (93°C, 30 sec), annealing (55-65°C (table 2.1), 30 sec) and
primer extension (72°C, 30 sec). The final cycle was completed by an extended final
stage at 72°C for 5 min. On completion of the reaction, samples were cooled to 4°C
prior to analysis by agarose gel electrophoresis. A 5pl aliquot of each reaction was
mixed with lpl of 6x loading buffer (Promega) and electrophoresed on a 3% (w/v)
agarose gel (2:1 mix of standard agarose (Appligene Oncor) and NuSieve GTG
(Flowgen) dissolved in lx TAE) with lx TAE running buffer. A DNA ladder (PCR
Markers; Promega) was included as a marker lane to confirm amplified fragment
size. After electrophoresis, the gel was stained with dilute ethidium bromide
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(0.5pg/ml; 30 min), destained in water (30 min) and photographed under UV
transillumination (Polapan 55PN film, Polaroid, supplied by HA West) (Figure 2.1).
Target Primer Sequences Annealing Product
sequence temperature gize ^ .
(EMBL)
IGF-I 5'-CCTCTGCGGGGCTGAGTTGGT-3' 65°C 196
(BTILGF1A) 5 '-CGACTTGGCGGGCTTGAGAGGC-3'
IGF-II 5' -TCTGTGCGGCGGGGAGCTGGT-3' 65°C 154
(BTILGF2) 5 '-AGTCTCCAGCAGGGCCAGGTCG-3'
Type 1 IGF 5'-CCAAGCTAAACCGGCTCAAC-3' 60°C 189
receptor 5' -TTATAACCAAGCCTCCCAC-3'
(BTIGF1B)




Details of PCR primers are shown for IGF-I, IGF-II, the type 1 IGF receptor and the
insulin receptor. (EMBL) refers to the 'ID' of each sequence in the EMBL database.
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Figure 2.1
Agarose gel electrophoresis of Reverse Transcription-PCR products.
a) 300
150
Amplified bands following RT-PCR of bovine luteal RNA, using
primers designed against bovine IGF-I (1,2) and IGF-II (3, 4).
Blanks (minus reverse transcriptase) (2, 4). PCR Markers (M).
Amplified bands following RT-PCR of bovine luteal (1,2) and
liver (3, 4) RNA, using primers designed against human insulin
receptor. Blanks (minus reverse transcriptase) (2, 4). PCR Markers (M).
Amplified bands following RT-PCR of bovine luteal RNA,
using primers designed against bovine typel IGF receptor.




Primers were designed to amplify positions 156-351 of bovine IGF-I mRNA (Fotsis
et al., 1990). The amplified product is within the coding region (1-462), and
corresponds to the region encoding the mature peptide (145-354). A porcine IGF-I
probe was kindly gifted by DrM Lucy (University ofMissouri). A comparison of the
bovine and porcine (Tavakkol et al., 1988) IGF-I mRNA sequences detailing the
primer positions is shown in Figure 2.2.
2.4.2 IGF-II
Primers were designed to amplify positions 7-160 of a partial bovine IGF-II mRNA
(Brown et al., 1990). The amplified product is within the coding region (1-451), and
by comparison to the human sequence (Rail et al., 1987) corresponds to the region
encoding the mature peptide. The human and bovine IGF-II mRNA sequences are
compared in Figure 2.3.
A Bestfit comparison (GCG Wisconsin package, GCG) of bovine IGF-I and bovine
IGF-II mRNA sequences demonstrates a 72% similarity as shown in Figure 2.4.
Despite this level of homology, bovine IGF-I and IGF-II primers specifically amplify
only their target mRNA, as determined by BLAST or FASTA analysis (GCG
Wisconsin package, GCG). The amplified regions of the mRNA sequences encoding
bovine IGF-I and -II are compared in Figure 2.4.
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2.4.3 Type 1 IGF receptor
Primers for the type 1 IGF receptor were designed to avoid regions of homology with
both the insulin receptor and insulin receptor related receptor. The lowest degree of
similarity is shown in the signal peptide and transmembrane sequences. The
available bovine mRNA sequence for the type 1 IGF receptor encodes only the P-
subunit (Sneyers et al., 1991a), whilst much more of the human mRNA sequence is
published (Ullrich et al., 1986). Therefore, initial searches were made using the
human sequence. Suitable primers were identified and checked for homology. Since
the most suitable primer pair was in the P-subunit the primers were then adapted to
the bovine sequence and subjected to FASTA analysis (GCG Wisconsin package,
GCG), which demonstrated specificity of amplification. Primers were designed to
amplify positions 2717-2905 of human type 1 IGF receptor mRNA which
corresponds to positions 491-679 of a partial bovine mRNA. A comparison of
human type 1 IGF receptor mRNA and human insulin receptor mRNA is illustrated
in Figure 2.5.
2.4.4 Insulin receptor
There is no published mRNA sequence data for the bovine insulin receptor. Primers
were designed to amplify positions 1493-1592 of human insulin receptor mRNA
(Figure 2.6) (Ebina et al., 1985), which corresponds to part of the alpha subunit.
FASTA analysis (GCG Wisconsin package, GCG) indicates that these primers
specifically amplify the insulin receptor, and not the type 1 IGF receptor.
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bIGF-I 62aggtgaagatgcccatcacatcctcctcgcatctcttctatctggccctg





I I I I I II I I I I I I I II I II I II I II II I I I I III MINN IMIII
55 tgcttgctctccttcaccagctctgccacggctggac<rfcgagacC€t;ctg 104
162 cggggctgagttggtggacactctccagttcgtgtgcggagacaggggct 211
I M I I I I I I I I I I I I I INN I I I I I I I I I I I I I I I I II I I II I I I
105 tggggctgagctggtggacgctcItcagttcgtgtgcggagacaggggct 154
212 tttatttcaacaagcccacggggtatggctcgagcagtcggagggcgccc 261
I I I I I I II I I I I I I I II II II I II I II II I I II I II II II II I I I I
155 tttatttcaacaagcccacagggtacggctccagcagtcggagggcgcea 204
262 cagacaggaatcgtggatgagtgctgcttceggagctgtgatctgaggag 311
I I I II II I I I I I I I I I I I I I I I I I I I I I I I I I I I MIM M.I I II II I
2 05 cagacgggc&tcgtggatgagtgctgcttccggagctgtgatctgaggag 2 5 4
312 gctggagatgtact.gcgcgcctctcaagcccgccaagtcggcccgctcag 361
II I I I II II II II II II II I I II II I I I I I I II I II II II II II I
255 gc tg g aga tg ta c Lg tgc a cccc tcaagcc t g cc a ag tcgg cc c g c t. c c g 3 04
362 tccgtgcccagcgccacaccgacatgcccaaggctcagaaggaagtacat 411
I II II I I I II I I I I I I I II II I I II I I I I I I I I I I I I II II I I I I I I I I
305 tccgtgcccagcgccacacggacatgcccaaggctcagaaggaagtacat 354
412 ttgaagaacacaagtagagggagtgcaggaaacaagaactacagaatgta 461
I I I I I I I I I I I I I I I I I I II II I I II I I I I I I I I I I I I II I II I I II I I
355 ttgaagaacacaagtagagggagttcaggaaacaagaactacagaatgta 404
462 ggaagaccttcctaaagagtgaagaatgacatgccaccggcaggatcctt 511
I I I I I I I I I I I I I II I I I I I I I II II II I I I II II I I I I I I I I I I I I I
405 ggaagaccttcctgaagagtgaagaatgacatgccactggcaggatcctt 454
512 cgctctgcacgagttacctgttaaacaccagaagacctacc..aaaaata 559
I I I I I I I I I I I I I I I II II I I I I I I II I I I II I I I II I I I I I I I II I
455 tgctctgcacgagttacctgttaaacaccagaagacctaccaaaaaaata 504
560 agtttgataacatttcaaaagatgggcatttcccccaatgaaat....aa 605
II I II II I II II I I I II I I I II I II II II I II I I II I II II I II
505 agtttgaaaacatttcaaaagatgggcattccccccaatgaaatacacaa 554
606 gtaaacattcc 616
II I II I II I II
555 gtaaacattcc 565
Figure 2.2
A Bestfit alignment of bovine and porcine IGF-I mRNA sequences. Primer positions
are emboldened and the region coding for the mature peptide highlighted.
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hlGF-11 338 qagaccctgtgcgqcgggqaqctggtqqacaccctccagttcgtctgtqg 387
I I II I I I II I I I I I I I I I I I I I I I II I I I I II I I I II I I I I II I II I I
bIGF-II 2 gagactctgtgcggcggggagctggtggacaccctccagtttgtctgtgg 51
388 ggaccgcggcttctacttcagcaggcccgcaagccgtgtgagccgtcgca 437
I I I I I I I I I I II I I I I I II I I I I II I I I I I I I I III I II I
52 ggaccgcggcttctacttcagccgaccatccagccgcataaaccgacgca 101
438 gccgtggcatcgttgaggagtgctgtttccgcagctgtgacctggccctc 487
I I I I I I II I I I II II I I I II II I I I II II I I I I I I I I II I I I I
102 gccgtggcatcgtggaagagtgttgcttccgaagctgcgacctggccctg 151
488 ctggagacgtactgtgctacccccgccaagfcccgagagggacgtgtcgac 537
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II I I I I
152 ctggagacttactgtgccacccccgccaagtccgagagggatgtgtctgc 201
538 ccctccgaccgtgcttccggacaacttccccagataccccgtgggcaagt 587
I II I I I I I I I I I I I I I I I I I II II II I I I I I I I II I I I I I I II
202 ctctacgaccgtgcttccggacgacgtcaccgcataccccgtgggcaagt 251
588 tcttccaatatgacacctggaagcagtccacccagcgcctgcgcaggggc 637
I I I I I I I I I I I II I I I I II II I I I I I I I I II I II II I I I I I I I I I I II I
252 tcttccaatatgacatctggaagcagtccacccagcgcctgcgcaggggc 301
638 ctgcctgccctcctgcgtgcccgccggggtcacgtgctcgccaaggagct 687
I I I I I III II I I I II II I I I I I I I I I I I I II I I I II I I I II II
302 ctgcccgccttcctgcgagcacgccggggtcgcacgctcgccaaggagct 351
688 cgaggcgttcagggaggccaaacgtcaccgtcccctgattgctctaccca 737
I II I I I I I I I I II I I I I I I I II I II I I II I I I II II II I I
352 ggaggccctcagagaggccaagagtcaccgtccgctgatcgccctgccca 401
738 cccaagaccccgc...ccacgggggcgcccccccagagatggccagcaat 784
II I I I I I I I I I I II I I I I I I II I I I I II II I I I I I
402 cccaggaccctgccatccacgggggcgcctcttccaaggcatccagcgat 451
785 cggaagtgagcaaaactgccgcaagtctgcagcccggcgccaccatcct. 833
I I II I I II I III II II II I I I I I III III I III
452 tagaagtgagccaaagtgtcgtaattctgccaagtggcaccatctacctc 501
834 gcagcctcctcctgaccacggacgtttccatcaggttccatcccgaaatc 883
II I I I I I I II I I I II II III I I I I I I II I II I
502 gcgccgacctcctgacc.gggaccgccccactaggtctctctctgaaatc 550
Figure 2.3
A Bestfit alignment of human and bovine IGF-II mRNA sequences. Primer positions




bIGF-I 150 cgagaccctotgcggggctgagttggtggatgctctccagttcgtgtgcg 199
I I I II I II I II I I I III I I I II I I I I I I I I I I I II II I
1 cgagactctgtgcggcggggagctggtggacaccctccagtttgtctgtg 50
200 gagacaggggcttttatttcaacaagcccacggggtatggctcgagcagt 249
I I I II I I II I I I I I II I II II II I I
51 gggaccgcggcttctacttcagccgacc atccagccg. 87
250 cggagggcgccccagac.aggaatcgtggatgagtgctgcttccggagct 298
I I II I I I I I I I I I I II I I I I I II I I I I I I II I I I I I
88 cataaaccgacgcagccgtggcatcgtggaagagtgttgcttccgaagct 137
299 gtgatctgaggaggctggagatgtactgcgcgcctctcaagcccgccaag 348
I I I II I I I I I I I I I I I I I I I I II I I I I II I I I





A Bestfit alignment of bovine IGF-I and IGF-II mRNA sequences. Primers are
emboldened.
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Ins R 2869 tgcaggctgcgtgggctgtcaccggggaactacagcgtgcgaatccgggc 2918
I I I I I Nile I II I II II I II II I I I I I I I I I
IGF R 2716 gccaagctaaaccggctaaacccggggaactacacagcccggattcaggc 2765
2919 cacctcccttgcgggcaacggctcttggacggaacccacctatttctacg 2968
I II I I I I I I I I I I I II II I I I II I I I II I I I I
2766 cacatctctctctgggaatgggtcgtggacagatcctgtgttcttctatg 2815
2969 t gacagactatttagacgtc..ccgtcaaatattgcaaaaa 3007
I II I I III I I I II II I I
2816 tccaggccaaaacaggatatgaaaacttcatccat|§ 2851
3008 ttatcatcggccccctcatctttgtctttctcttcagtgttgtgattgga 3057
I 1111111 i I 1 JJ 1 UJ 1 1 IJ 1 1 c i 1 g
2 8 52 r.gateaccgetctgcccgtcgcrgtcetgt'cgatcgtgggagggttggtg 2 9 01
3058 agta...tttatctattcctgagaaagag gcagccagatgggccg 3099
I a| I II I M il MINI II MM Mill I
2902 at$t;afcgct.gt.acgtCit.t!!&catagaaagagaaataacagcaggctggg. . q 2949
Figure 2.5
A Bestfit alignment of the human insulin receptor and type 1 IGF receptor mRNA
sequences, to illustrate primer positions for the type 1 IGF receptor. Primer positions
are emboldened, and the sequence coding for the transmembrane region is
highlighted. Letters are shown between the aligned sequences to illustrate when the
bovine type 1 receptor mRNA sequence varies from the human type 1 IGF receptor
mRNA sequence.
88
InsR 1405 gggaactactccttctatgccttggacaaccagaacctaaggcagctctg 1454
I I I I I I I I I I I! I I I I I I I I I I I I I I I I I I I I III II II
lUrr K. 1291 gggaattactccttctacgtcctcgacaaccagaacttgcagcaactgtg 1340
1455 ggactggagcaaacacaacctcaccaccactcaggggaaactcttcttcc 1504
I I II I II I I I I I I I II I I I I II I I I I I I I I III
1341 ggactgggaccaccgcaacctgaccatcaaagcagggaaaatgtactttg 1390
1505 actataaccccaaactctgcttgtcagaaatccacaagatggaagaagtt 1554
I II I I I I I I I I I I I I I I I I I II I I I I I I I II I
1391 ctttcaatcccaaattatgtgtttccgaaatttaccgcatggaggaagtg 1440
1555 tcaggaaccaaggggcgccaggagagaaacgacattgccctgaagaccaa 1604
I II II I I I I I I I I I I II I I I I I I I I I I I I
1441 acggggactaaagggcgccaaagcaaaggggacataaacaccaggaacaa 1490
1605 tggggacaaggcatcctgtgaaaatgagttacttaaattttcttacattc 1654
I II I I I I I I I I I I I I I I I I I I III III I I I I
1491 cggggagagagcctcctgtgaaagtgacgtcctgcatttcacctccacca 1540
1655 ggacatcttttgacaagatcttgctgagatgggagccgtactggcc 1700
I I II I I I I I II I I I I I I I I I II I I
1541 ccacgtcgaagaatcgcatcatcataacctggcaccggtaccggcc 1586
Figure 2.6
A Bestfit alignment of the human insulin receptor and type 1 IGF receptor
mRNA sequences, to illustrate primer positions for the Insulin receptor.
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2.5 Ligation of vector and insert DNA
pGEM-T (Promega) was used as the vector for PCR product cloning. pGEM-T is
prepared from the pGEM-5Zf(+) vector, cut at the EcoRV site and with 3' terminal
thymidines (3'-T overhangs) added to both cut ends for increased ligation efficiency.
The plasmid contains T7 and Sp6 RNA polymerase transcription initiation sites, a
sequence coding for the Lac a-peptide, interrupted by a multiple cloning site that
enables blue/white colour selection for insertion, ampicillin resistance in addition to
a number of restriction enzyme sites.
Aliquots of PCR product (0.5pl, 1.5pl or 4.5pl) or 2pl of pGEM-T vector control
(Promega) were added to a ligation reaction (10pl) containing lpl of T4 DNA Ligase
(lU/pl; Promega), lpl of T4 DNA ligase lOx buffer (Promega) and lpl of pGEM-T
vector (50ng). Reactions were mixed and incubated overnight at 4°C.
2.6 Bacterial transformation
2.6.1 Preparation of Luria bertani agar -ampicillin plates
Sterile Luria bertani (L.) agar was warmed to melting and mixed with antibiotic
(ampicillin, 6mg/100ml) and poured into sterile petri dishes (Bibby Sterilin). Plates
were allowed to set at room temperature. Prior to use L. agar-ampicillin plates were
coated with a layer of Isopropyl |3-D-Thiogalactopyranoside (IPTG) (4pl of 1M
IPTG/plate; Promega) and 5-Bromo-4-chloro-3-indolyl (3-D-galactopyranoside (X-
gal) (40pl of 50mg/ml X-Gal /plate; Promega) and allowed to absorb for
approximately 30 min at 37°C, for subsequent blue/white colour screening.
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2.6.2 Transformation of cells
Bacterial transformation of plasmids was performed using JM-109 High Efficiency
Competent Cells (Promega). A 2pl aliquot of each ligation reaction was placed into a
thin walled tube on ice. In addition, 0.5ng uncut pGEM-3Z plasmid was used as a
positive control to determine transformation efficiency. JM-109 cells were thawed on
ice and mixed by gentle flicking. A 50pl aliquot of cells was added to each pre-
chilled ligation reaction and mixed during dispensing. The cells were placed on ice
for 20 min, heat shocked for 45 sec at 42°C and returned to ice for 2 min. L. broth
(900pl) was added and the cells incubated with shaking (225 rpm) at 37°C for lhr.
L.agar-ampicillin plates (see section 2.6.1) were spread with lOOpl of each
transformation culture and incubated overnight at 37°C.
2.6.3 Blue/ white colour screening
After overnight culture on IPTG/X-gal supplemented plates possible positive
transformants were selected by colour. Bacterial colonies containing recombinant
vector constructs are white due to the insertional inactivation of the Lac-a sequence,
whilst in general non-recombinants produce functional (3 galactosidase as indicated
by a blue colour.
Single colonies were lifted from the plates and used to inoculate 5ml of L. broth plus
ampicillin (6mg/100ml). Cultures were incubated at 37°C overnight with shaking.
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2.7 Plasmid DNA preparation
2.7.1 Mini plasmid preparation
Small-scale DNA preparation was carried out using the Wizard Miniprep system
(Promega). A 2ml aliquot of each culture was removed and spun at high speed in a
microcentrifuge (Beckman-E) for 2 min. The pellet of cells was resuspended in
200pl of cell resuspension solution, prior to cell lysis in 200pl of lysis solution.
Neutralisation solution (200pl) was added to the mix and the resultant precipitate
containing protein and chromosomal DNA was pelleted by high-speed centrifugation
for 5 min. The supernatent was decanted to a fresh tube and mixed with 1ml ofDNA
purification resin. For each miniprep a 3ml-syringe barrel was attached to a Wizard
minicolumn and placed on a vacuum manifold (Vac-man; Promega). The resin mix
was then loaded on and drawn into the minicolumn under vacuum. Column wash
(2ml) was then applied and the resin allowed to dry for a further 2 min under
vacuum. The syringe barrel was removed and the minicolumn transferred to a
microcentrifuge tube and spun at high speed for 20 sec to remove any residual
column wash. The minicolumn was transferred to a fresh microcentrifuge tube and
50pl ofwater was applied to the minicolumn, and left for 1 min. To elute the plasmid
DNA the minicolumn was spun at high speed for 20 sec and stored at 4°C.
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2.7.2 Restriction digestion
Initial confirmation of successful ligation was by restriction enzyme digestion.
Restriction endonucleases were chosen for their ability to cleave DNA at specific
recognition sequences present within the desired insert but not the plasmid vector.
Potential target sites within the PCR product were analysed using the GCG
Wisconsin Mapping programme (GCG). Restriction enzymes were purchased from
New England Biolabs or Roche Diagnostics Ltd. Each restriction digestion reaction
was performed to digest approximately lpg of sample DNA in the presence of
excess enzyme (20U) and the appropriate enzyme lOx buffer diluted to a final lx
strength. Samples were incubated at 37°C for lhr. The result of restriction
endonuclease cleavage was analysed by gel electrophoresis (Figure 2.7). It would be
difficult to tell successful ligation by size difference alone. However, a single
cleavage of circular DNA substrate will linearise the DNA, creating a difference in
mobility through the gel that allows circular and cut to be resolved. Since the
restriction enzyme sites were chosen to be present only within the insert,
linearisation represents successful ligation.
Digestion with two enzymes was also performed when possible, to confirm ligation
by cutting out the insert from the plasmid cloning site. Digestion was carried out
with both enzymes acting simultaneously if buffer and temperature conditions for
both enzymes activity were compatible. However, when enzymes had different
digestion requirements and were known to perform poorly in a generalised multicore
buffer, digestion was carried out with first one of the enzymes and then the other,
with each enzyme in its own buffer with the lowest salt concentration used first.
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Figure 2.7
Agarose gel electrophoresis following single and double restriction enzyme
digests.
a)
M 1 2 3 4 5 6 7 8 9
IJ —: 'A- S3- v -•
'




Putative typel IGF receptor plasmid cut with BamHl (present in bovine sequence) (lanes 1, 4, 7), or
Smal (present in human sequence) (2, 5, 8), or uncut (3, 6, 9). DNA Marker X (M; Roche
Diagnostics Ltd).








Putative typel IGF receptor plasmid (lanes 1-4) and insulin receptor plasmid (5-8) cut with Notl and
Ncol (1, 3, 5, 7) or uncut (2, 4, 6, 8). PCR Marker (M; Promega).
c)
M C IJ C U C IJ C IJ C IJ C IJ C IJ C IJ M
2799 bp
Putative IGF-I plasmid cut with Xhol (C) or uncut (U). DNA Marker VII (M; Roche Diagnostics
Ltd)
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2.7.3 PCR confirmation of ligation
PCR was also used for further confirmation of successful ligation. To lpl of ligation
reaction (lOng) was added 11 pi of dH20, 2pl of deoxynucleotides (dNTPs)
(Promega), 2pl of lOx PCR buffer (Roche Diagnostics Ltd), and 3pl of MgCl2. The
samples were mixed, placed in the thermocycler at 93°C and lpl of taq/primer mix
added prior to continued cycles of amplification.
Following initial confirmation of successful ligation, cultures of putative
recombinants were used to streak out L. agar plus ampicillin plates (Section 2.7.1).
Plates were incubated overnight at 4°C, single colonies removed and used to
inoculate 5ml of L. broth plus ampicillin (6mg/100ml). Tubes were incubated at
37°C with shaking for approximately 8hr. The culture was then used to inoculate
500ml of L. broth plus ampicillin (6mg/100ml) grown overnight at 37°C with
shaking.
2.7.4 Maxi plasmid preparation
Large scale preparation of plasmid DNA was carried out using the Wizard Maxiprep
system (Promega). A 5ml aliquot of overnight culture was put aside for later use. The
remainder of the culture was pelleted by spinning in a centrifuge bottle at 5,000g for
10 min at 22°C (Beckman JA-14). The bacterial pellet was resuspended in 15ml of
resuspension solution and the pellet disrupted with a glass rod. Cell lysis solution
(15ml) was added, gently mixed and allowed to stand for 20 min. Neutralisation
solution (15ml) was then added, mixed gently by inversion and the precipitate
pelletted by centrifugation at 14,000g for 15 min at 22°C. The supernatant was then
filtered through 4 layers of muslin into a measuring cylinder and 0.5 volumes of
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isopropanol added. After mixing by inversion the sample was spun at 14,000g for 15
min at 22°C. The supernatant was poured off and the pellet ofDNA resuspended in
2ml of lx TE buffer. DNA purification resin (10ml) was added and swirled to mix,
and then loaded onto the Maxicolumn attached to a vacuum manifold. The centrifuge
bottle was rinsed with column wash solution (13ml) which was then applied to the
Maxicolumn under vacuum. A further 12ml of column wash was added, followed by
5ml of 80% (v/v) ethanol. Once the solutions had been drawn through the column,
the vacuum was maintained for a further minute to dry the resin. The column was
removed from the vacuum and placed inside a screw top tube. Residual column wash
was then removed by centrifugation in a swinging bucket rotor at 2,500 rpm for 5
min and a further 5 min on the vacuum. The column was transferred to a fresh screw
top tube and 1.5ml of preheated (65°C) water was applied to the column. After
standing for 1 min, DNA was eluted by centrifugation in a swinging bucket rotor at
2,500 rpm for 5 min and stored at 4°C. Optical density of a suitable dilution was
measured at 260nm using a 1-cm path-length spectrophometric cuvette. DNA
concentration was calculated using the formula
optical density of 1 at 260nm = 50pg/ml ofDNA.




Stocks of successful bacterial transformations were prepared for future use from 5ml
of overnight culture previously set aside. Cells were pelleted by centrifugation at
4000 rpm for 15 min at room temperature, resuspended in 1ml of TM buffer and 1ml
of glycerol, and stored in 0.5ml aliquots at -70°C.
2.8 DNA sequencing
DNA was sequenced using the Sequenase Version 2.0 kit (Amersham Pharmacia
Biotech UK Ltd), based on a dideoxy-mediated chain-termination method. The DNA
polymerase "Sequenase" initiates enzymatic synthesis of a DNA strand
complementary to the template at the site where an oligonucleotide primer anneals
specifically to the template. Deoxynucleotides are then added to the growing DNA
chain until a competing dideoxynucleotide (ddNTPs) is incorporated, blocking
further strand synthesis. Four separate reactions, each with a different ddNTP,
generate chains of various lengths that terminate at each Adenosine, Cytidine,
Guanosine or Thymidine in the template. The inclusion of a radiolabelled nucleotide
enables the chains to be visualised by autoradiography after separation by high-
resolution electrophoresis, and the template sequence deduced.
DNA sequencing was performed in five steps as detailed below.
2.8.1 Preparation of double stranded DNA
Double stranded DNA template was subjected to sequencing and required initial
denaturation. An aliquot of DNA (5pg in 50pl) was denatured under alkaline
conditions by the addition of 0.1 volume of 2M NaOFl, 2mM EDTA (30 min, 37°C).
The mixture was neutralised by adding 0.1 volume of 3M NaAc (pH 5.5) and the
DNA precipitated with 4 volumes of ethanol (-20°C, 30 min). The denatured DNA
was then pelleted at high speed in a microcentrifuge at 4°C, washed with 70% (v/v)
ethanol, air dried and resuspended in 7pl of dH20. A control reaction was also
performed using single stranded DNA of known sequence (5pi of DNA + 2pl of
water).
2.8.2 Anneal template and primer
To the DNA was added lpl of oligonucleotide primer and 2pl of reaction buffer. The
primer was annealed to the template by heating at 65°C for 2 min and cooling to
room temperature over a period of approximately 30 min, before being placed on ice.
2.8.3 Labelling reaction
To the annealed template-primer mix was added lpl of 0.1M DTT, 2pl of labelling
mix (1.5pM of dGTP, dCTP, dTTP), 0.5pl of [a-35S]dATP (Amersham Pharmacia
Biotech UK Ltd) and 2pl of prediluted Sequenase (diluted 1:8 in ice cold enzyme
dilution buffer). The contents were mixed thoroughly and incubated at room
temperature for 5 min.
2.8.4 Termination reaction
Aliquots of labelling reaction (3.5pi) were transferred to one of four termination
reactions containing prewarmed dideoxy GTP, dideoxy ATP, dideoxy TTP or
dideoxy CTP (2.5pl). Contents were mixed and DNA synthesis continued at 37°C
for 5 min, until halted by the addition of 4pl of stop solution. After thorough mixing
samples were placed on ice prior to electrophoresis.
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2.8.5 Acrylamide gel electrophoresis
A pair of glass plates, one slightly shorter in length, were repeatedly rinsed with
distilled water and dried. The inner side of the small plate was coated with an
acrylamide-releasing agent and both plates wiped with ethanol. The plates were
placed together, separated by a spacer and then sealed together along the sides and
bottom of the assembly using tape. A 6% monomer acrylamide gel was prepared
using the Sequegel Sequencing System (National Diagnostics). Sequegel concentrate
(24ml), diluent (66ml) and buffer (10ml) were mixed on ice and the polymerising
agents N,N,N',N'-tetramethylethylenediamine (TEMED) (40pl) and ammonium
persulphate (500pl of 10% v/v) were added. The solution was gently mixed and
poured between the plates using a syringe. An inverted comb was inserted between
the plates to form a flat upper surface, clamps were applied and the gel left to
polymerise for at least lhr. The clamps were then released and the comb removed.
The plates were rinsed and the sealing tape removed, prior to placing in the vertical
electrophoresis apparatus. Running buffer was poured into the top reservoir (lx
TBE) and the apparatus checked for leaks prior to the addition of buffer to the
bottom reservoir (lx TBE, 0.6M NaAc). Top buffer was used to rinse the gel surface
and the sharks-tooth comb inserted to form sample wells. Stop solution (3 pi) was
added to alternate wells to check against leaks, and the gel pre-run for at least 15 min
at 40W. Immediately before loading, samples were denatured by heating to 75°C for
2 min. Electrophoresis was then continued for approximately 2hr. Once the
bromophenol band reached the bottom gel edge the power supply was stopped and
the plates removed. The plates were levered apart, leaving the gel adhered to the
large plate. The gel was transferred to a solution of 10% (v/v) acetic acid, 10% (v/v)
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methanol in distilled water for 15 min before being lifted off onto fdter paper
(Whatman). The upperside of the gel was covered in clingfdm and the gel placed in a
vacuum dryer (Bio-Rad Laboratories Ltd). Once the gel was dry, the clingfilm was
removed and the gel exposed to X-ray film overnight in a cassette with intensifier
screens. The film was developed using an automatic film developer (X-OGraph
Compact X2, supplied by HA West).
2.9 Preparation of DNA template for transcription in vitro.
2.9.1 Plasmid linearisation
Following successful sequencing and comparison of insert to target, the DNA
plasmid was linearised to enable production of "run-off' transcripts derived largely
from the insert sequence alone. Restriction enzymes for linearisation were chosen to
avoid the generation of 3' protruding ends, which are linked to extraneous transcript
production, did not cut the insert and were present at only one site within the
plasmid. Plasmids were cut in the presence of excess enzyme. A typical reaction
(200pl) contained 50pg of template in the presence of 200 units of enzyme
appropriately buffered, incubated at 37°C for lhr and continued overnight at 4°C. In
order for subsequent transcription to be successful, digestion for linearisation must
be performed to completion. Aliquots of "cut" versus "uncut" were run on a 1%
(w/v) low melting point agarose gel (SeaPlaque; Flowgen) to check for complete
digestion (Figure 2.8). In the absence of complete linearisation following ethidium
bromide staining (0.5pg/ml; 30 min), destaining in water (30 min) and UV
visualisation, bands of cut
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Figure 2.8
Agarose gel electrophoresis to check for plasmid linearisation.
1 2 3 4 5 6
a)
IGF-I plasmid uncut (1), cut with Ncol (2) or Nsil (3).
IGF-II plasmid uncut (4), cut with Ncol (5) or Nsil (6).
Insulin receptor plasmid uncut (1), cut with Ncol (2) or Notl (3).
Typel IGF receptor uncut (4), cut with Ncol (5) or Notl (6).
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template were excised from the gel using a scalpel blade, placed into preweighed
1,5-ml tubes and weighed.
DNA was purified from the surrounding agarose either by phenol extraction or using
the QIAquick gel extraction system (Qiagen).
2.9.2 Extraction of linearised plasmid
2.9.2.1 Phenol extraction.
To the weighed slice was added 3 volumes of water. The agarose was remelted at
65°C for 10 min and mixed well. An equal volume of phenol pH8 (Appligene Oncor)
was added, well mixed and spun for 2 min. The supernatant was removed to a clean
tube and phenol extraction repeated until the solution appeared clear. The solution
was then subjected to phenol chloroform isoamyl alcohol (PCI), chloroform isoamyl
alcohol (CI), ethanol precipitation.
2.9.2.2 Phenol chloroform isoamyl alcohol (PCI), chloroform isoamyl alcohol
(CI), ethanol precipitation.
To the sample was added an equal volume of PCI (25:24:1 (v/v)). The sample was
vortexed, spun and the top layer removed to a clean tube. To the supernatant was
added 1 volume ofCI, the sample was then vortexed, spun and the top layer removed
to a clean tube. Then 0.1 volume NaAc (3M pH 5.5) was added, and then 2 volumes
of 100 % (v/v) ethanol. The sample was then mixed and placed at -20°C for at least
30 min to precipitate the DNA. The DNA was recovered by centrifugation at 4°C for
20 min, washed in 70 % (v/v) ethanol, and centrifuged again. The supernatant was
removed and the tube upturned and the pellet air dried for 10 min. The DNA was
then resuspended in 50pl ofDEPC water, and stored at -20°C in 1.5pl aliquots.
2.9.2.3 QIAquick Gel Extraction
The DNA fragment was removed from the agarose gel with a clean sharp scalpel,
trimmed to remove excess agarose and placed in a pre-weighed tube. The gel slice
was weighed and 3 volumes of buffer QX1 added to 1 volume of gel (where lOOmg
gel is equivalent to lOOpl of buffer). The gel slice was dissolved by incubation at
50°C for 10 min, with vortexing every 2-3 min. After the gel slice had completely
dissolved, lOpl of 3M NaAc (pH5) were added to ensure a pH suitable for adsorption
of DNA to the QIAquick membrane (pH<7.5). One gel volume of isopropanol was
added to the sample and mixed. The DNA sample was loaded onto a QIAquick
column placed in a 2ml collection tube, microcentrifuged for 1 min and the flow
through discarded. The column has a maximum volume of 800pl, sample volumes
greater than 800pl required multiple loading. To ensure complete removal of agarose
from the sample 0.5ml of buffer QX1 was added and centrifuged for 1 min. The
column was washed with 0.75ml of buffer PE, centrifuged for 1 min and the flow
through discarded. Residual column wash was removed by a further 1 min
centrifugation. The QIAquick column was transferred to a clean 1.5ml centrifuge
tube. To elute DNA, 50pl of H20 was added to the centre of the column, allowed to
stand for 1 min and then centrifuged for 1 min.
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2.9.3 Proteinase digestion
Following the removal of agarose contaminants by either method, proteinase K
digestion was performed. To the linearised plasmid sample was added lOpl of
proteinase K (lmg/ml 30U/mg; Promega) in the presence of lOpl of lOx proteinase
K buffer to a total volume of lOOpl. The sample was incubated for lhr at 65°C. The
digestion was halted by PCI:CI:Ethanol precipitation (Section 2.9.2.2) and the DNA
pellet resuspended in 50pl of DEPC-water. Template was stored in 2pl aliquots at -
20°C for subsequent riboprobe synthesis.
2.10 Synthesis of high specific activity radiolabelled RNA probes
2.10.1 Transcription
RNA synthesis in vitro was performed to produce radio-labelled RNA transcripts,
using P-UTP for RNase protection assays and S-UTP for in situ hybridisation
studies. To prevent the precipitation of template DNA in the presence of cold
spermidine from the 5x buffer, non-enzymatic components were allowed to
equilibrate at room temperature for lhr prior to transcription, and subsequently the
mixture was held at room temperature during successive additions.
The transcription mix contained 4pi of 5x transcription buffer (Promega), lpl of
1 OOmM DTT (Promega), 1 pi (20U) of RNasin ribonuclease inhibitor (Promega), 4pl
of nucleotide mix (ATP, GTP, CTP each at lOmM; Promega), lpl of linearised
template (0.2-lmg/ml), 2.5pl of 32P-UTP (20mCi/ml) or 5pl of 35S-UTP (20mCi/ml)
(Amersham Pharmacia Biotech UK Ltd), and lpl (20U) of RNA polymerase
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(typically Sp6, T7 or T3; Promega) in a volume of 20pl. The reaction mix was
incubated at 37°C for lhr.
Following transcription the DNA template was removed by digestion with DNase.
To the mix was added lOpl of yeast transfer ribonucleic acid (tRNA) (1 lmg/ml), 8pl
of 5x transcription buffer, lpl of RNasin and lp.1 (1U) of RNase-free DNase
(Promega). A lpl aliquot of labelled probe was removed and diluted 1:10 in water
for subsequent determination of percent incorporation and specific activity. The
remaining mix was incubated at 37°C for 15 min. In order to limit problems of high
background and to give optimum sensitivity, unincorporated nucleotides were
removed from the labelled probe by applying the transcription mix to a TE-Midi
select G-50 spin column (CP Laboratories).
The gel contained within the column was resuspended by inversion, and shaken with
a sharp downward motion to draw the resin from the top closure. The column
closures were removed and the column placed into a collection tube, prior to
microcentrifugation (90 sec). The collection tube was discarded and the column
placed in a second collection tube. The 50pl sample was applied to the surface of the
gel bed and allowed to stand for 2-3 min. The loaded column was then spun for 60
sec (Beckman E) to elute the labelled probe free of unincorporated nucleotides, into
a solution ofTE buffer.
2.10.2 Determination of percent incorporation and probe specific activity
Aliquots (lpl) of the 1:10 dilution of labelled probe removed previously were
spotted onto duplicate (1cm diameter) glass fibre filters (Whatman International
Ltd), allowed to air dry and used to determine total cpm per microlitre. In order to
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calculate incorporation, a further 1 pi of the 1:10 dilution was added to lOpl of yeast
tRNA (1 lmg/ml) in a total volume of lOOpl, mixed and 0.5ml of ice-cold 5% (w/v)
trichloroacetic acid (TCA) added. The mix was placed on ice for 5 min, then applied
to glass fibre filters prewetted with 5% TCA under vacuum. The mix was drawn
through the filters, washed three times with 1ml of 5% (w/v) TCA and rinsed once
with 3ml of 100% (v/v) ethanol. The filters were then dried under vacuum. To
calculate the specific activity of the probe lpl of eluted probe was applied to
duplicate glass fibre filters and allowed to air dry. The six dry filters were then
placed into scintillation vials, 2ml of scintillation fluid (Optiphase HiSafe 3, Fisher
Scientific UK Ltd) added and the samples counted in a P-counter.
Percentage incorporation was calculated as TCA precipitated cpm/ total cpm x 100.
Specific activity of the probe is expressed as the total incorporated cpm/ total pg
RNA synthesised.
2.11 In situ hybridisation
2.11.1 Prehybridisation
2.11.1.1 Cryostat sections
Sections of ovarian tissue (14pm) were cut at -20°C using a cryostat (Shandon OT,
Shandon Scientific Ltd), and mounted onto prechilled microscope slides (Superfrost-
Plus, Merck Ltd). Sections were stored in desiccated air-tight boxes at -80°C until
required. For each hybridisation, two sections per animal were hybridised with the
antisense probe and one section was hybridised with the sense probe.
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Slides were removed from -80°C and allowed to warm to room temperature. All pre-
hybridisation steps were performed to minimise RNase contamination, using DEPC
treated solutions and baked glassware. Sections were fixed in 4% (v/v) formaldehyde
in lx PBS for 5 min, and then hydrated in 2x SSC for 2 min at room temperature.
Sections were acetylated in 0.25% (v/v) acetic anhydride in 0.1M triethanolamine
HC1, 0.154 M NaCl (pH8) for 10 min with shaking. Sections were then rinsed in 2x
SCC and dehydrated in 60%, 80%, 95% and 100% (v/v) ethanol each for 2 min.
Sections were then delipidated in chloroform for 5 min, and returned to 100% and
then 95% (v/v) ethanol each for 2 min, before being left to air dry.
2.11.1.2 Paraffin embedded sections.
Sections of ovarian tissue fixed in 4% (w/v) paraformaldehyde and embedded in
paraffin were cut at 8 micron on a microtome and floated onto pre-coated microscope
slides (Super-Frost, Merck Ltd). Sections were twice placed in Histoclear (National
Diagnostics) for 10 min, followed by 100% ethanol (2x 2 min) and 95%, 80%, 60%,
and 30% (v/v) ethanol each for 2 min. Sections were then washed in 0.85% (w/v)
NaCl and lx PBS each for 5 min prior to fixation in 4% (w/v) paraformaldehyde in
lx PBS for 20 min. Tissue was then treated with proteinase K (lmg/ml) in 0.01M
EDTA, 0.1M Tris for 7.5 min, and twice washed in lx PBS for 5 min. Slides were
then placed into 4% (w/v) paraformaldehyde in lx PBS for a further 5 min, briefly
rinsed in dH20 and then twice washed in 2x SSC each for 2 min. Slides were





Hybridisation was performed using 50pl of S-labelled riboprobe diluted to 1 x
107cpm/ml in hybridisation buffer containing 50% (v/v) formamide, lx Denhardt's
solution, 0.05M DTT, 500pg/ml yeast tRNA and 10% (w/v) dextran sulphate. Slides
were placed in airtight chambers humidified with 50% (v/v) formamide in lx SSC,
diluted probe applied, and covered with a piece of parafilm. Hybridisation was
performed overnight at 55°C.
2.11.3 Post hybridisation
Following hybridisation, the parafilm was removed by repeatedly dipping the slides
in 2x SSC pre-warmed to 55°C. Excess probe was removed by washing the slides
twice in pre-warmed 2x SSC each for 15 min, at room temperature with shaking.
Sections were then treated with RNase A (20 mg/ml) in 2x SSC, to digest
mismatched probe and hence reduce non-specific binding. RNase digestion was
performed for 1 hour at 37°C in a slow shaking water bath. Slides were then washed
at 55°C in 2x SSC for 15 min, lx SSC for 15 min, 50% (v/v) formamide in lx SSC
for 30 min and twice in O.lx SSC each for 15 min, with each wash supplemented
with 0.1% (v/v) (3-ME. Sections were then dehydrated in 60%, 80%, 95% and 100%
(v/v) ethanol each for 2 min at room temperature and air dried.
Slides were dipped in (50% v/v) Ilford K-2 emulsion (HA West) warmed to 42°C,
and then left to dry overnight. Slides were then placed in air-tight desiccated boxes
and kept at 4°C for a three week exposure period. The slides were then placed in
50% (v/v) Kodak D-19 developer (HA West) for 2.5 min, rinsed in water for 30 sec
and fixed in 20% (v/v) Ilford Hypam Fix (HA West) for 3 min. Slides were then
lightly counterstained with haemotoxylin and eosin and mounted for microscopic
examination under light and darkfield illumination.
2.12 RNase protection assays
Total RNA (25 pg) from luteal and liver homogenates was incubated simultaneously
with low specific activity 18S ribosomal RNA antisense riboprobe (3000 cpm/
sample; 1.5 x 106 cpm /ml), synthesised using a T7 RNA 18S template (AMS
Biotechnology (UK) Ltd.) and high specific activity riboprobes directed against the
target RNA of interest (100,000 cpm/ sample; 5 x 107 cpm /ml). Riboprobes were
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synthesised as described above (see section 2.10) using P-UTP. Hybridisation was
performed in 1,4-piperazine-diethanesulfonic acid (PIPES) buffer (0.025M, pH 6.8)
containing NaCl (0.4M), EDTA (l.OmM, pH 8) and formamide (50% v/v). Samples
were incubated for 10-min at 85°C, and then overnight at 55°C. Following overnight
incubation 500pl of RNase digestion buffer (0.3M NaCl; 7.5M Tris-HCl buffer, pH
8; 5mM EDTA, pH7.5), containing 2pg/ml RNase T1 and 40pg/ml RNase A (Roche
Diagnostics Ltd) were added, and samples incubated for a further 30-min at 37°C.
RNase digestion was subsequently terminated by incubation with Proteinase K
(200pg 30U/mg; Promega) with 20pl 10% (w/v) sodium dodecyl sulphate (SDS) for
30 min at 37°C. Samples were then precipitated in isopropanol, resuspended in gel
loading buffer, heated to 90°C and loaded onto 6% monomer sequencing gels
(section 2.8.5) (Sequegel, National Diagnostics). Gels were run in lx TBE buffer,
and were subsequently lifted off onto filter paper, and exposed to X-ray film
overnight at -70°C with intensifying screens. Films were developed using an
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automated processor (X-OGraph Compact X2, supplied by HA West) and protected
RNA bands viewed.
The protection of bovine IGF-I, IGF-II, the type 1 IGF receptor, IGFBP-3, IGFBP-4
and porcine IGF-I riboprobes with total luteal and liver RNA are included in the
appendix for further confirmation of probe specificity.
2.13 Progesterone Assay
Plasma progesterone concentrations were analysed by radioimmunoassay as
described by Corrie et al., (1981) and modified using a non-extraction assay by Law
et al., (1992). All reagents were diluted in phosgel assay buffer. Standard solutions
were prepared from P-0130 progesterone (Sigma-Aldrich Company Ltd), to give
standards of 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000 and 2000 pg/tube. Plasma
(50pl) from ovariectomised animals was added to all standard tubes, which were
assayed in triplicate and made up to 500pl in assay buffer. Two quality controls (one
high progesterone and one low progesterone) were assayed with the plasma samples.
Plasma samples were dispensed in duplicate and made up to 500 pi 1 with assay buffer.
[125I]-Labelled progesterone (11a glucuronide hemisuccinate; Amersham Pharmacia
Biotech UK Ltd) was reconstituted in assay buffer to give 12-15,000 cpm per 100pl,
incorporating lmg/ml of 8-anilino-l-naphthalene sulfonic acid (ANS). Standards and
samples were incubated with lOOpl of label and 200pl rabbit antiprogesterone
antiserum (SAPU: diluted 1:50,000). Primary antibody cross reactivity is detailed in
the appendix. Blanks received 200pl assay buffer. All tubes were vortexed and left to
incubate at room temperature for at least 3hr. In order to separate free and antibody-
bound progesterone, donkey-anti-rabbit serum (lOOpl) (SAPU) (1:35 in assay buffer
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containing 10% 0.1M EDTA), and normal rabbit serum (SAPU) (1:300) were added
to all tubes except totals. The tubes were vortexed and left to incubate at 4°C
overnight. All tubes except totals were prewashed by adding 1ml of cold assay buffer
and spun at 2000g for 30 min at 4°C. The supernatant was then decanted and the
tubes allowed to dry briefly, before counting the activity of the precipitates.
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Chapter 3. Expression of mRNA encoding IGF-I, IGF-II and the
type 1 IGF receptor in the bovine corpus luteum at defined stages of
the oestrous cycle.
3.1 Summary
Previous studies have implicated insulin-like growth factors, IGF-I and -II, in the
regulation of ovarian function. We have investigated the localisation of mRNA
encoding IGF-I, -II and the type 1 IGF receptor to further determine the roles of the
IGFs within the bovine CL at precise stages of the oestrous cycle using in situ
hybridisation. Luteal expression of IGF-I, -II and the type 1 IGF receptor mRNA was
detected throughout the oestrous cycle. IGF-I mRNA expression varied significantly
during the cycle. IGF-I mRNA levels were significantly higher on day 15 than day
10, and IGF-I mRNA in the regressing CL 48 hours after exogenous PGF2a was
significantly greater than in the early or mid-luteal phase (day 5 and 10). In contrast,
there was no significant effect of day of the oestrous cycle on mRNA expression for
IGF-II and the type 1 IGF receptor in the CL. IGF-II mRNA expression was
localised to a subset of steroidogenic luteal cells and was also associated with cells
of the luteal vasculature. Messenger RNA encoding the type 1 IGF receptor was
widely expressed, in a pattern suggestive of steroidogenic luteal cell expression.
These data clearly demonstrate that the bovine CL is a site of IGF production and
reception throughout the luteal phase. Importantly however, this study highlights the




Whilst pituitary-derived LH is the primary regulator of CL function, it is becoming
apparent that other factors of extra- and intra- ovarian origin have the potential to
modulate the luteal response to gonadotrophins. The IGF system plays a central role
in these interactions and studies in vitro have shown that both IGF-I and IGF-1I have
wide ranging effects on luteal function (Giudice, 1992; Spicer and Echternkamp,
1995).
The formation of the CL in response to the preovulatory surge of LH involves
changes in cellular morphology and ultrastructure, and key alterations in steroid
hormone synthesis (Smith et al., 1994c). In sheep and cattle following the LH surge,
production by the ovulatory follicle of oestradiol and androstenedione ceases and
progesterone synthesis increases. This dramatic shift in steroidogenesis is the product
of changes in the tissue content of steroidogenic enzymes and factors involved in
steroid precursor provision (Couet et al., 1990; Rodgers et al., 1986b, 1987; Voss
and Fortune, 1993).
IGF-I enhances LH receptor binding capacity in rat granulosa cells luteinised in
culture, acting in synergy with FSH (Adashi et al., 1985c). The increase in receptor
numbers is accompanied by increased sensitivity to LH and potentiation of its
luteotrophic effects. In addition, IGF-I has direct stimulatory effects on key
components of the steroidogenic pathway, and increased progesterone secretion has
been demonstrated in rat (Talavera and Menon, 1991), ovine (Khan-Dawood et al.,
1994), porcine (Yuan and Lucy, 1996a), rabbit (Constantino et al., 1991), human
(Devoto et al., 1995) and bovine (McArdle and Holtorf, 1989; Sauerwein et al.,
1992) luteal tissue. IGF-I has potent actions on sterol metabolism that include
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amplification of StAR (Balasubramanian et al., 1997) and the delivery and utilisation
of steroid precursors (Veldhuis, 1989). The key steroidogenic enzymes P450scc and
3(3-HSD are also targets of IGF action, demonstrated by both increased gene
expression and enzyme activity in response to IGF-I stimulation in the rat (deMoura
et al., 1997; Magoffin et al., 1990; Magoffin and Weitsman, 1993).
Many studies have focused on the potential roles of IGF-I in ovarian function.
However, the regulatory effects of IGF-II have not been studied to the same extent,
possibly because IGF-II has been considered to exert its effects predominantly
prenatally (Hossner et al., 1997). Our recent results have indicated that IGF-II is the
major ligand of the IGF system in the bovine follicle (Armstrong et al., 2000a).
Moreover, IGF-II has been shown to increase progesterone production by luteal cells
in vitro (Sauerwein et al., 1992) and detailed studies in porcine granulosa cells have
demonstrated potent stimulatory effects of IGF-II on progesterone biosynthesis,
largely facilitated by enhanced sterol delivery via increased lipoprotein binding,
internalisation and utilisation, and P450scc enzyme activity (Garmey et al., 1993).
Studies in vitro strongly suggest a role for IGF-I and/or IGF-II in regulating the
acquisition and maintenance of differentiated function in the CL. However, the IGFs
may also have additional actions within the ovary, particularly within the CL, that
extend beyond the regulation of steroidogenesis to include angiogenesis and
apoptosis. The vascularisation of the developing CL increases significantly to
support tissue growth and steroid production, in addition to cellular differentiation of
luteal cells. The primary regulators of ovarian angiogenesis appear to belong to the
VEGF and FGF families (Reynolds and Redmer, 1998), though IGF-I has also been
implicated in neovascularisation occurring in response to injury (Hansson et al.,
1989), in some disease states (Vialettes et al., 1994) and in the classical angiogenic
model of the rabbit cornea (Grant et al., 1993). Immunohistochemical studies also
suggest a role for IGF-II in the regulation of luteal vasculature (Amselgruber et al.,
1994).
The CL is a transient endocrine gland, which must undergo functional and structural
regression in the absence of pregnancy. Morphological and biochemical events
suggestive of apoptotic cell death have been associated with this controlled demise
(Juengel et al., 1993; Sawyer et al., 1990; Zeleznik et al., 1989). The interaction of
the IGF receptor with IGF-I or IGF-II has been shown to protect a range of cell
types, including ovarian cells (Chun et al., 1994), from apoptosis (Harrington et al.,
1994; Parrizas and LeRoith, 1997; Robinson Singleton et al., 1996).
The aims were to understand the role of the IGFs in the growth and regression of the
bovine CL, by describing the temporal and spatial changes in the expression of the
mRNAs encoding IGF-I, IGF-II and the type 1 IGF receptor throughout the luteal
lifespan.
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3.3 Materials and Methods
3.3.1 Animals
The oestrous cycles of 9 Holstein/Friesian cows were synchronised with intravaginal
progesterone release (PRID; 1.55g P4, lOmg oestradiol benzoate; Sanofi Animal
Health Ltd) maintained for 12 days, and PGF2a analogue (Estrumate; 500 pg;
Coopers Animal Health Ltd) administered intramuscularly (i.m) on the day before
PRID removal to induce luteolysis. Ovaries were collected on days 5, 10 or 15 after
the onset of oestrus (day 0) in the subsequent cycle (n=3 per group). An additional
three animals were treated with PGF2a analogue and the ovaries collected 48 hours
later to study the regressing CL. Following ovariectomy, all corpora lutea were
excised and divided into blocks. Luteal pieces were either, 1) frozen in liquid
nitrogen and stored at -80°C prior to cryostat sectioning for in situ hybridisation or
RNA extraction, or 2) fixed in 4% (w/v) paraformaldehyde and processed for
paraffin embedding. Frozen sections from ovaries collected for follicular studies
(Armstrong et al., 1998) were also subjected to in situ hybridisation.
Blood samples (10ml) were collected on alternate days during the synchronised cycle
by jugular or coccygeal venepuncture into tubes containing 1 OOjul of sodium citrate
(0.35 g/ml), from haltered and restrained animals. All blood samples were
centrifuged (lOOOg), and plasma separated and frozen at -20°C until assayed for
progesterone (see section 5.3.2).
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3.3.2 RNA probes
Homologous bovine IGF-II and type 1 IGF receptor probes were prepared using the
primer pairs detailed in section 2.4. A plasmid containing a porcine IGF-I probe was
donated by Dr M Lucy (University ofMissouri). Riboprobe specificity was tested by
RNase protection assay (see section 2.12). The protection of [32P]-labelled
(Amersham Pharmacia Biotech) bovine IGF-II, bovine type 1 IGF receptor and
porcine IGF-I riboprobes with total luteal and liver RNA (25pg) is shown in the
appendix.
Isotopic antisense and sense RNA probes for in situ hybridisation were transcribed
from linearised cDNA templates following a standard transcription protocol (see
section 2.10.1) using [35S]-UTP (Amersham Pharmacia Biotech).
3.3.3 In situ hybridisation
Frozen sections (14 pm) of ovarian tissue were subjected to in situ hybridisation (see
section 2.11). Antisense RNA probes for IGF-I, IGF-II and the type 1 receptor were
each hybridised to two serial sections per CL or ovary. The sense probe for each
mRNA species was applied to a further serial section. The intensity of the in situ
hybridisation signal was quantified using a NIH-Image analysis system (NIH,
Bethesda, MD). Four fields of view were chosen within each slide and the number of
pixels occupied by silver grains counted. In order to minimise operator bias the
chosen fields of view corresponded to the points of the compass, North, South, East
and West on all sections. The position of each field was also selected to minimise
possible artefacts, for example, bright spots from scratches in the emulsion, holes or
tears in the tissue, and edge effects. The full extent of each field, viewed under the
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lOx objective, was then selected on the video screen and the signal quantified. This
was then presented as a percentage of the total number of pixels within the defined
area and antisense signals were then compared to their respective sense (background)
signals. Defined areas of a control slide were routinely selected and analysed to
ensure that alterations in microscope settings did not create between-session
variation.
3.3.4 Statistical Analysis
In situ hybridisation data was analysed using a split-plot analysis of variance
(ANOVA) (Genstat 5; Payne et al., 1993) to determine the effect of stage of the
oestrous cycle (treatment factor) on mRNA expression. Measurements made within
slides were nested within cows for use as the blocking factor. Significant differences
between timepoints were tested using least significant differences with a pooled
standard error of the difference (SED) determined by ANOVA. Differences between
stages were considered significant when P < 0.05.
3.4 Results
3.4.1 Expression of IGF-I mRNA
Messenger RNA encoding IGF-I was expressed in CL at all timepoints studied.
Expression was low and widespread, with areas of higher abundance towards the
periphery and in lines radiating through the CL (Figure 3.1). The exact identity of
these cells could not be determined. Concentrations of IGF-I mRNA varied
significantly with the day of the cycle (P = 0.027) (Figure 3.4a). Steady-state IGF-I
mRNA levels were significantly higher on day 15 than day 10, and the expression
observed in the regressing CL 48-hours after prostaglandin administration was
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significantly greater than IGF-I levels detected in the early and mid-luteal phase (day
5 and 10).
3.4.2 Expression of IGF-II mRNA
Messenger RNA encoding IGF-II was present in CL at all timepoints studied.
Expression was localised to a subset of steroidogenic luteal cells and was also
present in cells associated with blood vessels of the CL (Figure 3.2). Quantitative
analysis showed no significant effect (P > 0.05) of day of the oestrous cycle on IGF-
II mRNA expression (Figure 3.4b).
3.4.3 Expression of type 1 IGF receptor mRNA
At all timepoints studied, CL expressed mRNA encoding the type 1 IGF receptor.
The hybridisation signal was widespread and the pattern of hybridisation suggested
that expression was localised to steroidogenic luteal cells (Figure 3.3). Expression
was absent from peripheral (stromal/capsular) regions and some large blood vessels.
Statistical analysis revealed no significant changes (P > 0.05) in expression of
mRNA encoding type 1 IGF receptor throughout the luteal phase (Figure 3.4c).
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Figure 3.1. Bovine ovarian sections (14 urn) were probed with an IGF-I
antisense (a-f) or sense (g and h) riboprobe. The same fields of view are
shown under lightfield (a, c, e and g) and darkfield (b, d, f and h)
illumination. Localisation of mRNA encoding IGF-I is shown in luteal
tissue adjacent to a small follicle, at two different magnifications (a-d),
and in a further corpus luteum at higher magnification (e and f). Scale
bar represents 450 pm (a and b), 180 pm (c and d) and 90 pm (e-h ).
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Figure 3.2. Bovine ovarian sections (14 pm) were probed with an
IGF-II antisense (a-h) or sense (i and j) riboprobe. The same fields of
view are shown under lightfield (a, c, e, g, and i) and darkfield (b, d, f,
h, and j) illumination. Localisation of mRNA encoding IGF-II is
shown in a typical corpus luteum at three different magnifications
(a-f). Follicular expression is shown in theca tissue of a small follicle
(g and h). Scale bar represents 180 pm (a, b, g, and h), 90 pm (c, d, i,
and j) and 45 pm (e and f). *, G, and T represent a blood vessel,
granulosa cells, and theca cells respectively.
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Figure 3.3. Bovine ovarian sections (14 pm) were probed with a type 1
IGF receptor antisense (a-f) or sense (g and h) riboprobe, and the same
fields of view are shown under lightfield (a, c, e, and g) and darkfield
(b, d, f, and h) illumination. Localisation ofmRNA encoding the type
1 IGF receptor is shown in the same CL at two magnifications (a-d)
and in luteal tissue adjacent to a small follicle (e and f). The scale bar
represents 450 pm (a and b), 180 pm (e and f), and 90 pm (c, d, g and
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Figure 3.4.
Quantitative analysis of IGF-I (a), IGF-II (b) and the type 1 IGF receptor (c) mRNA
concentrations in bovine luteal tissue on days 5, 10 and 15 of the oestrous cycle, and
following exogenous prostaglandin (post PG). Luteal timepoints with different
superscipts are significantly different (P < 0.05). Bars represent pooled standard
error of the difference (SED). Messenger RNA concentration is expressed as the
percentage of the total number of pixels occupied by silver grains within a defined
area. Hybridisation with sense probes gave average background values of 2, 4 and 6
units for IGF-I, IGF-II and the type 1 IGF receptor respectively.
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3.5 Discussion
The present study describes the temporal and spatial changes in mRNAs encoding
IGF-I and -II, and the type 1 IGF receptor during growth and regression of the
bovine CL. It extends the current understanding of the IGF system in the CL of the
cow, being to our knowledge, the first detailed report of the localisation of mRNAs
encoding IGF-I, IGF-II and the type 1 IGF receptor throughout the luteal phase.
Messenger RNA encoding IGF-I, IGF-II and type 1 IGF receptor showed distinct
spatial patterns of expression within the bovine CL. IGF-I mRNA expression was
low throughout the CL, with areas of higher abundance towards the periphery and in
lines radiating through the CL. In contrast, mRNA encoding IGF-II was found in a
subset of steroidogenic luteal cells and also in association with luteal blood vessels.
Messenger RNA encoding type 1 IGF receptor was widely expressed throughout the
CL in a pattern suggestive of steroidogenic luteal cell expression, but was absent
from peripheral regions of the CL and some large blood vessels.
Whilst mRNA encoding IGF-I, IGF-II and type 1 IGF receptor differ spatially within
the bovine CL, only IGF-I mRNA showed significant temporal changes in
expression. In addition, follicular patterns of expression of mRNA encoding IGF-I,
IGF-II and the type 1 IGF receptor were in agreement with our previous observations
(Armstrong et al., 2000a).
Previous studies have reported the ability of IGF-I and IGF-II to regulate ovarian
function, and the expression of mRNA and protein components of the IGF system
within the ovaries of a range of species has led to the hypothesis that the IGF system
can exert its influence at the autocrine/paracrine level. Although studies of the local
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production of components of the IGF system is less complete for the CL than the
follicle, the bovine CL has been shown to express IGF-I mRNA (Einspanier et al.,
1990; Kirby et al., 1996; Vandehaar et al., 1995), and IGF-I and -II proteins have
also been localised in the bovine CL (Amselgruber et al., 1994). Moreover, binding
characteristic of the type 1 IGF receptor has been demonstrated in CL throughout the
luteal phase (Sauerwein et al., 1992). Messenger RNA encoding IGF-I, IGF-II and
the type 1 IGF receptor has recently been localised in bovine CL at uncharacterised
stages of the cycle (Perks et al., 1999). The present study further extends our
understanding of the role of the IGF system in bovine luteal function by the use of
precisely timed corpora lutea collected throughout the luteal phase.
In the present study, mRNA encoding IGF-I was demonstrated in the CL throughout
the oestrous cycle. However, the temporal changes in expression of IGF-I mRNA in
the ruminant CL remain controversial. An earlier study of the presence of IGF-I
mRNA in the bovine CL by Northern hybridisation demonstrated low expression in
the early luteal phase (days 1-5), which increased from days 6-11 to reach maximal
on days 12-17, before rapidly decreasing around the time of natural luteolysis (days
18-21) (Einspanier et al., 1990). In contrast, in the present study, IGF-I mRNA levels
were low in the early and mid luteal phase (day 5 and 10), increased significantly
between day 10 and 15, and were maximal following prostaglandin-induced luteal
regression. The increase in IGF-I mRNA between early and mid luteal groups
observed by Einspanier et al. (1990) is not supported by the results of the present
study. Differences in methodology may partly explain differences in IGF-I mRNA
expression patterns, since analysis of IGF-I mRNA expression by Northern
hybridisation is complicated by the similarity in size of major luteal IGF-I mRNA
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transcript(s) (3 to 5kb) and the 28S ribosomal RNA (4.7kb). The differences in IGF-I
mRNA expression observed between the present study and that of Einspanier et al.
(1990) might also be due in part to differences in tissue collection. The early luteal
phase group of Einspanier et al. comprises corpora lutea judged by macroscopic
observations to be 1 -5 days post-ovulation, and is therefore likely to include younger
CL than the present study where an oestrus synchronisation regime was used to
collect luteal tissue of a known age. If luteal IGF-I mRNA levels are lower prior to
day 5 this would not be reflected by the present study's first timepoint, but would
result in an increase between the early and mid luteal groups of Einspanier et al.
(1990). Indeed, luteal IGF-I mRNA concentrations were shown to increase between
day 3 and day 6 of the ovine oestrous cycle (Juengel et al., 1997), although others
had previously observed limited variation throughout the oestrous cycle of the ewe
(Perks et al., 1995).
An important regulatory role for IGF-I in the CL is suggested by IGF-I-stimulated
progesterone release in vitro, and further supported by positive immunostaining for
IGF-I in both large and small steroidogenic luteal cells (Amselgruber et al., 1994).
Expression of IGF-I mRNA in the bovine CL is confirmed by the present study, and
indicates that IGF-I may act as an autocrine/paracrine regulator of luteal function.
The correlation between increasing IGF-I mRNA and peak progesterone production
(Fields and Fields, 1996; Ireland et al., 1980) further implies a physiological
significance for locally produced IGF-I within the bovine CL. Increased IGF-I
expression during periods of high metabolic activity may reflect an important role for
IGF-I in stimulating key components of the steroidogenic pathway. It is interesting to
note that whilst IGF-I has been shown to influence the acquisition of differentiated
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function, that local expression is low during luteinisation.
It has also been suggested that IGF-I derived from the peripheral circulation might
act in an endocrine manner to regulate luteal function. Support for this theory is
provided by an apparent heterogeneity of immunostaining for IGF-I in the CL, which
may be dependent on the proximity of luteal cells to blood vessels, implying luteal
uptake of IGF-I (Amselgruber et al., 1994). In addition, there is evidence in extra-
ovarian tissues of IGF transport, whereby IGF peptides have been localised to
cellular sites within human foetal tissues which are distinct from the site of mRNA
expression (Hill et al., 1988), such that immunostaining reflects site of IGF binding
rather than production. Hence, although the IGF-I peptide is associated with luteal
cells (Amselgruber et al., 1994), these cells may not be the primary source of IGF-I
within the bovine CL. The relative importance of endocrine versus
autocrine/paracrine IGF-I stimulation in the CL remains to be determined.
Furthermore, the significance of high expression of IGF-I mRNA seen as radiating
lines within the CL remains unclear, though a similar pattern was described by Perks
et al. (1995) in the ovine CL. These cells may be endothelial in nature, although the
function and importance of IGF-I mRNA expression by cells lining a small number
of blood vessels in such a restricted pattern is unknown. Alternatively, the cells may
be steroidogenic luteal cells, and the expression pattern may be related to the
morphogenesis of the luteal lobules. Immune cells are also suggested sites of luteal
IGF-I expression (Perks et al., 1995).
The potential role of IGF-I during luteal regression also remains unclear. Einspanier
et al. (1990) demonstrated a reduction in IGF-I mRNA expression around the time of
natural luteolysis in the bovine CL, whilst induced luteolysis in the ewe (Juengel et
al., 1997) was not associated with any significant alteration in the expression of
mRNA encoding IGF-I up to 24 hours following the administration of PGF2a.
Furthermore, the expression of IGF-I mRNA was shown to be higher in the corpus
albicans than the CL of the ewe (Perks et al., 1995) and to double following
prostaglandin-induced luteal regression in the pregnant rat (Tamada et al., 1995).
The demonstration of a rapid decrease in IGF-I expression and content on days 18-21
of the cycle (Einspanier et al., 1990) suggests that bovine luteolysis is associated
with reduced IGF-I action. Since numerous stimulatory effects of IGF-I have been
shown in ovarian cells in vitro (Giudice, 1992; Spicer and Echternkamp, 1995), this
reduction of IGF-I expression in vivo might be expected to influence luteal function
both directly, and indirectly by modulating the trophic support of LH, so contributing
to the demise of the CL. In addition, decreased IGF-I and the subsequent abrogation
of type 1 IGF receptor activation may also influence apoptotic cascades. However,
studies to date have not addressed the potential of reduced IGF-I stimulation as a
proximal cause of luteal regression and cell death.
In the present study we observed maximal IGF-I mRNA expression 48 hours after
exogenous prostaglandin, at which time both functional and structural regressive
changes will have occurred (Juengel et al., 1993). As suggested in the ewe (Perks et
al., 1995) the high expression may be due to immune cell activity during the cellular
destruction and phagocytocis associated with structural luteal regression (Pate and
Townson, 1994; Penny et al., 1998). IGF-I is produced by immune cells (Baxter et
al., 1991; Rappolee et al., 1988), affects immunoregulation extensively (Renier et
al., 1996) and stimulates wound healing (Suh et al., 1992). Identification of the
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cellular source of IGF-I mRNA expression in the regressing CL will further our
understanding of the role of IGF-I in tissue remodelling.
The demonstration of local ovarian IGF-I mRNA production in previous studies has
favoured IGF-I rather than IGF-II as an autocrine/paracrine intra-luteal regulator. We
report here that the bovine CL is a site of high IGF-II mRNA expression, in
agreement with recent results from unstaged large bovine corpora lutea (Perks et al.,
1999). Although we were unable to detect any change in the level of IGF-II mRNA
expression throughout the luteal phase, the results highlight the importance of locally
produced IGF-II and suggest a major role in luteal function. It remains unclear
whether the balance of IGF-I to IGF-II has an important influence on luteal function
or if the growth factors serve different but crucial functions in different cell types.
The intense hybridisation for IGF-II mRNA in the luteal vasculature agrees spatially
with immunohistochemical observations (Amselgruber et al., 1994) which localised
IGF-II protein to perivascular cells. The site of IGF-II mRNA expression was not
fully determined in the present study. However, the hybridisation signal was not
limited to endothelial cells lining the vessels, and pericytes, fibroblasts or smooth
muscle cells may contribute to IGF-II mRNA expression. Whether the association of
IGF-II with blood vessels reflects a role for IGF-II in controlling angiogenesis, luteal
blood flow or interactions between vascular and steroidogenic cells requires further
investigation. Prior to this study, the interest in the potential role of IGFs in the CL
was based primarily on the ability of IGFs to stimulate luteal steroid biosynthesis.
However, for IGF-II in particular, additional functions and targets should now be
considered.
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The IGFs exert their effects by interacting with cell surface receptors. The type 1
IGF receptor is activated by both IGF-I and IGF-II binding. The presence of the type
1 IGF receptor within the bovine CL has been indicated by competitive binding
characteristics, as well as by the ability of IGF-I (and to a lesser degree IGF-II) to
modulate luteal function. The expression ofmRNA encoding the type 1 IGF receptor
throughout the lifespan of the CL therefore confirms and extends previous reports.
The spatial pattern of expression appears similar to that described in the ovine CL
(Perks et al., 1995). The lack of a temporal change in the pattern of expression is also
in agreement with the absence of alterations in receptor number observed previously
in the bovine CL (Sauerwein et al., 1992).
In addition to regulation at the level of gene expression, the IGFs are subject to
modulation by the specific binding of IGFBPs. IGFBPs control the bioactivity of
IGFs in a complex and incompletely understood manner, and can regulate the
bioavailability of IGFs and hence their interactions with IGF receptors. Future
studies of the complex interactions of IGFBPs with the IGFs and IGF receptors will
be necessary to further our understanding of the roles of IGF-I and IGF-II in
regulating bovine CL function.
In conclusion, the present study (i) describes the temporal and spatial patterns of
IGF-I, IGF-II and type 1 IGF receptor mRNA expression in the bovine CL
throughout the luteal phase, (ii) demonstrates that the bovine CL is a site of IGF
production and reception, and (iii) highlights the potential importance of IGF-II, in
addition to IGF-I, in bovine luteal function.
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Chapter 4. Expression of mRNA encoding insulin-like growth factor
binding protein -2, -3 and -4 in the bovine corpus luteum at defined
stages of the oestrous cycle
4.1 Summary
The insulin-like growth factors, IGF-I and -II, have important effects on luteal cells
in vitro, and the demonstration of luteal expression ofmRNA encoding IGF-I, IGF-II
and the type 1 IGF receptor in Chapter 3 is suggestive of paracrine/autocrine roles
for both IGF-I and IGF-II in the regulation of bovine luteal function. The actions of
IGF-I and IGF-II are modulated by association with members of a family of high
affinity IGFBPs, and to date the interaction of IGFs with IGFBPs has been shown to
attenuate the actions of IGFs on ovarian cells in vitro.
We have investigated the localisation ofmRNA encoding IGFBP-2, -3 and -4 using
in situ hybridisation to further determine the regulation of the IGFs within the bovine
CL at precise stages of the oestrous cycle. Luteal expression of mRNA encoding
IGFBP-2, -3 and —4 was detected throughout the oestrous cycle, and showed limited
temporal variation. Luteal expression of mRNA encoding IGFBP-2 and —4 was
predominantly low. In addition, a number of large blood vessels showed moderate to
intense hybridisation for IGFBP-2 mRNA. IGFBP-3 mRNA expression was also
associated with the luteal vasculature, and hybridisation was localised to cells lining
microvessels, suggestive of endothelial cell expression.
These data clearly demonstrate that the bovine CL is a site of IGFBP production and
hence IGF regulation throughout the luteal phase. In addition, this study highlights
the contribution of vascular expression of IGFBPs to bovine luteal function.
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4.2 Introduction
The actions of IGFs are modulated by binding to up to six high affinity IGFBPs
(Rechler and Clemmons, 1998). IGFBPs bind IGF-I and IGF-II with high affinity
and so regulate their access to IGF receptors. IGFBPs have been shown to
consistently block IGF-stimulation of ovarian cells. IGFBPs inhibit steroid
production (Mason et al., 1998; Spicer et al., 1997; Ui et al., 1989), and cell
proliferation (Bicsak et al., 1990), reduce ovulation rate and oocyte maturation
(Yoshimura et al., 1996), and induce apoptotic cell death (Chun et al., 1994).
However, in certain cases IGFBPs can potentiate IGF action (Conover et al., 1996).
IGFBP-2, -3 ,-4 and -5 have been detected in the follicular fluid of cattle, and
IGFBP concentrations vary with the stage of follicular development (Echternkamp et
al., 1994; Stewart et al., 1996). These changes are thought to regulate follicle
selection and dominance by altering IGF availability and follicular sensitivity to
gonadotrophins. Follicular fluid IGFBP concentrations are thought to be modulated
via changes in local production (Armstrong et al., 1998; Perks and Wathes, 1996),
changes in uptake from the plasma (Armstrong et al., 1996) or variable proteolysis
(Besnard et al., 1996, 1997).
IGFBPs have also been detected in both the CL and luteinised granulosa cells of
human and non-human primates (Fraser et al., 1998; Giudice et al, 1991), pig
(Gadsby et al., 1996; Samaras et al., 1992; Zhou et al., 1996,), rat (Erickson et al.,
1993, 1994; Nakatani et al., 1991) and sheep (Armstrong et al., 1996; Perks and
Wathes, 1996). In the cow, granulosa and theca cells in culture secrete IGFBPs
following luteinising stimuli (Sakal et al., 1992) and mRNA encoding IGFBP-2 and -
3 has been detected in luteal tissue (Kirby et al., 1996). Whilst marked species
variations have been shown to exist with regard to the expression of components of
the IGF system, evidence suggests that the IGFBPs could play important regulatory
roles in luteal function.
The work in this chapter aims to describe the temporal and spatial changes in
expression ofmRNA encoding IGFBP-2, -3 and -4 within the bovine CL throughout
the oestrous cycle.
4.3 Materials and Methods
4.3.1 Animals
The expression of mRNA encoding IGFBP-2, -3 and -4 was examined in the same
CL as described in section 3.3.1. In brief, CL were collected on day 5, 10 or 15
following oestrus synchronisation (n=3 per group), and 48 hours following PGF2a
administration (n=3).
4.3.2 RNA probes
A plasmid containing the bovine IGFBP-2 probe was a gift from Dr. M Lucy
(University of Missouri), and corresponds to positions 1084-1192 of a bovine
IGFBP-2 cDNA (Bourner et al., 1992). Homologous bovine IGFBP-3 and -4 probes
were prepared after reverse transcriptase PCR from total theca cell RNA (gifted by
Dr. DG Armstrong).
IGFBP-3 mRNA transcripts were amplified using a 21-mer upstream primer (5'-
ATTCCACCCCATCCACACCAA-3') and a 21-mer downstream primer (5'-
CACGTCCCCTTTCCCCTTCAC-3'). The amplified product (358 bp) corresponds
to position 611 to 968 of a bovine IGFBP-3 cDNA (Spratt et al., 1991). IGFBP-4
mRNA transcripts were amplified using a 21-mer upstream primer (5'-
ATCGAGGCCATCCAGGAAAGC-3') and a 21-mer downstream primer (5'-
CGCCCGGTGCAGCTCACTCTG-3'). The amplified product (228 bp) corresponds
to position 523 to 750 of a bovine IGFBP-4 cDNA (Moser et al., 1992).
Riboprobe specificity was tested by RNase protection assay (see section 2.12). The
protection of [32P]-labelled (Amersham Pharmacia Biotech) bovine IGFBP-3 and
IGFBP-4 riboprobes with total luteal and liver RNA (25 pg) is shown in the
appendix. A very weak protection of bovine IGFBP-2 was also detected in bovine
luteal RNA extracts (results not shown).
Isotopic antisense and sense RNA probes for in situ hybridisation were transcribed
from linearised cDNA templates using [35S]-UTP according to the protocol detailed
in section 2.10.
4.3.3 In situ hybridisation
Frozen sections (14 pm) of ovarian tissue were subjected to in situ hybridisation for
IGFBP-3 and IGFBP-4 as detailed in section 2.11. Additional paraffin sections were
utilised for IGFBP-2 (see section 2.11.1.2). Antisense RNA probes for IGFBP-2, -3
and -4 were each hybridised to two serial sections per corpus luteum or ovary. The
sense probe for each mRNA species was applied to a further serial section.
The intensity of the in situ hybridisation signal was quantified (see section 3.3.3),




The effect of stage of the oestrous cycle on mRNA concentration was determined by
a split-plot ANOVA (Genstat 5; Payne et al., 1993) using the hierarchical structure
previously described (see section 3.3.4).
4.4 Results
4.4.1 Expression of IGFBP-2 mRNA
Messenger RNA encoding IGFBP-2 was expressed in CL at all timepoints studied.
Luteal expression of IGFBP-2 was predominantly low. In several animals a more
intense punctate expression pattern was observed for IGFBP-2 mRNA (Figure 4.1a-
b). In addition, moderate to intense expression of mRNA encoding IGFBP-2 was
detected in large blood vessels within both the luteal and stromal tissue, and may be
localised to smooth muscle cells (Figure 4.1 d-f). Vascular expression was observed
to be heterogeneous, with some vessels appearing negative for IGFBP-2 adjacent to
those expressing IGFBP-2 mRNA. IGFBP-2 mRNA concentrations were not
significantly affected by day of the oestrous cycle (P >0.05).
4.4.2 Expression of IGFBP-3 mRNA
Messenger RNA encoding IGFBP-3 (Figure 4.2) was present in the CL at all
timepoints studied. Expression was predominantly localised to the vascular system,
and the strong expression by cells lining microvessels suggests that endothelial cells
are a probable site of expression. Quantitative analysis showed no significant effect
(P > 0.05) of day of the oestrous cycle on IGFBP-3 mRNA concentrations (Figure
4.4).
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4.4.3 Expression of IGFBP-4 mRNA
At all timepoints studied, CL expressed mRNA encoding IGFBP-4. The
hybridisation signal was diffuse and detected at moderate level. The pattern of
hybridisation is suggestive of steroidogenic cell expression (Figure 4.3). IGFBP-4
mRNA concentrations were similar throughout the oestrous cycle (P > 0.05).
4.5 Discussion
The present study describes the expression of mRNA encoding IGFBP-2, -3 and -4
during growth and regression of the bovine CL. Previous reports have demonstrated
that bovine theca and granulosa cells stimulated in culture to differentiate into luteal-
like cells secrete IGFBPs (Sakal et al., 1992) and bovine corpora lutea of the late
luteal phase (day 17) express mRNA encoding IGFBP-2 and -3 (Kirby et al., 1996).
The results presented here confirm that the CL of the cow is a local site of expression
ofmRNA encoding IGFBP-2, -3 and -4.
Messenger RNA encoding IGFBP-2 was detected at low levels within the CL
throughout the oestrous cycle. During the development of follicular dominance
IGFBP-2 concentrations in follicular fluid (Stewart et al., 1996) and IGFBP-2
mRNA expression were decreased (Armstrong et al., 1998). The low level of
expression demonstrated during the final stages of bovine follicular development was
maintained in the CL. IGFBP-2 mRNA expression has also been shown to persist at
low levels in the CL of the sheep (Perks and Wathes, 1996), pig (Gadsby et al., 1996;
Zhou et al., 1996) and rat (Erickson et al., 1994). In addition, the synthesis and
release of IGFBP-2 by human luteinising granulosa cells is inhibited by hCG
136
Figure 4.1. Bovine ovarian sections (14 pm) were probed with an IGFBP-2
antisense (a-h) or sense (i and j) riboprobe, and the same fields of view are shown
under lightfield (a, c, e, g and i) and darkfield (b, d, f, h and j) illumination.
Localisation of mRNA encoding IGFBP-2 is shown in luteal tissue at low
magnification (a and b), and in a further corpus luteum at two different
magnifications (c-f). Follicular expression is shown in the granulosa cell layer of a
small follicle (g and h). The scale bar represents 100 pm (a, b, e, fi g, and h), and
200 pm (c, d, i and j ).G and T represent granulosa cells and theca cells respectively.
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Figure 4.2. Bovine ovarian sections (14 |xm) were probed with an IGFBP-3 antisense
(a-f) or sense (g and h) riboprobe, and the same fields of view are shown under
lightfield (a, c, e, and g) and darkfield (b, d, f, and h) illumination. Localisation of
mRNA encoding IGFBP-3 is shown in typical corpora lutea at three different
magnifications (a-f). The scale bar represents 100 pm (c and d) and 200 pm (a, b, e, f,
g, and h).
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Figure 4.3. Bovine ovarian sections (14 (am) were probed with an IGFBP-4 antisense
(a and b) or sense (c and d) riboprobe, and the same fields of view are shown under
lightfield (a and c) and darkfield (b and d) illumination. Localisation of mRNA
encoding the IGFBP-4 is shown in luteal tissue adjacent to a small follicle (a and b).
The scale bar represents 200 jam (a - d). G, T, and CL represent granulosa cells, theca
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Figure 4.4
Quantitative analysis of IGFBP-3 mRNA concentrations in bovine luteal tissue on
days 5, 10 and 15 of the oestrous cycle, and 48 hours after PGF2a treatment (post
PG). There was no effect of stage of cycle on the concentration ofmRNA encoding
IGFBP-3 (P > 0.05). Bar represents pooled standard error of the difference (SED).
Messenger RNA concentration is expressed as the percentage of the total number of
pixels occupied by silver grains within a defined area. Hybridisation with an IGFBP-
3 sense probe gave an average background value of 4 units.
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(Cataldo et al., 1993). This low expression of IGFBP-2 mRNA is suggestive of a
limited role for this binding protein in luteal function.
IGFBP-2 expression was predominantly low throughout the whole CL, although a
more punctate pattern was observed in several animals. However, additional intense
hybridisation was observed associated with a small number of large blood vessels,
probably arterioles. Since this high concentration of IGFBP-2 mRNA was
heterogeneous, and not observed in all sections, it remains unclear whether such
expression is restricted to a certain size or type of vessel, or alternatively whether it
reflects a difference in expression between animals, or between stages of luteal
development. The association of IGFBP-2 with blood vessels has been shown
previously in other tissues. IGFBP-2 mRNA has been detected in bovine aortic
vascular smooth muscle cells, although at comparatively low levels (Boes et al.,
1996). Since IGF-I has been implicated in the regulation of vascular tone (Walsh et
al., 1996) the intense hybridisation suggests a role for IGFBP-2 in modulating
regional blood flow.
Bovine granulosa and theca cells in culture have previously been shown to secrete
IGFBPs, and luteinising stimuli caused a shift in this secretion to high molecular
weight binding proteins, putatively identified as IGFBP-3 (Sakal et al., 1992). The
present data confirm the local expression of IGFBP-3 mRNA within the bovine CL,
and demonstrate that IGFBP-3 mRNA is readily detectable within the corpus luteum
throughout the oestrous cycle.
IGFBP-3 mRNA was also detected in the ovine CL throughout the cycle. However,
in contrast to the present study, luteal IGFBP-3 mRNA concentrations were very low
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(Perks and Wathes, 1996). Studies in the pig have shown that IGFBP-3 mRNA was
abundantly expressed by the CL and was maintained at levels that display no stage-
dependant changes (Gadsby et al., 1996) until the onset of luteolysis when
expression was significantly decreased (Samaras et al., 1992). Similarly high
concentrations of IGFBP-3 mRNA were observed in the marmoset CL until the late
follicular phase when levels showed a marked decline (Fraser et al., 1998).
Additionally, mRNA encoding IGFBP-3 was detected at high levels during the early
luteal phase in the human CL, and was significantly reduced during the mid- and
late-luteal phase (Fraser et al., 2000). The rat exhibited a different temporal pattern
of luteal IGFBP-3 expression. In situ hybridisation has shown that IGFBP-3 mRNA
was absent from newly formed CL, became detectable with continuing luteal
development and was most abundant during luteolysis (Erickson et al., 1993). Whilst
luteolysis was associated with an upregulation of IGFBP-3 mRNA concentrations in
the rat, the absence of any increase of IGFBP-3 mRNA following prostaglandin-
induced luteolysis suggests this is not the case in the cow CL. Indeed the presence of
IGFBP-3 mRNA from early in the luteal phase is more suggestive of a role in CL
formation and function rather than regression.
IGFBP-3 mRNA was distributed throughout the entire structure of the bovine CL.
The hybridisation signal was particularly intense in cells associated with blood
vessels, and based on the intensity of hybridisation signal lining microvessels,
endothelial cells are a probable site of IGFBP-3 mRNA expression. Where cellular
identification has been possible in other studies this spatial pattern of expression
seems well conserved between species, despite marked temporal differences in the
expression of IGFBP-3 mRNA. In the rat IGFBP-3 mRNA was detected throughout
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the CL (Nakatani et al., 1991) predominantly localised to endothelial cells, some
perivascular cells and for a short period during luteolysis granulosa and theca lutein
cells (Erickson et al., 1993). In the porcine CL following dissociation and elutriation,
IGFBP-3 mRNA was enriched in the small-cell fraction which contains endothelial
cells (Gadsby et al., 1996). Vascular cells of the human and non-human primate CL
also showed the most intense localisation of IGFBP-3 mRNA (Fraser et al., 1998,
2000). Whilst the temporal pattern of expression of IGFBP-3 in the rat suggests a
role for vascular IGFBP-3 in luteal regression, the presence of IGFBP-3 mRNA from
early in luteinization through the functional lifespan of the CL in the cow, pig,
human and monkey is more suggestive of actions in angiogenesis. An important role
for vascular IGFBP-3 in other reproductive tissues has also been suggested. In the
bovine uterus during pregnancy IGFBP-3 mRNA was detected in vascular
endothelial cells of the myometrium (Keller et al., 1998).
Whilst IGFBP-3 is the most abundant IGFBP in serum (Clemmons, 1997) and the
predominant IGFBP in the follicular fluid of pre-ovulatory follicles (Funston et al.,
1996), mRNA encoding IGFBP-3 has only been detected at low levels and does not
increase with follicular development (Yuan et al., 1998). This lack of follicular
IGFBP-3 expression is in sharp contrast to the detection of luteal IGFBP-3
expression. Since IGFBP-3 mRNA was detected in the bovine CL early in the luteal
phase we hypothesise that it plays an important role in luteinisation. The earliest
timepoint in the present study was day 5 of the luteal phase. It remains to be
established how early in luteal development IGFBP-3 mRNA expression was
upregulated.
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Messenger RNA encoding IGFBP-4 was detected within the bovine CL throughout
the oestrous cycle. This is the first report of IGFBP-4 expression within the luteal
tissue of the cow to our knowledge. IGFBP-4 mRNA has been detected in the CL of
the pig (Zhou et al., 1996), where it was determined to be the most abundant IGFBP
(Gadsby et al., 1996) and the sheep (Perks and Wathes, 1996), where expression
levels were low by contrast. An IGFBP putatively identified as IGFBP-4 was also
present in culture medium conditioned by human luteinising granulosa cells (Cataldo
et al., 1993). An association of IGFBP-4 with luteal formation and function was also
suggested by increased IGFBP-4 production and mRNA expression following the
addition of a luteinizing dose of LH to ovine and bovine theca cell cultures
(Armstrong et al., 1996, 1998).
IGFBP-4 mRNA was detected throughout the bovine CL, and did not appear to be
associated with major structural components such as blood vessels. Whilst the
identification of the cellular site of expression was limited by low resolution, the
diffuse pattern is suggestive of steroidogenic cell expression of IGFBP-4 mRNA. In
the bovine follicle mRNA encoding IGFBP-4 was localised in the theca cell layer
(Armstrong et al., 1998). However, it remains to be established whether luteal
IGFBP-4 expression is predominantly localised to large or small luteal cells.
Whilst IGFBPs have been shown to potentiate IGF-stimulation in certain cases
(Conover et al., 1996), IGFBPs inhibit the actions of IGFs on ovarian cells in
culture. Therefore it is unclear why mRNA encoding any IGFBP should be
synthesised throughout the functional lifespan of the corpus luteum. However, the
present study details changes in local IGFBP mRNA concentration and additional
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post-transcriptional events may serve to vary the final IGFBP protein concentration
and hence the regulation of IGFs during the luteal phase.
The actions of IGFs are regulated in part by the relative abundance of IGFBPs, since
the high affinity binding of IGFBPs for IGF-I and IGF-II prevents ligand-receptor
interactions. In addition to regulation of the IGFs:IGFBPs ratio, IGFBPs can undergo
post-synthetic modification. The affinities of IGFBPs for IGFs can be significantly
lowered by variable proteolytic cleavage, phosphorylation and binding to cell
surfaces or extracellular matrix in ways that may lead to the potentiation of IGF
actions (Clemmons, 1997). It is unknown whether such changes modulate luteal
IGFBP function.
IGFBP proteases have been identified in a variety of physiological and pathological
conditions (Fowlkes, 1997; Rajaram et al., 1997). IGFBP-degrading activity has
been identified in human (Chandrasekhar et al., 1995), porcine (Besnard et al.,
1997), ovine (Besnard et al., 1996) and bovine (Chandrasekhar et al., 1996)
follicular fluid. IGFBP-specific proteolytic activity has also been detected in human
and rat granulosa cell conditioned media (Iwashita et al., 1998; Liu et al, 1993), and
bovine theca cell conditioned media (Nicholas et al., 2000). Whilst protease activity
has been correlated with follicular growth and development, the possible role of
IGFBP proteases in regulating luteal function has not been investigated. Our
understanding of the roles of IGFBPs in luteal function is further complicated by the
possibility that IGFBPs can exert IGF-independent inhibitory effects on target cell
growth and DNA synthesis. However, it remains to be determined how widespread
these effects may be (Rechler, 1997).
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In conclusion, the present study (i) describes the temporal and spatial patterns of
IGFBP-2, -3 and -4 mRNA expression in the bovine corpus luteum throughout the
luteal phase, (ii) demonstrates that the bovine CL is a site of IGF regulation and (iii)
highlights the potential importance of vascular expression of IGFBPs in bovine luteal
function.
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Chapter 5. Follicular response to an ovulatory challenge of GnRH in
the early luteal phase.
5.1 Summary
The CL is essential for the establishment and maintenance of pregnancy, and luteal
insufficiency is therefore a major contributor to infertility. Measures to reduce
reproductive wastage have included supplemental progesterone regimes to augment
inadequate luteal function. One strategy to improve endogenous progesterone
concentrations is via the induction of accessory corpora lutea.
The oestrous cycles ofmature dairy cows were synchronised and follicular dynamics
observed by ultrasonography. Administration ofGnRH on day 6 caused ovulation of
the dominant follicle of the first wave and formation of a secondary luteinized
structure. There was a trend for plasma progesterone concentrations to be increased
in animals treated with GnRH when compared to control animals, although no
significant effect was detected on day 14. The GnRH-induced CL has been shown
previously to have limited progesterone secreting capacity. The luteal insufficiency
observed following GnRH administration may be the result of sub-optimal follicular
development, inadequate luteotrophic support or premature luteolytic stimuli.
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5.2 Introduction
The CL is essential for the establishment and maintenance of pregnancy. Inadequate
or abnormal luteal function therefore has significant implications for fertility. Indeed,
insufficient progesterone levels have been associated with early embryo loss (Mann
et al., 1999), which accounts for the majority of reproductive wastage, with the
greatest losses occurring within 20 days of fertilisation (Sreenan and Diskin, 1983).
Cows in which pregnancy failed had significantly lower milk progesterone
concentrations on day 6 and between days 12 and 15 after mating, when compared
with pregnant cows (Mann et al., 1999). In addition, pregnancy failure has been
associated with delayed increases in post-ovulatory concentrations of progesterone
(Lamming and Darwash, 1995). These results suggest that progesterone
concentrations critically regulate early embryo growth and survival. In contrast,
others have failed to demonstrate a positive relationship between pregnancy outcome
and peripheral progesterone concentrations (Hasler et al., 1980).
Measures to improve reproductive efficiency have included the use of exogenous
progesterone supplementation (Robinson et al., 1989), and the administration of
human chorionic gonadotropin (hCG) (Breuel et al., 1990) or GnRH (Lewis et al.,
1990), the rationale being that increased peripheral progesterone would support
embryo survival, until such time as the corpus luteum could be maintained through
the embryo's own luteotrophic and/ or anti-luteolytic effects (Sreenan and Diskin,
1983). This assumes that supplemental therapy is additive to endogenous
progesterone, although there is evidence to suggest that whilst supplemental
progesterone increases plasma progesterone concentrations it also decreases
endogenous luteal progesterone production (Robinson et al., 1989). However, these
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methods have had some success, although they have not consistently improved
pregnancy rates (Robinson et al., 1989; Sreenan and Diskin, 1983).
It has been postulated that the most efficient means to augment endogenous
progesterone production is via the induction of accessory corpora lutea
(Rajamahendran and Siangama, 1992). The induction of a second CL is expected to
increase plasma progesterone levels, despite the lack of significant difference in
progesterone between animals displaying single or twin ovulations (Morris et al.,
1987). The induction of accessory CL formation should coincide ideally with the
presence of large follicles on the ovary. The bovine oestrous cycle is characterised
by waves of follicular growth and development, as demonstrated by peaks of
oestradiol secretion and daily ultrasound observations. Large luteal-phase follicles,
whilst destined not to spontaneously ovulate are responsive to gonadotrophin
stimulation and oestrogen-active (Ireland and Roche, 1983a). Large follicles respond
to hCG and GnRH treatment with ovulation, and produce a secondary luteinized
structure (Fricke et al., 1993; Price and Webb, 1989; Rajamahenran and Sianangama,
1992; Schmitt et al., 1996a, 1996b). Large follicles were most responsive to
exogenous hCG during the early luteal phase (days 4-7) (Price and Webb, 1989), at
which time the large follicle of the first wave displays increased LH-binding (Ireland
and Roche, 1983b).
The luteinized structure formed in response to a second gonadotrophin surge has
been characterised and treatment with either hCG or GnRH induces a functional CL.
However, peripheral progesterone concentrations were markedly higher in hCG
treated animals, when compared to those induced to ovulate with GnRH-agonist
(Schmitt et al., 1996a, 1996b). In addition, GnRH agonist-induced CL displayed
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reduced LH-stimulated progesterone secretion in vitro (Schmitt et al., 1996a). The
formation of a CL with reduced steroidogenic capacity following the administration
of GnRH was demonstrated both in vivo and in vitro (Rusbridge, 1993). Serum
progesterone levels produced by the GnRH-induced CL following removal of the
original CL failed to reach those following spontaneous ovulation, whilst in culture,
cells of the induced CL displayed reduced cAMP-stimulated progesterone secretion
(Rusbridge, 1993).
IGF-I and -II have been shown to have numerous stimulatory effects on ovarian
steroidogenesis. We hypothesised, therefore, that the reduction in steroidogenic
capacity shown by the GnRH-indueed CL could be due to a disruption of the
expression of the local IGF system in the CL. This chapter describes the production
of accessory CL in response to GnRH treatment in the early luteal phase (day six),
and the following chapter describes the effect of GnRH-administration on the luteal
IGF system.
5.3 Materials and Methods
5.3.1 Animals
All animals were Friesian/Holstein crossbred cows, aged between 3 and 8 years,
housed at the Roslin Institute Farm at Blythbank. Cows were housed in covered
courts with straw bedding. Water was available ad libitum and cows were fed a
maintenance diet. All experiments were carried out in accordance with the 1986 UK
Animals (Scientific Procedures) Act.
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5.3.2 Procedures
The experimental protocol is illustrated in Figure 5.1. The oestrous cycles of
fourteen mature dairy cows were synchronised by intravaginal progesterone release
(PRID; 1.55g P4, lOmg oestradiol benzoate; Sanofi Animal Health Ltd) over 9 days.
Luteolysis was induced by PGF2a analogue (Estrumate; 500 pg; Coopers Animal
Health Ltd) administered i.m on the day of PRID removal. Oestrous behaviour was
monitored by daily observation, together with the use of heat detection devices
(Heatmount Detectors, Kamar Inc). Oestrus was expected to have occurred within 48
hours of progesterone withdrawal, and ovulation was confirmed by ultrasound
scanning. Ovarian dynamics were monitored by daily rectal ultrasound scanning
using a real-time B-mode ultrasound scanner (Echo Camera SSD-220 DX II, Aloka
Company Ltd) equipped with a 7.5 MHz intrarectal probe. Scans were recorded on
videotape, and ovarian structures mapped. Six days after the synchronised oestrus
(oestrus = Day 0) cows received 0.5 mg synthetic GnRH (Fertagyl, Intervet
Laboratories Ltd) by i.m injection, and daily ultrasonography was continued until
slaughter 5 or 10 days later. Blood samples (10ml) were taken by jugular or
coccygeal venepuncture into tubes containing lOOpl of sodium citrate (0.35 g/ml),
from haltered and restrained animals at the time of scanning. All blood samples were
centrifuged (lOOOg), and plasma separated and frozen at -20°C until assayed for
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Figure 5.1
Oestrous cycles were synchronised by intravaginal progesterone release and i.m
PGF2a. Ultrasonography and blood sampling were performed daily from the expected
day of oestrus (Day 0). GnRH analogue was administered on day 6 to cause
ovulation of the first wave dominant follicle and the formation of a GnRH-induced
CL. Cows were slaughtered on day 10 or day 15 and the spontaneous CL and GnRH-
induced CL from each pair of ovaries collected.
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Peripheral progesterone concentrations were compared between control animals
following oestrous synchronisation (see section 3.3.1) and animals induced to
ovulate in response to GnRH administration and form a second CL. Samples were
assayed in two assays. The mean sensitivity was 0.26 ng/ml. The intra- and inter-
assay coefficients of variation were 8.1% and 9.1% respectively. The effect of GnRH
treatment on progesterone concentrations on day 14 of the control and GnRH-treated
cycles (9 days post-GnRH) was analysed using an unpaired Student's t-test.
5.3.3 Tissue collection
Ovaries were collected at slaughter, and photographed in pairs from each cow
(Figure 5.2). Corpora lutea were excised, divided and frozen in liquid nitrogen within
20mins of slaughter, and stored at -80°C prior to cryostat sectioning or RNA
extraction.
5.3.4 In situ hybridisation
In situ hybridisation was performed to detect the expression ofmRNA encoding the
LH receptor and cytochrome P450arom in CL from GnRH-treated animals, and
similar-aged control CL from the synchronised cycle (see section 3.3.1). Ovarian
tissue collected for follicular expression studies (Armstrong et al., 1998) was also
subjected to in situ hybridisation.
[35S]-UTP-labelled riboprobes were generated from templates kindly gifted by
Professor A. Garverick (University of Missouri) (Xu et al., 1995b, 1995c) using the
transcription protocol described previously (see section 2.10). The 730-bp LH
receptor riboprobe encodes a portion of the extracellular domain of the ovine LH
receptor, and corresponds to positions 193-922 of porcine (p) and human (h) LH
1 cm
Figure 5.2 Pairs of ovaries were collected 4 days (a) and 9 days (b-d) after GnRH
administration. Ovulation was induced both on the ovary ipsilateral (c) and contralateral
(a, b, d) to the ovary bearing the spontaneous CL. In one animal (041) ovaries were found
to bear a spontaneous CL, a GnRH-induced CL and a large follicular cyst (d).
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receptor (LHr) cds (EMBL id: pLHr - SSLHHCGA; hLHr - HSLHHCGR) (Loosfelt
et al., 1989; Minegish et al, 1990). The 579-bp aromatase riboprobe corresponds to
positions 139-718 of human P450arom cDNA (EMBL id: HSARMA) (Harada,
1988).
Antisense RNA probes for LH receptor and cytochrome P450arom were each
hybridised to two serial sections per corpus luteum or ovary. The sense probe for
each mRNA species was applied to a further serial section. The intensity of the in
situ hybridisation signal was quantified (see section 3.3.3), and antisense signals
were then compared to their respective sense (background) signals.
The effect of GnRH administration on LH receptor mRNA concentration was
determined by a split-plot ANOVA (Genstat 5; Payne et al., 1993), using the
blocking factor cow/ slide/ replicate as previously described (see section 3.3.4).
5.4 Results
5.4.1 Ovarian observations
One animal had an ossification of the left ovary following oestrous synchronisation
and was removed from the experiment. The remaining 13 animals used for this study
all displayed three waves of follicular growth and development. Ultrasound
observations confirmed the presence of a large preovulatory follicle following PRID
withdrawal, which was subsequently replaced by a "spontaneous" CL. The
emergence of a large follicle from the first wave of follicle growth was observed
following synchronised oestrus. Ultrasonography confirmed ovulation and the
presence of an "induced" accessory CL in the GnRH responders following GnRH
treatment (Figure 5.3a). All 13 animals formed an additional CL. However, in two
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animals the second ovulation was not due to ovulation of the largest follicle present
at GnRH injection. The time from GnRH injection to the appearance of a newly
formed CL was markedly extended (5 days and 4 days) in these animals, and there
was no clear ovulation of a dominant follicle. In one of these late-responding
animals, the large follicle present at GnRH administration failed to ovulate, and
became cystic reaching a maximum diameter of 25mm: this animal was not included
in further experimental analysis (Figure 5.4). Ovulation occurred in the remaining 11
animals within 48 hours. It is of note that the largest follicles present in the ovaries of
both late responding animals were under 9mm in diameter at the time of GnRH
administration. Among all 13 cows, the large follicle at the time of GnRH
administration ranged from 8-19mm, with a mean diameter of 13.7mm. A bolus of
GnRH induced single ovulations in all animals, and led to the formation of accessory
CL contralateral (n=6) or ipsilateral (n=6) to the spontaneous CL. The dynamics of
medium-sized follicle development was also recorded by ultrasonography, and a
reduction in medium follicle number was observed which was associated with the
acquisition of dominance of the large follicle in each wave (Figure 5.3b).
5.4.2 Plasma progesterone concentrations
No difference in plasma progesterone concentration was observed between control
animals and animals treated with GnRH in the period prior to GnRH administration.
Profiles of progesterone concentrations were unaffected by GnRH treatment until
day 14, when there was a tendency for progesterone concentrations in the GnRH
treated animals to be higher than control levels (Figure 5.5). However, no significant
effect of treatment on day 14 was detected by the Student's t-test (P = 0.12).
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Days after spontaneous ovulation
Figure 5.3
Follicle dynamics of GnRH responders as assessed by ultrasonography.
Growth profile of the largest follicle (a) and changes in the number of
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Days after spontaneous ovulation
Figure 5.4
Ultrasound assessment of follicle dynamics in animal 041, which developed
a follicular cyst. Growth profile of largest follicle (a) and changes in the
number ofmedium-sized follicles (b).
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Days after spontaneous ovulation
Figure 5.5
Plasma progesterone concentrations before and after administration of
GnRH (day 6). Mean values ± SEM.
5.4.3 In situ hybridisation
Messenger RNA encoding P450arom was detected in sections of bovine follicular
tissue, and was localised to granulosa cells. Expression of mRNA encoding
P450arom was absent from CL of the control cycle and CL induced by GnRH
treatment.
Messenger RNA encoding the LH receptor was detected in the GnRH-induced
corpora lutea. LH receptor mRNA levels in GnRH-induced corpora lutea were not




This study has confirmed that the administration of GnRH on day 6 of the oestrous
cycle results in ovulation of the dominant follicle of the first wave, and the
subsequent formation of a secondary luteinized structure in >80% of animals.
Previous studies in our laboratory have demonstrated that following the removal of
the spontaneous CL, the luteinized structure formed in response to a second surge
release of LH begins to secrete progesterone in vivo. However, its steroidogenic
activity falls markedly below that of a spontaneously formed CL of a similar age. In
addition, the induced CL has a shortened lifespan, with progesterone concentrations
falling below 1 ng/ml within 10 days ofGnRH administration (Rusbridge, 1993).
Abnormal luteal function may be the result of one or more of the following
generalised effects: 1) sub-optimal follicular development, 2) inadequate luteotrophic
support or 3) premature luteolytic stimuli.
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5.5.1 Sub-optimal follicular development
Whilst the early stages of folliculogenesis are gonadotrophin-independent, FSH and
LH are the primary regulators of the final maturation and development of antral
follicles. FSH is required for the growth of follicles up to 9mm, whilst pulsatile LH
is essential for continued growth (Gong et ah, 1996a, 1996c). The period of
ovulatory follicle selection is characterised by low progesterone concentrations,
decreasing FSH support and high frequency-low amplitude LH pulses prior to the
LH surge (Campbell et ah, 1999; Scaramuzzi et ah, 1993). Following ovulation, the
dominant follicle of the first wave develops in a very different hormonal
environment, which may not provide the follicle with sufficient stimulation in
preparation for subsequent luteal function. Indeed in the ewe, premature induction of
ovulation resulted in luteal phase insufficiency, suggestive of a lack of suitable
follicular maturation (Murdoch et ah, 1983). The first wave dominant follicle is
exposed to increasing progesterone concentrations produced by the developing
spontaneous CL, and studies using exogenous progesterone supplementation in the
early luteal phase significantly reduced the growth rate and size of the first dominant
follicle in cattle (Adams et ah, 1992; Burke et ah, 1994), demonstrating the potential
for progesterone to be inhibitory to follicle development. This suppressive effect may
be the result of the negative feedback of progesterone on the frequency of release of
LH pulses by the pituitary gland (Bergfeld et ah, 1995), as the abolition of
preovulatory LH pulses has been shown to limit CL development (Quintal-Franco et
ah, 1999).
Short-lived CL are often observed following reproductive quiescence in cows and
sheep (Braden et ah, 1989a; Keisler et ah, 1983; Knight et ah, 1981; Lamming et ah,
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1981) and it has been suggested that this naturally occuring reduction in luteal
lifespan may also be partly the result of altered follicular development (Garverick et
al., 1992; Hunter, 1991). Indeed, developing follicles expected to form short-lived
CL post-partum were shown to have fewer gonadotrophin receptors and lower
follicular fluid oestradiol concentrations than preovulatory follicles of normally
cycling cows (Braden et al., 1989b).
No comparison of the steroidogenic capacity of the ovulatory and anovulatory
follicles was made in the present study. However, the mean diameter of the largest
follicle present at GnRH administration was lower than that preceding spontaneous
ovulation, suggesting that progesterone production by the spontaneous CL may have
had an inhibitory effect on subsequent follicle waves.
5.5.2 Inadequate gonadotrophic support
Corpus luteum formation is a complex process involving tightly co-ordinated
changes in cellular form and function (Smith et al., 1994c). The primary drive for
luteinization is the preovulatory LH surge, and sustained luteotrophic support in the
form of LH pulses post-ovulation are required for both structural and functional
luteal development (Quintal-Franco et al., 1999). It is clear therefore that alterations
in LH stimulation have the potential to disrupt CL function greatly. However, despite
the requirement of LH for normal luteal development and function, there is little
evidence to suggest that naturally occurring short-lived CL are the result of reduced
luteotrophic support (Garverick et al., 1992; Hunter, 1991) Indeed, premature
luteolysis is thought to be the primary cause of an inadequate luteal phase (Hunter,
1991). Gonadotropic stimulation was not significantly different between post-partum
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cows having short or normal oestrous cycles (Garverick et al., 1988), and repeated
injections of hCG failed to decrease the incidence of short cycles in cows following
prolonged postpartum anoestrous (Carruthers et al., 1986).
Whilst luteotrophic support was not reduced in short-lived CL, abnormal luteal
function might result from a lack of sensitivity to LH. However, besides receiving
the same LH stimulation, short-lived and normal CL in the early luteal phase had
similar numbers of LH receptors (Rutter et al., 1985), and adenylate cyclase and
phosphodiesterase activities were not different (Smith et al., 1986). However, day 7
corpora lutea expected to have a short lifespan were less responsive to LH in vitro
than cyclic CL (Kesler et al., 1981) and short-lived CL had significantly reduced LH
receptor mRNA on day 8 (Smith et al., 1996).
In the present study induced CL did not exhibit significantly reduced LH receptor
mRNA levels when compared to spontaneous CL of similar age. Indeed, Rusbridge
(1993) demonstrated that the GnRH-induced CL had increased LH receptor numbers,
suggesting that the limited function of the GnRH-induced CL was not caused by a
lack of LH reception. However, GnRH-induced CL had a reduced response to
cAMP-stimulation in vitro, suggesting that alterations downstream of the LH
receptor may serve to limit the response to LH stimulation.
The transition from follicle to CL following the LH surge is characterised by
increased progesterone production. In the bovine CL this is also accompanied by a
decrease in oestradiol secretion, resulting from decreased cytochrome P450arom and
P450cl7 mRNA levels and enzyme content (Rodgers et al., 1986b, 1987; Voss and
Fortune, 1993). Whilst it has been suggested that GnRH-induced ovulation of the
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first-wave dominant follicle might not allow sufficient follicle maturation, and that
the normal transition from the follicular to the luteal phase might be disrupted, the
results of the present study indicate that cytochrome P450arom mRNA expression
was similar in the GnRH-induced CL and the spontaneous CL.
5.5.3 Premature luteolytic stimuli
There is considerable evidence to suggest that naturally occurring CL displaying a
short lifespan are not pre-programmed to be short-lived, but regress prematurely in
response to an early luteolytic stimuli. Prevention of the luteolytic signal by
hysterectomy, indomethacin infusion and immunisation against PGF2a extended the
lifespan of CL anticipated to be short-lived (Copelin et al., 1987, 1989; Troxel and
Kesler, 1984). In further support of advanced secretion of PGF2a, short luteal phases
have been correlated with increased PGFM and endometrial oxytocin binding sites
when compared to normal corpora lutea (Hunter, 1991; Hunter et al., 1989).
In the studies by Rusbridge which established the GnRH-induced CL model
(Rusbridge, 1993), prostaglandin was administered on day 9 after oestrus (day 3 of
the induced cycle) to cause regression of the spontaneous CL. At this time the
spontaneous CL was sensitive to the luteolytic signal, whilst the GnRH-induced CL
did not undergo luteolysis. The lack of responsiveness of the 3 day old induced CL to
prostaglandin treatment is in agreement with data from the natural cycle, where
corpora lutea acquire sensitivity to PGF2ct after day 5 of the oestrous cycle. This
suggests therefore that the GnRH-induced CL does not develop sensitivity to
prostaglandin in advance of normal CL. In contrast, others have shown that CL
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induced with hCG on day 10 undergo luteolysis following exogenous PGF2a
administered within 2 days of ovulation (Howard and Britt, 1990).
To further examine the development of the luteolytic response in animals with
induced CL, heifers were subjected to an oxytocin challenge 7 days post-GnRH.
Administration of oxytocin resulted in a PGFM response which was of similar
magnitude to that of control animals, and it was concluded that there was no
alteration in uterine secretory responsiveness that might account for the short luteal
phase observed following GnRH-induced ovulation (Rusbridge, 1993). Prostaglandin
was released in response to oxytocin despite the low levels of progesterone produced
by the GnRH-induced CL. However, the uterus had previously been exposed to
progesterone produced by the spontaneous CL, which would be expected to have
contributed to uterine priming.
The results of Rusbridge demonstrated that animals bearing a GnRH-induced CL
were able to respond to an oxytocin challenge with a PGFM response within the
normal range. Whilst this suggests that there was no increase in uterine sensitivity to
oxytocin, it does not preclude the possibility of raised endogenous PGF2a
concentrations. Intrauterine indomethacin infusion was used to determine the effect
of prostaglandin-suppression on the development and function of hCG-induced CL
(Sianangama and Rajamahendran, 1996). Indomethacin treatment prevented pulsatile
PGFM secretion, but did not enhance the growth of the induced CL. Progesterone
production was significantly increased during the infusion period, but PG-
suppression was unable to elevate progesterone concentrations beyond levels
observed in control cows during the early luteal phase. The authors concluded that
whilst endogenous prostaglandin may have contributed to the limited secretory
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function of the hCG-induced CL, the luteal inadequacy could not be wholly
attributed to the luteolysin PGF2ct (Sianangama and Rajamahendran, 1996). However,
whilst indomethacin reduces luteolytic prostaglandins, it is not specific for PGF2a and
also reduces luteotrophic prostaglandins.
In summary, early embryonic death accounts for a major proportion of reproductive
wastage, and evidence suggests that luteal dysfunction contributes significantly to
infertility. Progesterone supplementation has been proposed as a possible corrective
measure and one possible route is via the induction of accessory corpora lutea. The
present study confirms that administration of GnRH to cows in the early luteal phase
induces ovulation of the first wave dominant follicle and formation of an induced
CL, and plasma concentrations of progesterone were increased in the presence of a
GnRH-induced CL. However, previous studies have demonstrated that the
contribution of the induced CL to progesterone production is limited. The inadequate
function of the GnRH-induced CL may be the result of a number of factors including
sub-optimal follicular development, inadequate luteotrophic support or premature
luteolytic stimuli. Messenger RNA encoding LH receptor was not reduced in the
present study, suggesting that the induced CL did not lack luteotrophic support.
However, LH responsiveness may be altered downstream of the LH receptor as
suggested by the reduced response of cells from the induced CL to cAMP
stimulation in vitro (Rusbridge, 1993). Previous suggestion of aberrant luteal
oestradiol production are not supported by the present study, since mRNA encoding
P450arom was undetectable in the GnRH-induced CL. There is substantial evidence
to suggest that inadequate luteal function occurring naturally often results from
premature induction of luteolysis, although others have suggested that luteal
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inadequacy is not wholly attributable to the actions of PGF2a. Whilst the
development of the CL induced in response to GnRH is likely to be markedly
different from that of naturally occurring inadequate corpora lutea, the possible
causes of its limited function warrant future study.
167
Chapter 6. Effect of GnRH administration in the early luteal phase
on the IGF system in the bovine corpus luteum
6.1 Summary
The administration of GnRH to cattle on day 6 causes ovulation of the first wave
dominant follicle and formation of an additional corpus luteum. This GnRH-induced
CL has been characterized and displays reduced steroidogenic capacity. Studies in
vitro have demonstrated that IGF-I and -II regulate many aspects of ovarian
function, including steroidogenesis. We have tested the hypothesis that diminished
IGF stimulation may contribute to the limited function of the GnRH-induced CL.
In situ hybridization has demonstrated that mRNA encoding IGF-I, IGF-II, the type 1
IGF receptor and IGFBP-2, -3 and -4 were expressed within the GnRH-induced CL.
The spatial patterns ofmRNA expression were not different between GnRH-induced
and control corpora lutea. In contrast however, significant differences were detected
in mRNA concentrations following GnRH-administration in both the induced CL
and the original CL present on the ovary at the time of treatment compared to control
CL levels. The concentration of type 1 IGF receptor mRNA was significantly
decreased in the GnRH-induced CL when compared to early luteal phase control, and
there was a trend for increased IGFBP-3 mRNA concentrations in the GnRH-induced
CL when compared to day 10 control CL. These changes are expected to reduce both
the bioavailability and bioactivity of IGF-I and IGF-II in the GnRH-induced CL, thus
compromising the response to luteotrophic support. This may in part explain the




IGF-I and IGF-II are important regulators of ovarian steroidogenesis. IGF-
stimulation of luteal cells in vitro increases progesterone release in a number of
species (Constantino et al., 1991; Devoto et al., 1995; Khan-Dawood et al., 1994;
McArdle and Holtorf, 1989; Talavera and Menon, 1991; Yuan and Lucy, 1996a),
resulting from multiple effects on the steroidogenic pathway. IGFs augment sterol
uptake and utilisation (Veldhuis, 1989), transport of steroid precursors to
mitochondria (Balasubramanian et al., 1997), and the subsequent enzymatic
conversion of cholesterol to pregnenolone, and of pregnenolone to progesterone
(deMoura et al., 1997). The in vitro results suggest therefore that the IGFs have great
potential to regulate luteal progesterone production in vivo.
The first-wave dominant follicle can be induced to ovulate in response to a second
surge release of LH and subsequently form a secondary luteinized structure (Fricke
et al., 1993; Price and Webb, 1989; Rajamahenran and Sianangama, 1992;
Rusbridge, 1993; Schmitt et al., 1996a, 1996b; see chapter 5). However, whilst
corpora lutea formed following GnRH administration in the early luteal phase (day
6) begin to secrete progesterone, peripheral progesterone concentrations fall below
those produced by spontaneously formed CL of a similar age (Rusbridge, 1993).
We hypothesise that the subnormal steroidogenic function of the GnRH-induced CL
is the result of changes in the luteal IGF system, resulting in reduced IGF
bioavailability and /or bioactivity and hence diminished local IGF-stimulation of
luteal function.
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6.3 Materials and Methods
6.3.1 Tissue collection
6.3.1.1 GnRH-treated animals
Secondary corpora lutea were induced by early luteal phase GnRH administration, as
detailed in section 5.3.2. In brief, the oestrous cycles of mature dairy cows were
synchronised by intravaginal progesterone release (PRIDs) and PGF2a analogue
(Estrumate) injection. On day 6 after oestrus cows received 0.5mg synthetic GnRH
(Fertagyl) to induce ovulation of the first-wave dominant follicle and formation of a
second corpus luteum. Pairs of ovaries were collected on either day 10 or day 15 of
the oestrous cycle (Figure 5.1), and both the GnRH-induced and spontaneously
formed CL within each pair were processed for in situ hybridisation using frozen
sections.
6.3.1.2 Control animals
The oestrous cycles ofmature dairy cows were synchronised using PRIDs and PGF2a
analogue injection (see section 3.3.1). Corpora lutea collected on day 5, 10 and 15
after oestrus were studied.
6.3.2 In situ hybridisation
In situ hybridisation (see section 2.11) was performed to detect the expression of
mRNA encoding IGF-I, IGF-II, the type 1 IGF receptor and IGFBP-2, -3 and -4 in
frozen sections of luteal tissue (14pm). Antisense and sense riboprobes were
generated using a standard transcription protocol and labelled with [35S]-UTP (see
section 2.10.1). Target sequences are detailed in sections 2.4 and 4.3.2. The intensity
of the in situ hybridisation signal was quantified by image analysis (see section 3.3.3)
and mRNA concentrations were compared between similar aged corpora lutea of the
control cycle, GnRH-induced CL and spontaneous CL present at the time of GnRH
administration.
6.3.3 Statistical Analysis
The effect of GnRH administration on mRNA concentration was determined by a
split-plot ANOVA (Genstat 5; Payne et al., 1993), using the blocking factor cow/
slide/ replicate as previously described (see section 3.3.4).
6.4 Results
In situ hybridisation detected mRNA encoding IGF-I, IGF-II, the type 1 IGF receptor
and IGFBP-2, -3 and -4 within GnRH-induced CL at both timepoints studied (4 and
9 days post GnRH). The spatial pattern ofmRNA localisation was similar for GnRH-
induced and spontaneously-formed CL, and is detailed in chapter 3 and 4. Analysis
of the intensity of the in situ hybridisation signal demonstrated a significant
difference in the concentration ofmRNA encoding the type 1 IGF receptor between
GnRH-induced and control CL of a similar age. Differences in expression of IGFBP-
3 mRNA approached significance. There was no significant effect of treatment on
the concentrations ofmRNA encoding IGF-I, IGF-II, IGFBP-2 or -4.
IGFBP-3 mRNA levels were not significantly different fP>0.05) between control CL
of the early luteal phase and GnRH-induced CL of a similar age (Figure 6.1a).
Differences in IGFBP-3 mRNA expression between control CL, GnRH-induced CL
and the spontaneous CL present at GnRH administration of around 10 days old
approached significance (/>=0.052) (Figure 6.1b). IGFBP-3 mRNA levels in control







































Quantitative analysis of IGFBP-3 mRNA concentrations in bovine luteal tissue.
Concentrations were compared between 5 day old (a), 10 day old (b) and 15 day old
(c) corpora lutea from control animals, and animals treated with GnRH bearing both a
spontaneous and GnRH-induced CL. Luteal timepoints with different superscipts are
significantly different (P < 0.05). Bars represent pooled standard error of the
difference (SED). Concentration ofmRNA is expressed as the percentage of the total
number of pixels occupied by silver grains within a defined area. Hybridisation with
an IGFBP-3 sense probe gave an average background value of 5 units.
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Messenger RNA encoding IGFBP-3 was not significantly different (P>0.05) between
control CL of the late luteal phase and age-matched spontaneous CL (Figure 6.1c).
Messenger RNA encoding type 1 IGF receptor was observed at significantly higher
levels (P =0.045) in CL of control animals on day 5 than similar aged GnRH-induced
CL (Figure 6.2a). A significant difference (P=0.05) in type 1 IGF receptor mRNA
concentration was detected amongst control CL, GnRH-induced CL and spontaneous
CL around day 10; concentrations of type 1 IGF receptor mRNA were highest in
control CL and lowest in the spontaneous CL (Figure 6.2b). Type 1 IGF receptor
mRNA levels were not significantly different (PN3.05) between day 15 CL of control
animals and age-matched spontaneous CL (Figure 6.2c).
6.5 Discussion
GnRH-treatment in the early luteal phase causes ovulation and formation of a
secondary luteal structure (Rusbridge, 1993). However, the GnRH-induced CL has
reduced secretory function (Rusbridge, 1993) that is correlated with significant
alterations in the local IGF system.
This study demonstrates that the GnRH-induced corpora lutea expresses mRNA
encoding IGF-I, IGF-II, the type 1 IGF receptor and IGFBP-2, -3 and -4 at both
timepoints studied. The spatial patterns of expression were not different between CL
induced by a second surge release of LH and those formed during the natural cycle.
In addition, there was no significant effect of treatment on the concentrations of
mRNA encoding IGF-I, IGF-II, IGFBP-2 or -4. However, there were significant
differences in the levels ofmRNA encoding the type 1 IGF receptor and a trend for
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Figure 6.2
Quantitative analysis of type 1 IGF receptor mRNA concentrations in bovine luteal
tissue. Concentrations were compared between 5 day old (a), 10 day old (b) and 15
day old (c) corpora lutea from control animals, and animals treated with GnRH
bearing both a spontaneous and GnRH-induced CL. Luteal timepoints with different
superscipts are significantly different (P < 0.05). Bars represent pooled standard
error of the difference (SED). Concentration of mRNA is expressed as the
percentage of the total number of pixels occupied by silver grains within a defined
area. Hybridisation with a type 1 IGF receptor sense probe gave an average
background value of 6 units.
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Concentrations of mRNA encoding the type 1 IGF receptor were significantly
reduced in GnRH-induced CL compared to similar-aged CL from the early luteal
phase of the control cycle. The reduction in mRNA is assumed to result in reduced
receptor numbers, and subsequently reduced IGF-stimulation in GnRH-induced CL.
Since progesterone production by luteal cells is stimulated in vitro by IGF-I and IGF-
II a reduction in IGF-reception in the GnRH-induced CL may contribute to the
diminished steroidogenic output observed experimentally. However, induced corpora
lutea of around 10 days old did not exhibit significantly different type 1 IGF receptor
concentrations compared to control levels.
There was a trend for increased concentrations of mRNA encoding IGFBP-3 in
GnRH-induced corpora lutea compared to age-matched CL of the mid-luteal but not
early-luteal phase. In its IGF-dependant role, IGFBP-3 binds both IGF-I and -II with
high affinity, preventing ligand-receptor interaction IGFBP-3 inhibits IGF-I-
stimulated progesterone production by bovine granulosa and theca cells in culture,
and this inhibitory effect is thought to result from IGFBP-3 sequestering IGF-I
(Spicer and Chamberlain, 1999; Spicer et al., 1997). Therefore, increased IGFBP-3
would be expected to further reduce IGF-stimulation of luteal cell steroidogenesis.
Failure of the IGF system to develop to normal levels in the GnRH-induced CL may
be the result of disruption to both follicular and luteal events. The hormonal
environment of the first-wave dominant follicle differs markedly from that of the
ovulatory follicle. In particular, the dominant follicle of the first wave is exposed to
increasing progesterone produced by the spontaneous CL and subsequently reduced
LH-pulse frequency (Bergfeld et al, 1995; Rahe et al., 1980).
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Bovine dominant follicles undergo atresia in response to exogenous progesterone
treatment. The concentrations of low molecular weight IGFBPs were increased in
follicular fluid during progesterone-induced atresia, with a profile similar to natural
atresia. In addition, atresia was associated with reduced follicular fluid IGF-I and -II
concentrations (Manikkam and Rajamahendran, 1997). In the present study
progesterone produced by the original CL was not sufficient to cause atresia of the
first wave follicle, since GnRH administration resulted in ovulation. However,
progesterone concentrations may regulate components of the IGF system in the first
wave dominant follicle and subsequently the GnRH-induced CL.
In the follicle, the IGFs stimulate cellular proliferation and steroidogenesis, and in
synergy with gonadotrophins, stimulate follicular growth and differentiation. The
actions of both IGF-I and -II are mediated via the type 1 IGF receptor and a
reduction in IGF-reception and hence IGF-stimulation would be expected to have
major implications for both the follicle and CL. IGF-receptor binding and mRNA
encoding the type 1 IGF receptor have been detected within bovine follicles.
However, it remains unclear whether receptor numbers alter with follicular
development or hormonal regulation (Spicer and Echternkamp, 1995). In vitro,
granulosa cells from large bovine follicles had greater IGF-I binding than those of
small follicles (Spicer et al., 1994). In contrast, expression of mRNA encoding the
type 1 IGF receptor did not vary with follicle size in vivo, although this study did not
examine changes in expression at different points during follicle growth (Armstrong
et al., 2000a).
Type 1 IGF receptor levels are regulated in response to a number of physiological
and pathological stimuli (LeRoith et al., 1995; Werner et al., 1995). The binding of
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IGF-I to cultured rat granulosa cells was increased by FSH and LH treatment (Adashi
et al., 1988). However, neither LH nor progesterone influenced IGF-I binding in
cultured bovine granulosa cells (Spicer et al., 1994). This lack of regulatory action
suggests that differences in LH and progesterone secretion between the growth of the
ovulatory follicle and the dominant follicle of the first wave may not be the cause of
reduced type 1 IGF receptor mRNA levels in the induced CL. A significant
difference in type 1 IGF receptor mRNA concentrations was observed between early
luteal CL from control animals and similar aged GnRH-induced CL. This result
suggests that the type 1 IGF receptor is sensitive to changes in the hormonal
environment, however it remains unclear whether this reflects a response to changes
in late follicular or early luteal development. Whilst progesterone did not influence
IGF-I-binding to cultured bovine granulosa cells, steroid hormones have been shown
to regulate type 1 IGF receptor gene expression in reproductive tissues. Oestradiol
caused a two- to three-fold increase in type 1 IGF receptor mRNA levels in normal
human breast xenografts, whilst progesterone treatment down-regulated type 1 IGF
receptor mRNA concentrations to half that of controls (Clarke et al., 1997).
Progestins also reduced mRNA encoding the type 1 IGF receptor in cultured T-47D
human breast-cancer cells (Goldfine et al., 1992), an effect that may be mediated by
enhanced IGF-II secretion (Papa et al., 1991). It remains to be determined whether
type 1 IGF receptor mRNA concentrations are similarly reduced in the GnRH-
induced CL in response to the high levels of progesterone produced by the CL
present at GnRH administration. Type 1 IGF receptor gene expression is also
regulated by local and circulating levels of IGF-I. Patients with low circulating IGF-I
levels as a result of GH deficiency or Laron-type dwarfism display raised
erythrocytic IGF-I binding sites and increased lymphocytic type 1 IGF receptor
mRNA levels (Eshet et al., 1993). An inverse correlation between IGF-I
concentration and receptor number has also been demonstrated in cell culture.
Increasing concentrations of IGF-I cause a reduction in IGF receptor number in vitro
in a number of different cell types (Hernandez-Sanchez et al., 1997; Rosenfeld and
Dollar, 1980; Rosenfeld and Hintz, 1980). However, it is not clear whether a similar
relationship operates in the ovary.
A number of other growth factors regulate type 1 IGF receptor abundance. Basic
FGF, for example, stimulates IGF-I binding and type 1 IGF receptor mRNA levels in
muscle cells (Pfeifle et al., 1987; Rosenthal et al., 1991). In contrast, in bovine
granulosa cells bFGF decreased IGF-I receptor numbers (Spicer et al., 1994). PDGF
also increases the number of IGF-I binding sites and the expression of the IGF-I
receptor gene, an effect that is due at least in part to PGDF-stimulation of IGF-
receptor promoter activity (Rubini et al., 1994). The physiological role of these
factors in regulating luteal type 1 IGF receptor numbers remains uncertain.
IGFBP-3 is the most abundant IGFBP in serum (Rajaram et al., 1997) and the
predominant IGFBP in bovine preovulatory follicular fluid (Funston et al., 1996).
However, mRNA encoding IGFBP-3 is expressed at low levels in the follicle, and
does not vary with follicle size (Yuan et al., 1998), and neither ovine granulosa or
theca cell cultures produced significant quantities of IGFBP-3 (Armstrong et al.,
1996). It has been suggested therefore that follicular fluid IGFBP-3 is primarily the
product of transudation from serum. There is limited information on the regulation of
IGFBP-3 expression in the ovary. Messenger RNA encoding IGFBP-3 is abundant in
the bovine CL by day 5 (Chapter 4). However, it remains to be established when in
early luteal development IGFBP-3 mRNA expression is upregulated, and whether
this occurs as a direct response to the LH surge. An increase in IGFBP-3 mRNA
concentration was observed between day 10 control CL and similar aged GnRH
induced CL, whilst no effect was detected in the early luteal phase. The lag between
GnRH treatment and significant alterations in IGFBP-3 concentrations may suggest
that IGFBP-3 mRNA is more sensitive to hormonal changes during luteal growth and
development than during follicular growth and development. In addition, it suggests
that the signal which upregulates IGFBP-3 mRNA levels from the relatively low
follicular levels is still in place following GnRH treatment.
A number of IGFBPs are expressed at any one time within the ovaries of many
species. The IGF system may have in-built redundancy, such that an increase in the
concentration of one IGFBP can be accompanied by a compensatory decrease in the
concentration of another. However, the addition of IGFBP-3 to ovarian cells in
culture or its administration to the whole ovary in vitro has had dramatic results,
suggesting a lack of compensation. IGFBP-3 profoundly inhibited IGF-stimulated
cell proliferation and steroidogenesis in bovine theca and granulosa cells in culture
by sequestering IGF-I and -II (Spicer and Chamberlain, 1999; Spicer et al., 1997).
The addition of IGFBP-3 to perfused rabbit ovaries in vitro inhibited hCG-induced
ovulation, oocyte development and oestradiol production (Yoshimura et al., 1996).
In human luteinising granulosa cells IGFBP-3 reduced the stimulatory effect of IGF-I
on oestradiol production (Barreca et al., 1996).
The primary regulator of plasma IGFBP-3 concentrations is GH, produced by the
pituitary somatotrophs. Analysis of the rat and cow IGFBP-3 gene promoters
localized consensus sequences for a number of putative response elements including
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GH (Albiston et al., 1995; Erondu et al., 1997). The secretion of IGFBP-3 by human
luteinising granulosa cells in culture was stimulated by GH (Barreca et al., 1996),
supporting a role for GH in ovarian IGFBP-3 regulation. However, in the
reproductive tissues of cattle, concentrations of mRNA encoding IGFBP-3 were
unaffected by exogenous GH treatment, suggesting that GH does not directly affect
gene expression in this species (Kirby et al., 1996). Hence, with the limited
information available it remains unclear to what extent GH may regulate IGFBP-3
expression in the cow CL. Furthermore we have no clear understanding of how GH-
stimulated IGFBP-3 mRNA expression might be altered in the GnRH-induced CL to
account for increased IGFBP-3 concentrations.
However, regulatory actions of GH within the ovary have been demonstrated (Lucy
et al., 1999). Treatment of mature ewes with GH resulted in enhanced follicle
development and increased follicular secretion of IGF-I in culture, in addition to
increased peripheral concentrations of IGF-I (Gong et al., 1996b). Many of the
actions of GH are mediated by IGF-I, which is released from the liver in response to
GH-stimulation. However, GH may also act directly on the ovary, since the GH
receptor has been detected in the bovine ovary and GH receptor concentrations were
20-fold higher in the CL than in follicles (Lucy et al., 1993). Abnormalities of GH
receptor expression (either occurring naturally or following gene knockout
experiments) have demonstrated that GH is not essential for reproduction, but it
appears to have an important facilitatory role (Chase et al., 1998; Zhou et al., 1997).
In CL, GH influences luteal growth and development (Juengel et al., 1997) and
increases progesterone secretion in vitro (Liebermann and Schamms, 1994).
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A number of other factors have been shown to modulate the production of IGFBP-3
by a range of cell types in culture. IGFBP-3 protein and mRNA levels are increased
by treatment with factors including IGF-I, the tumour suppressor p53, retinoic acid,
PDGF and vasopressin (Buckbinder et al., 1995; Corps and Brown, 1991; Gucev et
al., 1996). In addition, porcine granulosa cells respond to oestradiol and EGF
treatment with increased IGFBP-3 production, whilst the addition of FSH and TGF-|3
inhibited IGFBP-3 secretion (Mondschein et al., 1990). Under luteinising conditions
porcine granulosa cell IGFBP-3 production is stimulated by PGF2a and attenuated by
PGE2 (Grimes et al., 1993). It is unknown whether any of these factors regulate
IGFBP-3 mRNA concentrations in the bovine corpus luteum during the oestrous
cycle, or whether these factors are influential in creating the changes in IGFBP-3
mRNA concentrations observed in the GnRH-induced CL.
The inhibitory effects of IGFBP-3 on ovarian function (Barreca et al., 1996; Spicer
and Chamberlain, 1999; Spicer et al., 1997; Yoshimura et al., 1996) have been
largely attributed to the sequestering of IGFs and subsequent prevention of IGF
receptor activation. However, IGFBPs can exert additional IGF-independent actions
that do not involve IGF binding or influence IGF reception. The growth inhibitory
actions may be mediated by binding of IGFBP-3 to cell surface proteins (Oh et al.,
1993b, 1993c). In addition, the type V TGF-P receptor has been suggested to be a
putative IGFBP-3 receptor, although the nature of any signalling response to IGFBP-
3 is unknown (Leal et al., 1997). IGF-independent actions of IGFBP-3 have also
been proposed to occur intracellularly (Li et al., 1997), although the extent and
mechanism by which IGFBP-3 interacts with the nuclear machinery remain to be
determined. The growth inhibitory actions of IGFBP-3 may also involve the
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induction or accentuation of apoptotic cell death (Gill et al., 1997; Rajah et al.,
1997), via an IGF-receptor independent pathway and possible interaction with other
growth inhibitors. It remains to be established whether IGFBP-3 influences follicular
and luteal function via IGF-independent mechanisms, in addition to its ability to bind
IGF.
Whether IGFBP-3 exerts IGF-independent luteal growth inhibition or sequesters
stimulatory IGFs, it is unclear why the CL should express IGFBP-3 from the early
luteal phase in the natural cycle and at times of high steroidogenesis. Despite this
paradox, increased expression of IGFBP-3 mRNA in the induced CL would be
expected to be detrimental to both luteal lifespan and function.
Our understanding of the role of IGFBP-3 in ovarian function is further complicated
by its ability to potentiate the effects of IGF in vitro. Potentiation is thought to
involve IGF-binding to cell surface-associated IGFBP-3, and may enhance delivery
of IGF to its receptor (Conover et al., 1990). Cell associated IGFBP-3 has a 10-fold
lower binding affinity for IGF-I than IGFBP-3 in solution, and a 2-fold lower affinity
for IGF-I than the type 1 IGF receptor (Conover, 1991). Additionally proteolysis of
IGFBP-3 may potentiate IGF action, since cleavage of IGFBP-3 produces a fragment
with reduced IGF-binding affinity (Schmid et al., 1991). Reduced affinity of binding
proteins for IGF would then be expected to increase the IGF available for ligand-
receptor interactions.
GnRH treatment in the early luteal phase causes ovulation and subsequent formation
of a luteinised structure. In addition, the administration of GnRH and/or the presence
of the induced CL also influence the spontaneous corpus luteum present on the ovary
at the time of treatment. Concentrations of mRNA encoding both IGFBP-3 and the
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type 1 IGF receptor were altered in the spontaneous CL when compared to control
corpora lutea of a similar age. IGFBP-3 mRNA levels were raised above control
levels in the mid-luteal spontaneous CL, but were not different in the late luteal
phase. In contrast, type 1 IGF receptor mRNA concentrations in GnRH-treated
spontaneous CL were significantly below the levels in control CL of the mid-luteal
phase, whilst no difference was observed in the late luteal phase.
Exposure of the developing corpus luteum to an LH surge following GnRH
administration has been shown to impair the function of the original CL (Martin et
al., 1990). This effect may be the result of LH receptor down-regulation (Rodger and
Stormshak, 1986) or post LH-receptor disruptions (Conti et al., 1977) leading to
desensitisation to gonadotrophin stimulation. In contrast, others have suggested that
increases in plasma progesterone observed two days post-hCG could not be
accounted for by the induced CL and must therefore result from a stimulatory effect
of hCG on the original CL (Fricke et al., 1993).
In the present study the relative contributions of the original and GnRH-induced CL
to plasma progesterone production were not determined, therefore it remains unclear
whether GnRH had a stimulatory or supressive effect on the progesterone secretion
of the original CL. However, the observed increase in IGFBP-3 and decrease in the
type 1 IGF receptor mRNA levels would not be expected to be consistent with
increased progesterone production, therefore, the functional capacity of the original
CL may also have been compromised. Interestingly, whilst the GnRH-induced CL
exhibited alterations in mRNA concentrations at both timepoints studied, the original
CL was only affected when compared to mid-luteal CL of control animals and no
differences in mRNA concentrations were detected when compared to late luteal
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control CL. The original CL therefore appears to display only a transient variation
from control IGFBP-3 and type 1 IGF receptor mRNA levels. It is unclear whether
this reflects an intrinsic quality of the original CL or its advanced stage of luteal
development to recover from earlier hormonal changes. Alternatively, there may
have been a diminution of the signal that caused the initial variations or the
sensitivity of the original CL to that signal, although the increase in IGFBP-3 mRNA
levels observed in the GnRH-induced CL also present on the ovary suggests the
former not to be the case.
In conclusion, this study demonstrates that (1) many components of the IGF system
are expressed in the GnRH-induced CL, (2) differences in type 1 IGF receptor and
IGFBP-3 mRNA concentrations from control levels may contribute to the reduced
functional capacity of the GnRH-induced CL (3) GnRH administration also affects
the original CL present on the ovary at the time of treatment.
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Chapter 7. General Discussion
The corpus luteum is crucial to reproductive success. Its primary secretory product
progesterone is required for the establishment and maintenance of pregnancy, and
inadequate progesterone production is a major cause of infertility and embryonic
loss. The corpus luteum is also central to the regulation of cyclicity. Whilst LH and
PGF2a are the principal luteotrophic and luteolytic hormones in domestic animals,
there is increasing interest in the potential of local factors to modulate the response
of the CL to hormonal action.
The insulin-like growth factors are putative regulators of ovarian function, and both
IGF-I and IGF-II have direct effects on ovarian cells in culture. Whilst there is
considerable evidence to support a role for the IGFs in regulating normal follicular
development, there is a relative paucity of information regarding the actions of the
IGFs in the CL. However, an important role for the IGFs in regulating luteal function
is suggested both by the multiple stimulatory effects of the IGFs on follicular
steroidogenesis, and by the direct stimulation of progesterone production by luteal
cells in vitro.
Whilst the in vitro evidence suggests that the IGFs are important regulators of both
follicular and luteal function, the local expression of mRNAs encoding the IGFs in
the bovine ovary remains controversial.
This series of studies has examined the temporal and spatial pattern of expression of
mRNA encoding IGF-I, IGF-II, the type 1 IGF receptor and IGFBP-2, -3 and -4
during the growth and regression of the bovine corpus luteum. Corpora lutea were
collected at defined stages of the oestrous cycle after synchronised oestrus (see
Chapter 3), and following GnRH-induced ovulation of the first wave dominant
follicle (see Chapter 5).
The expression of IGF-I mRNA in the ruminant ovary has been the subject of much
debate. This study confirms that the bovine corpus luteum is a site of IGF-I
production (see Chapter 3), and suggests an important regulatory role for locally
produced IGF-I. Expression of IGF-I mRNA was low and widespread, but increased
towards the periphery and in lines radiating through the corpus luteum. The exact
identity of these cells could not be determined, however, endothelial cells,
steroidogenic cells and immune cells are all suggested sites of IGF-I mRNA
expression. It is clear that accurate identification of the cellular sites of IGF-I mRNA
expression is essential to a greater understanding of the role of locally produced IGF-
I in luteal function.
The results of follicular cell culture suggest that IGF-I acts with the gonadotrophins
to regulate the acquisition of differentiated function. However, the results of the
present study do not support a similar role in the bovine corpus luteum for
endogenously produced IGF-I, since the expression of mRNA encoding IGF-I was
low during luteinisation. However, the correlation between increasing luteal IGF-I
mRNA concentrations and peak progesterone production observed in the present
study, in addition to enhanced progesterone biosynthesis in response to IGF-I in
vitro, suggests that local IGF-I might act as a stimulator of luteal steroidogenesis.
The variation in IGF-I mRNA concentrations during the oestrous cycle suggests that
regulated local expression is important for luteal function. However, it is unclear
how critical a role is played by the low levels of locally produced IGF-I, since there
are high levels of IGF-I present in the circulation. It is not known whether the CL
receives significant IGF-I stimulation from peripheral sources, and if so, whether
locally produced IGF-I supplements the actions of endocrine IGF-I or serves an
entirely different role in CL regulation. Liver-specific inactivation of the IGF-I gene
caused a large decrease in blood IGF-I concentrations (Sjogren et al., 1999; Yakar et
al., 1999). However, mutant mice with liver IGF-I gene deletion were fertile and had
litters of normal size (Yakar et al., 1999), suggesting that systemic IGF-I may not be
crucial to the stimulation of reproduction in the mouse. There is little known about
the contribution of circulating IGF-I to luteal function. An endocrine effect of IGF-I
on luteal growth was suggested in nutrient-restricted heifers, where reduced CL size
was correlated with low blood IGF-I, whilst luteal IGF-I mRNA expression was
unaffected (Vandehaar et al., 1995). However, whilst the treatment of cows with GH
increases peripheral IGF-I concentrations, subsequent progesterone secretion has
been unaffected (Gong et al., 1991), increased (Lucy et al., 1994) or decreased
(Jimenez-Krassel et al., 1999).
Maximal expression ofmRNA encoding IGF-I was detected in the regressing CL, 48
hours after exogenous prostaglandin. The role of IGF-I in luteolysis is unclear, given
the potential of IGF-I to stimulate luteal function. However, the high expression may
reflect the intense immune cell activity associated with luteal regression. The role of
IGF-I in the regulation of immune cell function during luteal regression could be
further examined by the collection of CL at additional timepoints following natural
or induced luteolysis, and the subsequent identification of the sites of IGF-I mRNA
expression.
Previous studies have concentrated on the potential of IGF-I rather than IGF-II to
regulate ovarian function. The present study reports that the bovine corpus luteum is
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a site of IGF-II mRNA expression (see Chapter 3). Despite the limited number of
studies that have previously examined the potential role of IGF-II in the ovary, IGF-
II has been shown to enhance steroidogenesis (Garmey et al., 1993; Kamada et al.,
1992; Mason et al., 1994), including the stimulation of progesterone production by
bovine luteal cells in culture (Sauerwein et al., 1992). The local production of IGF-II
by the bovine corpus luteum suggested by the detection of IGF-II mRNA therefore
allows for local regulation of steroidogenesis. However, the expression of mRNA
encoding IGF-II was shown to be particularly intense in the luteal vasculature, and
suggests that IGF-II may regulate aspects of luteal function in addition to the
stimulation of steroid biosynthesis. Hybridisation was not limited to endothelial cells,
and pericytes, fibroblasts or smooth muscle cells may also be sites of IGF-II mRNA
expression. Indeed, previous immunohistochemical observations localised IGF-II
protein to perivascular cells (Amselgruber et al., 1994). It remains unclear whether
this reflects a role for locally produced IGF-II in the control of vascular growth and
function, or the regulation of vascular and steroidogenic cell interactions, and
warrants further examination.
IGF-I and IGF-II interact with the same receptor and binding proteins, albeit with
different affinities. It is unclear how the IGFs might co-operate to support luteal
growth and development. However, the distinct cellular sites of expression ofmRNA
encoding the IGFs suggest that these factors may serve different functions in
different cell-types. It remains to be determined whether locally produced IGF-II is
sufficient to influence luteal function in the presence of a potential excess of IGF-I
from circulatory sources, since IGF-I has a higher affinity for the type 1 IGF receptor
than IGF-II.
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The detection of mRNA encoding the type 1 IGF receptor within the corpus luteum
throughout the oestrous cycle (see Chapter 3) suggests that stimulation by IGF-I and
IGF-II (produced locally or derived from the circulation) may be important
throughout the lifespan of the corpus luteum. Whether these multifunctional proteins
stimulate different aspects of luteal function at different times is unknown.
Type 1 IGF receptor mRNA was widespread, and steroidogenic luteal cells are the
suggested site of mRNA expression. These results confirm and extend previous
reports of binding characteristic of the type 1 IGF receptor in bovine luteal
membrane preparations (Sauerwein et al., 1992). The diffuse pattern of mRNA
expression encoding the type 1 IGF receptor suggests that IGFs may influence luteal
cells which do not themselves produce IGF-1 or -II, given the low levels of locally
produced IGF-I, and the predominant association of IGF-II mRNA with the luteal
vasculature. This suggests that local IGFs may act as paracrine regulators of non-
expressing cells. Additionally it may further support a role for IGFs derived from the
circulation in the regulation of luteal function.
The actions of IGF-I and IGF-II are modulated by association with members of a
family of high affinity IGFBPs (Clemmons, 1997; Jones and Clemmons, 1995;
Rechler and Clemmons, 1998). Current evidence suggests that the interaction of
IGFs with IGFBPs serves to attenuate the actions of IGFs on ovarian cells (Bicsak et
al., 1990; Chun et al., 1994; Mason et al., 1998; Spicer et al., 1997; Ui et al., 1989;
Yoshimura et al., 1996). This study has determined that the bovine CL is a site of
IGFBP expression (see Chapter 4) and indicates that there is a requirement for the
regulation of IGF-actions in the CL. Messenger RNA encoding IGFBP-2, -3 and -4
was detected throughout the oestrous cycle, and showed limited temporal variation.
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IGFBP-4 mRNA was expressed by steroidogenic luteal cells and may act to block
IGF-stimulation of steroid production as has been demonstrated in vitro. However,
mRNA encoding IGFBP-2 and -3 was predominantly localised to non-steroidogenic
luteal cells. Indeed, mRNA encoding IGFBP-2 and -3 showed particular association
with the luteal vasculature. A number of large blood vessels showed moderate to
intense hybridisation for IGFBP-2 mRNA which may be localised to smooth muscle
cells. Messenger RNA encoding 1GFBP-3 was detected in cells lining microvessels,
suggestive of endothelial cell expression. IGFBP-2 and -3 may therefore serve a
number of functions. They may 1) regulate the actions of IGFs on vascular function,
2) act as paracrine factors outwith the vasculature in the regulation of IGF-stimulated
steroidogenic cell function, or 3) act as a sink for peripheral IGFs, enabling
subsequent controlled release of the ligands in response to changes in affinity of the
IGFBPs for the IGFs due to proteolysis or ECM-binding.
The IGFBPs exhibit different binding preferences for IGF-I and -II. IGFBP-2, -5 and
-6 bind IGF-II with higher affinity than IGF-I (Jones and Clemmons, 1995). It is not
known whether luteal IGFBP-2 is therefore primarily involved in regulating the
actions of IGF-II within the corpus luteum due to differential binding affinity, whilst
other IGFBPs such as IGFBP-3 and -4 may interact predominantly with IGF-I.
These studies have detected limited temporal variation in mRNA levels throughout
the oestrous cycle, despite the dramatic changes in luteal growth and function that
occur during the oestrous cycle. Evidence from in vitro studies support a role for the
IGFs in enhancing steroidogenic activity. However, only IGF-I mRNA levels varied
significantly with day of the oestrous cycle, whilst concentrations of mRNA
encoding IGF-II and the type 1 IGF receptor showed no correlation with changes in
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steroidogenic activity. The bioactivity of IGF-I and -II can be further modified by
changes in levels of IGFBPs. However, IGFBP mRNA concentrations did not vary
with day of the oestrous cycle.
The lack of a correlation between major luteal events and alterations in steady-state
mRNA levels might imply a lack of critical function. However, in vitro evidence
supports an important role for the IGFs in vivo (Poretsky et al., 1999; Spicer and
Echternkamp, 1995). A reduction in IGF-bioavailability following the addition of
exogenous IGFBPs to ovarian cells in culture and the subsequent sequestration of
IGFs had dramatic effects on steroid production (Mason et al., 1998; Spicer et al.,
1997; Ui et al., 1989), cell proliferation (Bicsak et al., 1990), ovulation rate and
oocyte maturation (Yoshimura et al., 1996), and apoptosis (Chun et al., 1994).
GnRH-administration on day 6 of the oestrous cycle results in ovulation of the first
wave dominant follicle and subsequent formation of a secondary luteinized structure
(see Chapter 5). Removal of the spontaneous CL has previously demonstrated that
the GnRH-induced CL does secrete progesterone. However, the steroidogenic
activity of the induced CL falls below that of a spontaneously formed CL of a similar
age. Ovulation of the first wave dominant follicle and formation of an induced CL
has been demonstrated in response to the administration of hCG, synthetic GnRH or
GnRH-agonist. However, peripheral progesterone concentrations were greater
following hCG treatment than GnRH-agonist treatment (Schmitt et al., 1996a,
1996b). This may be due to differences in LH-like exposure induced by the two
treatments. Human chorionic gonadotrophin has a markedly slower clearance rate
than LH, and hence an increased plasma half-life. In addition, hCG bound to the LH
receptor is internalised much slower than LH bound to its receptor resulting in
extended stimulation. The increase in plasma progesterone concentrations in
response to hCG may be the result of increased stimulation of the original CL or
greater differentiation of the induced CL.
There may also be differential effects of hCG and GnRH-agonist on luteal
morphology. Alterations in the size distribution of steroidogenic luteal cells could
potentially affect the luteal response to both LH-like stimulation and PGF2a binding,
since large luteal cells contain the majority of PGF2amembrane receptors, whilst only
small luteal cells respond to LH stimulation with increased progesterone production.
The extent ofmorphological differences induced by GnRH treatment is unknown and
warrants further investigation.
In the present study GnRH-induced CL did not exhibit significantly reduced LH
receptor mRNA levels when compared to spontaneous CL of similar age, suggesting
that a lack of LH reception was not the cause of the limited function of the induced
CL. Indeed, Rusbridge (1993) demonstrated that the GnRH-induced CL had
increased LH receptor numbers. The cause and biological significance of increased
LH receptor concentration observed by Rusbridge remains unclear (1993), however,
it was suggested that progesterone production by the endogenous CL may have been
responsible for the premature induction of LH receptors. The reason for the
discrepancy in LH receptor concentration assessed by LH-binding (Rusbridge, 1993)
or detection ofmRNA encoding the LH receptor is unknown.
Evidence from the GnRH-induced CL demonstrates that significant alterations to the
luteal IGF system are correlated with reduced functional capacity (see Chapter 6).
Increased IGFBP-3 mRNA concentrations and decreased type 1 IGF receptor mRNA
concentrations are expected to result in reduced bioavailability and bioactivity of
192
IGF-I and -II. The resultant reduction in IGF-stimulation may compromise the
response of the GnRH-induced CL to luteotrophic support, and thus contribute to its
limited steroidogenic function. Abnormal luteal function such as that exhibited by
the GnRH-induced CL may also reflect a lack of suitable follicular maturation prior
to CL formation. A reduction in progesterone secretion has critical implications for
subsequent fertility, since low luteal phase progesterone concentrations are
detrimental to the successful maintenance ofpregnancy (Mann et al., 1999).
The current studies were designed to determine the local production of components
of the IGF system, and were therefore limited to detection at the RNA level.
Determination of IGF and IGFBP protein concentrations would reflect changes in
both local production and transudation from plasma. Any resultant changes in IGF
bioavailability and bioactivity are beyond the scope of this work, but would be a
valuable extension of the present studies. Indeed they may even provide insights into
the relative importance of endocrine versus autocrine/paracrine IGF stimulation of
luteal function.
IGFBPs are subject to proteolytic degradation (Fowlkes, 1997; Maile and Holly,
1999). IGFBP-specific proteases have been identified within follicular fluid, and
their ability to alter IGF-bioavailabilty related to follicular growth (Besnard et ah,
1996, 1997; Cwyfan Hughes et al., 1997; Grimes and Hammond, 1994; Mason et al.,
1996). IGFBP-4 proteolytic activity has also been identified in luteinized human
granulosa cells (Iwashita et al., 1996). However, there has been little research thus
far on the role of IGFBP-specific proteases in the regulation of the luteal IGF system.
IGFBP- proteases are potentially important regulators of the IGF system within the
CL and hence luteal function.
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Much of this study is based on results generated by in situ hybridisation. In situ
hybridisation reveals the cellular localisation of specific nucleic acids in cells and
tissues, and therefore has the potential to greatly increase our understanding of
cellular function. However, the technique does have associated difficulties and
limitations.
Accurate identification of cell-types was not always possible in this study, thus
limiting the power of the analysis. In order to identify the precise positions of gene
transcription target nucleic acids must be immobilised. A number of methods are
suitable for the preparation of tissue prior to in situ hybridisation, and this study
primarily utilised tissue snap-frozen in liquid nitrogen and prepared as cryostat
sections. The use of frozen tissue allows good penetration of the probe to the in situ
target, but the preservation of tissue morphology can be poor. In contrast,
paraformaldehyde-fixation and paraffin-embedding stabilises the tissue, but the
creation of cross-links can cause problems of probe penetration. Paraffin sections
were used to detect luteal IGFBP-2 mRNA expression, and tissue integrity was much
improved without increased problems of probe accessibility. Future studies are likely
therefore to use fixed tissue sections for improved identification of the cellular sites
of expression. Further improvement might also be achieved by a reduction in the
thickness of tissue sections which may have contributed to limited resolution.
In the follicle, theca and granulosa cells are physically separated into distinct layers
by the basement membrane allowing for easy cell identification, in contrast, the
corpus luteum is a complex tissue comprised of a number of different cell-types
which display a heterogeneous distribution. In order to distinguish more precisely
between different cells, specific markers of cell-type can be detected by
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immunohistochemistry. Cell-specific markers have previously been used in the
corpus luteum to identify steroidogenic cells, endothelial cells and a number of
immune cells (Jablonka-Shariff et al., 1993; Penny et al., 1999). Immunolocalisation
performed in conjunction with the standard in situ hybridisation protocol, either on
the same or parallel slides, could be used in subsequent studies to more accurately
determine the sites ofmRNA expression.
In tissues where the expression of a specific mRNA is restricted to a small sub-
population of cells in situ hybridisation may prove more sensitive than techniques
which rely on the extraction ofRNA by tissue disruption. However, quantification of
selected fields of view may prove to be unrepresentative if the pattern of
hybridisation is non-uniform. In this situation techniques such as RNase protection
assays or Northern blotting may provide a more representative approach to
quantitative analysis. In addition, these methods have the further advantage that they
allow for both relative and absolute quantification of mRNA concentrations. The
analysis of mRNA expression levels by in situ hybridisation may also be subject to
more bias than RNase protection assays or Northern blotting, since the investigator
must locate the fields of view to be quantified.
The accuracy of quantification can also be affected by the process of exposure and
development. In order for expression levels to be compared it is assumed that a
doubling of hybridisation signal reflects a doubling in target mRNA, however, the
response of photographic film or emulsion to exposure is not a simple linear one. By
exposing slides to emulsion or gels to film for varying times an appropriate length of
exposure can be chosen to ensure that readings are taken from the linear part of the
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sigmoid curve, and that saturation has not been reached. The linearity of signal is
also influenced by the specific activity of the probe hybridised to the RNA target.
In spite of potential limitations, in situ hybridisation studies have extended our
knowledge of the spatial patterns of mRNA expression for components of the IGF
system. Whilst it is clear that there is much still to be learnt about the complex
interactions of the IGF system within the CL, the work presented here supports a role
for the modulation of luteal function by locally produced IGFs. In general terms,
much of our understanding of the importance of IGF-I and -II to luteal function
relies heavily on information gained from follicular studies, and IGF-actions in the
follicle are extrapolated to the CL, often with little direct evidence. Clearly, the luteal
targets of IGF-stimulation should be the subject of further detailed study, and should
consider IGF effects on both the steroidogenic and non-steroidogenic components of
the CL. However, collectively the data in this thesis have demonstrated that the
bovine CL is a site of IGF production, reception and regulation.
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Figure I.
The protection of 32P-labelled porcine IGF-I and 18S ribosomal RNA
probes with total RNA (25jig) isolated from bovine luteal and liver
tissue.
Protected hybrid of size 80 base pairs was detected with the 18S
ribosomal RNA riboprobe. Full length porcine IGF-I probe (472 bp)
was not protected in bovine tissue due to mismatches. Undigested














The protection of 32P-labelled bovine IGF-I RNA probe with total
RNA (25pg) isolated from bovine luteal and liver tissue.
Protected hybrid of size 196 was detected with a bovine IGF-I probe.














The protection of 32P-labelled bovine IGF-II RNA probe with total
RNA (25pg) isolated from bovine luteal and liver tissue.
Protected hybrid of size 154 base pairs was detected with a bovine
IGF-II probe. Undigested probe of size 242 base pairs is also shown.
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Bovine type 1 IGF receptor, IGFBP-3 and 18S
ribosomal RNA.
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The protection of 32P-labelled bovine type 1 IGF receptor , IGFBP-3
and 18S ribosomal RNA probes with total RNA (25pg) isolated from
bovine luteal and liver tissue.
Protected hybrids of size 189, 358 and 80 base pairs were detected with
type 1 IGF receptor (IGFr), IGFBP-3 and 18S ribosomal RNA probes
respectively. Undigested probe of sizes 251 and 433 base pairs for the
type 1 IGF receptor and IGFBP-3 are also shown.
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Figure V.
The protection of 32P-labelled bovine IGFBP-4 and 18S ribosomal
RNA probes with total RNA (25pg) isolated from bovine luteal and
liver tissue.
Protected hybrids of size 227 and 80 base pairs were detected with
IGFBP-4 and 18S ribosomal RNA probes respectively. Undigested




47.264g guanadine thiocyanate (4M)
10ml 250mM trisodium citrate (25mM)
Adjust to pH 7 with NaOH (5M), filter through 0.22pm nylon bottle top filter




0.02% (w/v) bovine serum albumin (BSA)-Fraction V





Adjust pFI to 7.5 with NaOH, and autoclave.
Remelt in microwave when required, and allow to cool to 55°C before adding
ampicillin. For liquid media omit the agar.
MOPS (lOx)




Add 80g paraformaldehyde to 1000ml DEPC H20,
heat to 60-70°C until the paraformaldehyde dissolves,
add a few drops of 2M NaOH until the solution clears,
make up to 2000ml with 200mM PBS (pH 7.4) and







2g swine skin gelatin
200mg thimerosal
200ml 0.5M P04 buffer (pH7.5)
Proteinase K buffer (lOx)
O.lMTris pH7.8
0.05M EDTA
5% (w/v) SDS (warm to dissolve).
Reverse transcription mix
42pl 50mM MgCl2,
42pi lOx RTase buffer,
42pl dNTP mix (each at lOmM; Promega),
12pl RTase Superscript II (25U/pl; Life Technologies) and








0.02M EDTA (disodium salt)
258
TAE (Tris/acetate/EDTA) electrophoresis buffer (50x)
242g Tris base
57.1 ml glacial acetic acid
100 ml 0.5M EDTA pH8
final working concentration 40mM Tris acetate, ImM EDTA.
TBE (Tris/borate/EDTA) (lOx)
108g Tris base (890mM)
55g boric acid (890mM)
40ml 0.5M EDTA pH8 (20mM)
TE buffer
lOmM Tris-HCl pH 7.5
ImM EDTA
TM buffer




Anti-progesterone (rabbit) antibody; SAPU product S235-201
Cross reactivities;
11 Hydroxyprogesterone < 300%
17 Hydroxyprogesterone <5%
11 Deoxycorticosterone < 10%





Amersham Pharmacia Biotech UK Ltd
Little Chalfont, Buckinghamshire, UK.




Beckman Instruments (UK) Ltd






Hemel Hempstead, Hertfordshire, UK.
Coopers Animal Health Ltd
Crewe, Cheshire, UK.
CP Laboratories
Bishop's Stortford, Hertfordshire, UK.
Cruachem
Glasgow, UK.
Fisher Scientific UK Ltd
Loughborough, Leicestershire, UK.
Flowgen
Ashby de la Zouch, Leicestershire, UK.
261

















Crawley, West Sussex, UK.
Roche Diagnostics Ltd
Lewes, East Sussex, UK.
Sanofi Animal Health Ltd
Watford, Hertfordshire, UK.
SAPU (Scottish Antibody Production Unit)








HA West (X-ray) Ltd
Edinburgh, UK.
